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ABSTRACT 
 
Restoring the functionality of the heart after the occurrence of an acute myocardial infarction 
requires the design of specific therapies aimed to induce an intricate cascade of biological events 
necessary to promote myocardium regeneration. To achieve such a challenging task, it is necessary 
to consider the milieu of proangiogenic, anti-inflammatory and anti-apoptotic paracrine molecules 
involved in the process of myocardial remodeling that occurs after an acute myocardial infarction. 
A potential approach is the use of stem cell-derived secretome-based strategies. The secretome is 
an array of multiple factors including growth factors, cytokines, microRNA (miRNA), and 
extracellular vesicles (EVs) that are secreted by stem cells to regulate tissue homeostasis. Several 
pre-clinical studies have shown that the secretome can be delivered to the peri-infarct area of the 
heart to improve cardiac function and prevent heart failure.  
Unfortunately, the clinical translation of secretome-based therapies has been hampered by its 
heterogeneous nature and by the limited identification of key therapeutic factors responsible for 
its regenerative potential. Additionally, the lack of retention of the therapeutic factors at the 
damage site upon delivery imposes another obstacle. Therefore, it is necessary to identify new 
strategies to standardize the production of secretome and to develop new carriers that will allow 
the efficient delivery and retention of these therapeutic factors at the therapeutic site. 
To address these challenges, the work presented in this thesis aimed to accomplish the following 
goals: (1) identify the optimal culture strategies for the production of a reproducible stem cell-
derived secretome that exhibits cardioprotective and angiogenic properties in vitro and in vivo as 
well as, (2) to deliver them efficiently using hydrogels. Several methods have been investigated to 
reach this goal (1). The first strategy represented the use of stem cell spheroids to produce a 
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concentrated secretome enriched with angiogenic growth factors that could display a superior 
angiogenic and cardioprotective efficacy. Additionally, the work of this thesis has been focused 
on another approach in which stem cells were genetically modified to upregulate the production 
of a miRNA-146a (miR-146a) in the secretome to further enhance its therapeutic properties 
(proangiogenic and anti-inflammatory). Finally, to address goal (2), this thesis has also been 
focused on designing a suitable strategy for the delivery of secretome in a non-invasive manner to 
the peri-infarct area of the heart. Therefore, a novel nanocomposite injectable hydrogel has been 
designed as a delivery platform for the secretome and tested both in vitro and in vivo in an acute 
myocardial infarction rat model. 
Overall, the strategies and findings of this thesis are beneficial to further advance the therapeutic 
efficacy of secretome-based therapies to promote myocardial regeneration by inhibiting of 
cardiomyocyte apoptosis, promoting angiogenesis, and modulating of inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGMENTS 
I would like to begin by thanking my advisor, Dr. Arghya Paul for his support and guidance 
throughout my research project and time at KU. I am extremely grateful for the freedom and 
flexibility you gave me to pursue my scientific interests in the lab as well as, various outreach and 
career development opportunities that have helped guide my career choices after graduate school. 
In addition, opening a new lab at a university is undoubtedly a huge challenge and I am grateful to 
have had the opportunity to work for someone with your level of enthusiasm and drive. 
I would like to thank my committee members, Dr. Cory Berkland, Dr. Steve Soper, Dr. Elizabeth 
Friis and Dr. Clay Quint for their time and guidance which have brought immense value to my 
thesis and resulted in several meaningful scientific discussions. In particular, thank you Dr. Cory 
Berkland for always providing a comfortable place to share all the trials and tribulations I have 
faced in graduate school. I sincerely appreciate all the advice and support you have given me as I 
try to figure out my path. Lastly, thank you for the constant encouragement to have faith that 
everything will work out.  
I could not have wished for better group of current and former labmates. In particular, I would like 
to thank Dr. Settimio Pacelli, Aparna Chakravarti, Saman Modaresi, Jon Whitlow, Vijayan 
Monoharan, Jeannie Salash and Sayantani Basu for their unwavering help with all the lab work, 
writing, editing and planning necessary to complete this thesis. You all are truly inspirational 
people who have a work ethic and dedication second to none and I feel so incredibly blessed to 
have worked beside you these past several years. Also, thank you for your friendship and enriching 
my life by sharing little pieces of your culture and traditions. I would like to specifically thank Dr. 
Settimio Pacelli for always going above the call of duty to support us graduate students. You are 
absolutely the glue that keeps us all together and I would not be where I am today without your 
support.  
vi 
 
I have also had the opportunity to work with some hardworking and dedicated undergraduate 
students and research associates who were instrumental in completing the experiments outlined in 
this thesis including, Francisca Acosta,  Siddharth Subham, Divya Murali, Keiko Suzuki, 
Kartikeya Jodha, Kyley Burkey, and Kyle Rampetsreiter. These students also provided me the 
opportunity to learn and grow as a mentor and teacher which is a privilege I am extremely grateful 
for. I would like to specifically thank Siddharth Subham for enduring the last semester of my thesis 
with me when each day required a unique level of perseverance. I am extremely grateful for your 
positive attitude, conversation, and willingness to always help no matter what the current 
unforgiving circumstances were.  
In addition, there were many individuals that took the time to train me and help me learn techniques 
while using the facilities at KU including, Dr. Karen Peltier of the TORP lab, Dr. Prem Singh 
Thapa-Chetri of the Rosa-Molinar Lab, and Dr. Qingfu Zhu of the He Lab. I would also like to 
thank our collaborator, Dr. Rafeeq P.H. Ahmed, from the University of Cincinnati for providing 
the facilities and expertise to test what I had developed in animals.   
I am indebted to all the professors associated with the NIH-sponsored Biotechnology Predoctoral 
Training Program including, Dr. Teruna Siahaan, Dr. David Volkin, Dr. Russ Middaugh, Dr. 
William Picking, Dr. Wendy Picking, Dr. John Stobaugh, and Dr. Michael Hageman. Thanks to 
their commitment to share their extensive knowledge of the biotech industry with the next 
generation of scientists, I received a grant that funded two years of my graduate career and 
provided me with unparalleled opportunities for training in science and leadership that is directly 
applicable to industry. This program exposed me to all the opportunities available for scientists to 
make a tangible impact on the development of live saving medication and has played a key role in 
deciding my plans after I graduate. In addition, the program allowed me to work at Genentech for 
vii 
 
six months where I met several influential scientists that taught me how the drug development 
process works in industry and confirmed my aspirations to pursue a career in a similar department. 
I would like to specifically thank Dr. Ann Woys, Dr. Dan Zarraga, Dr. John Wang, Stephanie 
Yarborough, Alison Bailey, Sasha Howes and Sigurlín Björg Atladóttir for the friendship, support, 
and advice while I was there.  
I am also grateful for the Bioengineering Graduate Program, which allowed me the flexibility to 
explore different research areas and gain the interdisciplinary training that aligned with my 
interests. To Denise Bridwell, thank you for all your support with everything from paperwork to 
the real life implications of graduate school. I would also like to thank Dr. Michael Detamore for 
his support, advice, and always being willing to assist me with my career and graduate school 
questions.  
In addition to the people that have helped me in graduate school, there have been several teachers 
and professors that have made an enormous impact on my path to get me to where I am today. 
Specifically, I would like to thank my undergraduate advisors Dr. Dan Heglund, Dr. Linda 
DeVeaux, and Lori Coble for first introducing me to research and biomedical engineering. Also, I 
would like to thank Dr. Prajna Dhar for all her support and guidance while I worked as an 
undergraduate research associate at KU.  
Lastly, I am deeply grateful for all of their love, support, and understanding my family and friends 
have given me throughout this roller coaster ride. To the women who somehow understand every 
piece of the puzzle, Jeannie Salash, Aparna Chakravarti, and Jordan Needens, thank you for always 
being there and listening when I felt like no one could possibly understand. You all have such 
caring hearts and fierce ambitions and I cannot thank you enough for being there for me throughout 
my graduate career.  
viii 
 
To my mom, Juliann Hull, thank you for being an amazing role model and my biggest cheerleader. 
I am where I am today because of your sacrifices and for that I am eternally grateful. You were 
always available when I just needed to vent about my challenging day or needed a reminder of 
how far I had come. Thank you for always reminding me that nothing is impossible with hard work 
and faith. Last, but certainly not least, thank you for being my ride-or-die hiking buddy and 
knowing sometimes being at the top of a mountain is just what my soul needs.  
To my two amazing sisters, Stephanie Waters and Stacie Hull, thank you for all your unique 
support and love that has kept me moving on the most challenging days. Stephanie, thank you for 
your surprise visits, long conversations on my commute, and always making me feel like I am 
some sort of superhero in my lab coat. Stacie, thank you for all the unparalleled joy your jokes and 
wit bring to my life as well as, giving me a fellow engineer companion in the family to talk math 
and science with.   
To my husband, Marshall Davis, thank you for being my teammate on this journey and always 
saying yes to every adventure that comes our way. I can honestly say that your support is the 
reason I have taken advantage of several opportunities and cannot thank you enough for your 
unwavering faith in me and us. Thank you for being strong enough to love me on my worst days 
and always being up for a game of one-on-one when I need a stress relief. I can’t wait to see 
what this next phase has in store for us.  
Finally, I want to thank my two cats who are actually part dog, Fausto and Maya, for always 
bringing a smile to face and giving me a cuddle buddy at the end of the day.  
Most of all, I thank God for all of these blessings.  
 
ix 
 
TABLE OF CONTENTS 
 
ABSTRACT ................................................................................................................................... iii 
ACKNOWLEDGMENTS .............................................................................................................. v 
LIST OF FIGURES ...................................................................................................................... xii 
LIST OF TABLES ....................................................................................................................... xiii 
CHAPTER 1. INTRODUCTION TO THESIS .............................................................................. 1 
CHAPTER 2. STEM CELL-DERIVED SECRETOME FOR CARDIAC REGENERATION .... 5 
ABSTRACT .................................................................................................................................... 5 
2.1 Introduction ........................................................................................................................... 5 
2.2 Stem Cell-Based Therapy for Cardiac Regeneration ............................................................ 9 
2.3 Stem cell-derived secretome ............................................................................................... 14 
2.3.1 Secretome composition and therapeutic action in cardiac regeneration ....................... 14 
2.3.2 Methods of Modifying the Secretome Composition .................................................... 15 
2.3.3 Clinical Translation of secretome-based therapies ....................................................... 17 
2.4 Injectable hydrogels ............................................................................................................ 19 
2.4.1 Natural vs. Synthetic Polymers .................................................................................... 20 
2.4.2 Composite hydrogels .................................................................................................... 22 
2.4.3 Biomolecule delivery using injectable hydrogels ......................................................... 23 
3. CONCLUSIONS ................................................................................................................... 25 
CHAPTER 3. STEM CELL SECRETOME-RICH NANOCLAY HYDROGEL: A DUAL 
ACTION THERAPY FOR MYOCARDIAL REGENERATION ............................................... 27 
ABSTRACT .................................................................................................................................. 27 
3.1 INTRODUCTION ............................................................................................................... 28 
3.2 MATERIALS AND METHODS ........................................................................................ 30 
3.2.1 Preparation of the nanocomposite hydrogels ................................................................ 30 
3.2.2 Harnessing the MSC secretome using a microfluidic device ....................................... 30 
3.2.3 Characterization of nanocomposite hydrogels ............................................................. 31 
3.2.4 Analysis of angiogenic potential of hydrogels ............................................................. 31 
3.2.5 Analysis of the cardioprotective properties of hydrogels ............................................. 32 
3.2.6 Scanning Electron Microscopy (SEM) ......................................................................... 33 
3.2.7 Swelling studies ............................................................................................................ 33 
3.2.8 Statistical analysis......................................................................................................... 34 
x 
 
3.3 RESULTS AND DISCUSSION ......................................................................................... 34 
3.3.1 Spheroid formation and secretome characterization .................................................... 34 
3.3.2 Nanocomposite hydrogel characterization ................................................................... 35 
3.3.3 Angiogenic studies ....................................................................................................... 36 
3.3.4 Assessment of the secretome cardioprotective properties ............................................ 37 
3.4 CONCLUSIONS ................................................................................................................. 39 
CHAPTER 4. STEM CELL-DERIVED SECRETOME-RICH INJECTABLE HYDROGEL FOR 
MYOCARDIAL REGENERATION............................................................................................ 40 
ABSTRACT .................................................................................................................................. 40 
4.1 INTRODUCTION .......................................................................................................... 40 
4.2 MATERIALS AND METHODS ................................................................................... 43 
4.2.1 Preparation and physical characterization of the nanocomposite hydrogels ................ 43 
4.2.2 Harnessing the hASCs secretome using a microchip device ........................................ 45 
4.2.3 Rheological analysis ..................................................................................................... 46 
4.2.4 Biocompatibility of the nanocomposite hydrogel in vitro ............................................ 47 
4.2.5 HUVEC proliferation, migration and tube formation assays ....................................... 48 
4.2.6 qPCR analysis of apoptotic and stress-related genes in spheroids ............................... 49 
4.2.7 Biocompatibility assessment of nanocomposite hydrogel in vivo ................................ 50 
4.2.8 In vivo acute myocardial infarction surgery ................................................................. 52 
4.2.9 In vivo assessment of cardiac function ......................................................................... 53 
4.2.10 Immunostaining of heart sections ............................................................................... 54 
4.2.11 Statistics ...................................................................................................................... 54 
4.3 RESULTS AND DISCUSSION .................................................................................... 55 
4.3.1 Secretome preparation and characterization ................................................................. 55 
4.3.2 In vitro proangiogenic activity of secretome ................................................................ 57 
4.3.3 Formation and characterization of the injectable nanocomposite hydrogel ................. 58 
4.3.4 In Vivo Biocompatibility of the injectable nanocomposite hydrogels .......................... 62 
4.3.5. In vivo therapeutic efficacy in myocardial infarcted rat model ................................... 63 
4.4 CONCLUSIONS ............................................................................................................ 65 
CHAPTER 5. DEVELOPMENT OF SUPERIOR THERAPEUTIC SECRETOME ENRICHED 
WITH MIR-146A FOR MYOCARDIAL REGENERATION..................................................... 67 
ABSTRACT .................................................................................................................................. 67 
5.1 INTRODUCTION ............................................................................................................... 68 
xi 
 
5.2 MATERIALS AND METHODS ........................................................................................ 70 
5.2.1 hASCs culture conditions and transfection with miR-146a ......................................... 70 
5.2.2 EV isolation from transfected cells and morphological characterization ..................... 71 
5.2.3 Western blot analysis of isolated EVs .......................................................................... 72 
5.2.4 miRNA analysis of isolated EVs .................................................................................. 73 
5.2.5 Assessment of transfected cell-derived secretome protein composition ...................... 74 
5.2.6 HUVEC proliferation assay with secretome146a ........................................................... 74 
5.2.7 HUVEC migration and tube formation assay with secretome146a ................................ 75 
5.2.8 Assessment of anti-inflammatory properties of secretome146a on HUVECs ................ 76 
5.3 RESULTS AND DISCUSSION ......................................................................................... 77 
5.3.1 Isolation and characterization of miR-146a enriched EVs derived from hASC .......... 77 
5.3.2 Angiogenic properties of secretome146a ........................................................................ 79 
5.3.3 Immunomodulatory properties of secretome146a .......................................................... 81 
5.4 CONCLUSIONS ................................................................................................................. 83 
CHAPTER 6. CONCLUSIONS ................................................................................................... 85 
REFERENCES ............................................................................................................................. 90 
APPENDIX A: Figures ............................................................................................................... 109 
APPENDIX B: Tables ................................................................................................................ 141 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF FIGURES 
CHAPTER 1 
No Figures 
 
CHAPTER 2 
Figure 2.1 Schematic diagram of an acute myocardial infarction…………………………..111  
 
CHAPTER 3 
Figure 3.1      Development of hMSC secretome-loaded hydrogel treatment schematic.……...112 
Figure 3.2      In vitro characterization of the developed nanocomposite hydrogel carrying 
secretome of hMSC spheroids…………………………………...……….……...113 
Figure 3.3      Angiogenic potential the developed bioactive nanocomposite hydrogel…..…....114 
Figure 3.4      Cardioprotective nature of the developed bioactive nanocomposite 
hydrogel……………………………………………………………………….....115 
Figure S3.1    SEM images of Gel-MA nanocomposite hydrogels having different  
concentration of Laponite………………...……………………………………...116 
Figure S3.2  Swelling equilibrium profiles of the different nanocomposite hydrogels over 
time………………………………………………………...…………………….117 
Figure S3.3    Calcein staining of HUVECs in 3D GelMA nanocomposite hydrogels  
containing different concentration of Laponite…..………...……………………118 
CHAPTER 4 
Figure 4.1      Preparation and characterization of secretome isolated from both hASC  
spheroids (3D secretome) and hASC monolayer (2D secretome).……..…….....119 
Figure 4.2      In vitro superior angiogenic potential of hASCs spheroid-derived secretome......120 
Figure 4.3      Effect of Laponite® on the rheological properties of the nanocomposite    
hydrogel……………………………………………………………………….....121 
Figure 4.4      Positive effect of the secretome loaded nanocomposite hydrogel on cardiac  
function in vivo..…………………………………………………………..…......122 
Figure 4.5      Assessment of the in vivo proangiogenic and scar area reduction capability  
of the secretome loaded nanocomposite hydrogel.……………….......................123 
Figure S4.1    Characterization of the injectable nanocomposite hydrogel ……………….…...124 
Figure S4.2    Effect of Laponite on nanocomposite hydrogel stiffness.…………………...….125 
Figure S4.3    Influence of Laponite concentration on the injectable hydrogel stability 
and protein release.…………..………………………………….………………126 
Figure S4.4    Effect of secretome on in vitro tube network length using tube formation 
assay......................................................................................................................127 
Figure S4.5    Biocompatibility assessment of the injectable nanocomposite hydrogels……....128 
Figure S4.6    In vivo assessment of pro-inflammatory markers post nanocomposite  
 hydrogel injections.…………………………………………….………………..129 
Figure S4.7    Cardiac damage assessment post in vivo nanocomposite hydrogel injections......130 
Figure S4.8    In vivo biocompatibility of the injectable nanocomposite hydrogel……….........131 
Figure S4.9    Retention of cardiac function post intramyocardial injection of  
nanocomposite hydrogel.……..............................................................................132 
Figure S4.10  In vivo cardiac function assessment after secretome delivery with and  
without the nanocomposite hydrogel…………………………………...…….....133 
 
xiii 
 
CHAPTER 5 
Figure 5.1      Schematic representing the process of hASCs transfection with miR-146a….....134 
Figure 5.2      Extracellular vesicle characterization....................................................................135 
Figure 5.3      Comparison of the growth factor composition and angiogenic properties 
of the secretome derived from transfected vs not-transfected hASCs  
with miR-146a.……………...………………………………………….………..136 
Figure 5.4      Tube formation assay of HUVEC to test the proangiogenic properties of  
  the secretome...……………………………………………………………….....138 
Figure 5.5      Assessment of the anti-inflammatory response of the secretome146a..…….….....139 
Figure S5.1    SEM image displaying the morphological structure of EV.. ……………..….....140 
 
CHAPTER 6 
No Figures 
 
LIST OF TABLES 
CHAPTER 1 
No Tables 
 
CHAPTER 2 
Table 2.1        Clinical Trials Assessing Adult Stem Cell Therapy for AMI and IHD.………...142 
Table 2.2        Key Paracrine Molecules for Cardiac Regeneration………...……………...…...144 
 
CHAPTER 3 
No Tables 
 
CHAPTER 4 
No Tables 
 
CHAPTER 5 
No Tables 
 
CHAPTER 6 
No Tables 
 
 
 
 
 
 
 
 
 
CHAPTER 1. INTRODUCTION TO THESIS 
 
The overall objective of this thesis was to develop an alternative treatment to stem cell therapy that 
would promote cardiac tissue regeneration for patients that have suffered from acute myocardial 
infarction. To achieve this goal the milieu of angiogenic, cardioprotective, and anti-inflammatory 
growth factors, cytokines and extracellular vesicles secreted by stem cells (secretome) was 
thoroughly investigated in vitro and tested in vivo to prove its efficacy. Precisely, stem cells culture 
conditions were varied and optimized to obtain a reproducible secretome composition with an 
angiogenic, anti-inflammatory and cardioprotective effect. In addition, a biocompatible, clinically 
feasible delivery vehicle that would be mechanically stable after placement into the myocardium 
was developed to retain the therapeutic secretome at the treatment site. The characterization and 
development of this treatment is comprised of the following three specific aims: (1) Identify an 
optimal method of stem-cell derived secretome production and characterize its cardioprotective 
and angiogenic properties in vitro by using a model nanocomposite hydrogel scaffold, (2) Develop 
an injectable nanocomposite hydrogel for the delivery of stem cell-derived secretome in vivo to 
assess its cardiac regeneration potential, and (3) Enhance the miRNA composition of stem cell-
derived secretome and evaluate the angiogenic and anti-inflammatory efficacy in vitro.  
The first aim was to identify an ideal method to culture stem cells that would cause the production 
of an angiogenic and cardioprotective secretome. Additionally, a hydrogel scaffold made of gelatin 
methacrylate (GelMA) and the nanosilicate (Laponite®) was developed and tested in vitro for its 
feasibility to deliver secretome in a controlled manner while maintaining their biological activity 
(angiogenic and cardioprotective). The second aim was to develop a hydrogel formulation that can 
be used in vivo for the delivery of the therapeutic secretome. To achieve this goal, a nanocomposite 
injectable hydrogel based on gelatin and the nanosilicate was developed and used as a carrier of 
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the secretome. The loaded hydrogels were tested in vivo in an acute myocardial infarction rat model 
and assessed for their cardiac regeneration efficacy. The third aim was to improve the angiogenic 
and anti-inflammatory efficacy of the secretome by transfecting stem cells with miR-146a, whose 
therapeutic efficacy for myocardial regeneration post-AMI has been well characterized.1 The 
subsequent chapters reflect the chronological order of these aims and are organized as described 
below. 
 
Chapter 2 provides a background of the pathophysiology of an acute myocardial infarction and 
subsequent ischemic heart disease. Then, a literature review on the pivotal clinical trials using 
adult stem cell therapy for myocardial regeneration in AMI and IHD patients is discussed with the 
intention of providing the scientific context that supports the widely accepted mode of action being 
largely mediated by the secretion of paracrine factors. Additionally, the chapter provides a 
literature review on the development of paracrine factors secreted by mesenchymal stem cells 
(MSC) (secretome) as an alternative treatment for myocardial regeneration. Lastly, injectable 
hydrogels are reviewed as potential delivery devices for MSC-derived secretome. Chapter 2 
provides the necessary background knowledge to explain the scientific rationale that guided the 
choices to use the materials and techniques in each of the subsequent chapters. In addition, this 
chapter provides valuable insight on the complexity and challenges associated with the 
development and clinical translation of a treatment that efficiently regenerates the myocardium 
and restores proper heart function post-AMI. 
 
Chapter 3 addresses the first aim of the thesis by describing different methods for stem cell-derived 
secretome production. The first strategy consisted of culturing bone marrow derived stem cells 
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(hMSCs) in spheroids using a polydimethylsiloxane (PDMS) microwell device, while the second 
method involved the traditional culture of hMSCs as a monolayer. The concentration of the 
angiogenic growth factors secreted by hMSCs using the two separate culture methods were 
compared to determine which had the greatest therapeutic potential.  Furthermore, the chapter 
discusses the design of a model hydrogel delivery system to promote the sustained release of 
angiogenic growth factors present in the secretome.  The hydrogel was fabricated using a photo-
crosslinked network made of GelMA in combination with various concentrations of the 
nanosilicate. The release profile of key angiogenic growth factors from the secretome-loaded 
nanocomposite hydrogels were monitored to evaluate whether the nanosilicate had any effect in 
controlling the rate of diffusion of the loaded proteins. Lastly, the angiogenic and cardioprotective 
efficacy of the released growth factors were assessed upon delivery from the model hydrogel 
platform using several cell assays in vitro. Overall, this chapter provides the foundation for the 
subsequent thesis by confirming the angiogenic and cardioprotective potential of secretome 
isolated from stem cell spheroids and validate the selection of nanosilicate as an effective strategy 
to control the delivery of secretome-based angiogenic growth factors.  
 
Chapter 4 addresses the second aim of the thesis by describing the development of an injectable 
nanocomposite hydrogel to serve as a secretome delivery device for in vivo cardiac regeneration. 
Gelatin was combined with various concentrations of nanosilicate and the biocompatibility, 
viscosity, stiffness, thixotropic behavior, ability to modulate protein release, and degradation of 
each of the resulting nanocomposite hydrogels were evaluated. Secretome was isolated from 
human adipose-derived stem cells (hASCs) due to their ease of harvest, high proliferation rate and 
inherent ability to produce angiogenic growth factors. hASCs were cultured as spheroids and the 
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secretome composition was evaluated by quantifying the concentration of the different key 
angiogenic growth factors and testing their proangiogenic efficacy using in vitro cell assays. 
Lastly, the secretome was loaded in the optimized nanocomposite hydrogel and assessed in vivo 
in an acute myocardial infarction rat model by confirming the biocompatibility and monitoring the 
improvement in heart function, increase in angiogenesis, and decrease in infarct size after 
treatment in vivo. These results were vital for moving forward to the third aim where the 
composition of the therapeutic ASC derived secretome was further refined.   
 
Chapter 5 addresses the third aim by focusing on refining the miRNA composition of ASC derived 
secretome. A non-viral transfection method was used to increase the amount of a well-
characterized therapeutic miRNA, miR-146a, within the exosomes present in the ASC derived 
secretome. The size, protein composition, and morphology of the extracellular vesicles within the 
secretome was characterized. In addition, the cytokines, angiogenic growth factors and 
extracellular vesicle miRNA composition within the secretome derived from non-transfected and 
transfected ASCs was compared. Finally, cell-based assays were used to evaluate the angiogenic 
and anti-inflammatory efficacy of the secretome.  
 
Chapter 6 addresses the concluding statements of this thesis. The key findings from each aim are 
summarized and their contribution to the collective goal of identifying a therapeutic treatment for 
cardiac regeneration is elucidated. Finally, recommendations are made for future work using stem 
cell-derived secretome for cardiac regeneration. Overall, the work completed in this thesis is a 
proposed solution to overcome the drawbacks associated with traditional stem cell-based therapies 
for cardiac regeneration.
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CHAPTER 2. STEM CELL-DERIVED SECRETOME FOR CARDIAC 
REGENERATION 
ABSTRACT 
 
The aim of cardiac regenerative medicine is to restore the structural and functional characteristics of 
the heart tissue in patients who have suffered an AMI by promoting myocardium and vascular tissue 
growth at the infarct site. This chapter first discusses the pathophysiology of an acute myocardial 
infarction and the current progress made in the field of stem cell-based therapies for cardiac 
regeneration. Next, the current insights, production methods and the clinical translation of stem cell-
derived secretome as an alternative therapeutic tool for ischemic heart disease are explained. Lastly, 
the use of various types of injectable hydrogels as delivery strategies for proteins, cytokines, miRNA 
extracellular vesicles and other therapeutic molecules is described.  
 
2.1 Introduction 
 
On average, one person dies of a cardiovascular disease (CVD) every 40 seconds in the United States 
making CVD the leading cause of death in this country.2, 3 Additionally, according to the American 
Heart Association Heart Disease and Stroke Statistics 2018 Update, the annual direct and indirect costs 
of CVD and stroke in 2013 and 2014 were $329.7 billion in the United States accounting for 14% of 
total health expenditures.4 Specifically, ischemic heart disease (IHD) has a higher mortality rate than 
any other CVD accounting for one third of deaths worldwide 5, 6 This disease is caused by the inhibition 
of blood flow to the left ventricle (LV) due to plaque buildup within the coronary arteries (Fig. 2.1). 
The resulting inadequate perfusion of the LV causes a lack of delivered oxygen to the highly aerobic 
tissue causing
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 cardiomyocyte necrosis and a myocardial infarction (MI). Due to the inadequate regenerative capacity 
of the myocardium, adverse LV remodeling occurs after a MI which ultimately leads to ischemic heart 
failure caused by changes in LV size, shape, function, cellular and molecular composition.7  
The intrinsic mechanism of chronic cardiac remodeling after an AMI consists of a complex cascade of 
events that involves interactions between several different cell types present in the heterogeneous heart 
tissue, including inflammatory cells, endothelial cells, fibroblasts, and myofibroblasts. Specifically, 
the mechanism can be divided into two distinct phases, the inflammatory and reparative phase.8, 9 The 
hypoxia of IHD initiates a significant increase in necrotic, apoptotic and autophagic cardiomyocytes 
which begins within hours of the initial coronary artery occlusion. The subsequent release of 
substances called danger associated molecular patterns (DAMPs) from these cardiomyocytes robustly 
activates a cascade of inflammatory mediators, including inflammatory cytokines, chemokines, and 
cell adhesion molecules.10-12 These DAMPs are also upregulated and released by damaged extracellular 
matrix, recruited and activated leukocytes, and fibroblasts. DAMPs are also responsible for endothelial 
activation that leads to the extravasation of recruited leukocytes, originating from the spleen, into the 
infarct area.13, 14 Specifically, endothelial adhesion molecules are upregulated and facilitate the binding 
of leukocyte ligands. This leukocyte binding causes neutrophils and monocytes to roll along the 
venular endothelium, eventually firmly adhering to the endothelium, and ultimately transendothelial 
migration occurs by paracelluar trafficking between endothelial cells or intracellular trafficking 
through endothelial cytoplasmic pores.15 Following leukocyte infiltration, neutrophils, monocytes and 
M1 macrophages orchestrate the complex inflammatory response which serves to clear damaged 
extracellular matrix tissue and cells by promoting phagocytosis of dying cells and tissue digestion via 
protease and oxidase release.8 It should be emphasized that the importance of this inflammatory phase  
has been proven and is a necessary precursor for the subsequent reparative phase to occur.16  
Inflammation resolution happens within the reparative phase and is also accompanied by myofibroblast 
proliferation, scar formation, and neovascularization. Specifically, neutrophil apoptosis is a critical 
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mechanism that facilitates the transition from an inflammatory to a reparative state. Apoptotic 
neutrophils induce the polarization of macrophages from M1 to M2 by two primary methods. First, the 
expression on the surface of phosphatidylserine signals on apoptotic neutrophils promotes the 
phagocytic clearance of the apoptotic cells by M1 macrophages. In addition, apoptotic neutrophils 
express scavenging cytokines and chemokine receptors that result in tissue depletion of these 
proteins.17 Furthermore, the secretion of anti-inflammatory and profibrotic cytokines including IL-10 
and TGF-β also are key regulators in the activation of intracellular signals that inhibit the innate 
immune response and promote tissue repair.  
Neovascularization is another key process that occurs in the reparative phase and is crucial for 
supplying nutrients and oxygen to the infarct region. Vasculature growth into the infarct region is 
promoted by the upregulation of growth factors, such as vascular endothelial growth factor (VEGF), 
and growth factor receptors on endothelia cells within the peri-infarct region. Initially, the neo-vessels 
are formed by the migration, proliferation, and alignment of endothelial cells into tubular structures. 
In the later phases of healing, growth factors, such as the platelet-derived growth factor (PDGF), 
promote the reinforcement of the neo-vessels with a mural coating composed of pericytes and smooth 
muscle cells.18 The formation of this mural coating is vital for infarct healing because the attenuation 
of vascular permeability leads to a reduction in leukocyte infiltration and facilitates the transition into 
the reparative phase of cardiac remodeling.  
The increased presence of cardiac fibroblasts and subsequent transdifferentiation to myofibroblasts is 
a hallmark process of the reparative phase in cardiac remodeling. The origin of the fibroblast 
population that is recruited to the infarct region is unclear, however, experimental studies have 
suggested circulating bone marrow progenitors,19 endothelial cells undergoing mesenchymal 
transdifferentiation,20 pericytes,21 resident fibroblasts,22 and interstitial fibroblasts from viable 
periphery tissue are possible sources.23 Once recruited to the infarct site, soluble factors, such as 
transforming growth factor beta (TGF-β), and mechanical stress cause fibroblast conversion to a 
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myofibroblast phenotype which induces proliferation and the promotion of the matrix synthesis.24 
Specifically, a temporary highly plastic matrix primarily comprised of collagen (types I, III, V), fibrin, 
fibronectin, and laminin is formed, which guides migrating cells, and provides a scaffold for 
proliferating cells and allows for the dynamic changes to occur throughout the remodeling process.25 
Furthermore, this ECM deposition is vital to maintain mechanical integrity of the LV after the removal 
of the necrotic tissue. Inadequate ECM accumulation has been shown to cause infarct wall thinning, 
LV dilation, rupture of the LV, and systolic and diastolic dysfunction post-MI.25, 26 In addition, the 
upregulation of matricellular proteins in the infarct region provides binding sites for matrix proteins 
and cell receptors therefore, modulating the behavior of the heterogeneous cell population involved in 
cardiac remodeling.27 Matricellular proteins have also been linked to the regulation of collagen 
fibrillogenesis which is ultimately a precursor to scar maturation.28 The final step of the reparative 
phase is characterized by the maturation and stabilization of the scar tissue that has been deposited. 
This maturation includes the increased deposition of collagen I, degree of matrix crosslinking, 
deactivation of reparative cells, and the reduction in myofibroblasts within the infarct region.29, 30  
Ultimately, the damage to the LV myocardium and subsequent scar formation causes a reduction in 
the cardiac output. Neurohormonal systems are subsequently activated in an effort to maintain adequate 
blood circulation to the body.31 Two primary examples of these mechanisms are sodium and fluid 
retention driven by the release of angiotensin II and aldosterone, and vasoconstriction induced by 
activation of the adrenergic system to increase the blood pressure.32, 33 Although these mechanisms 
initially compensate for the loss in the LV function, they become maladaptive, causing fluid overload, 
steady cardiomyocyte death, and myocardial hypertrophy, which promotes additional LV dysfunction 
and ultimate leads to hearth failure.   
Although many patients survive the myocardial infarction (MI) caused by IHD, the absence of robust 
intrinsic regenerative responses in the heart ultimately leads to heart failure due to the left ventricular 
dysfunction caused by the replacement of functional myocardium with fibrotic scar tissue. Clinical 
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practices aim to limit infarction magnitude by providing timely coronary reperfusion, and reduction in 
microvascular obstruction using pharmacological interventions. These strategies along with significant 
advances in LV mechanical assistance devices have improved patient survival, however, the only 
definitive cure for IHD is heart transplantation which is plagued by the organ-donor shortage.7, 34-36 
Therefore, it is imperative that an alternative treatment option is developed to restore proper heart 
function.  
The following sections review how adult stem cells (Table 2.1) and stem cell-derived secretome have 
been used in cardiac regeneration. In addition, a section will discuss the use of injectable hydrogels as 
delivery devices for growth factors, cytokines, and extracellular vesicles highlighting the criteria 
required for their design for secretome delivery.  
 
2.2 Stem Cell-Based Therapy for Cardiac Regeneration 
Within the last decade, the use of stem cells for cardiac regeneration has emerged as a leading strategy 
in the development of a novel treatment to prevent end-stage heart failure in IHD patients that have 
previously suffered from an acute MI.37 Adult mesenchymal stem cells (MSCs) have emerged as an 
ideal option for clinical translation due to their relative ease of isolation from multiple tissue sources, 
including bone marrow, adipose tissue, umbilical cord blood, and Wharton jelly.38 Furthermore, their 
ability to be expanded ex vivo and lack of major histocompatibility type II markers allows for the 
development of an off-the-shelf product from an allograft.39 Lastly, they exhibit immunosuppressive 
properties and secrete an extensive profile of anti-apoptotic and angiogenic paracrine factors that can 
promote cardiac repair.40 The identification of these positive attributes has led to dedicated efforts to 
assess the safety and efficacy of adult stem cell therapy in clinical trials.41 Therefore, this section is 
dedicated to reviewing the clinical research that has framed the current knowledge on adult stem cell 
therapy for cardiac regeneration in acute MI and IHD patients. Specifically, the focus will be on the 
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promising results derived from Phase I-III clinical trials and how these results have caused a shift in 
the hypothesized mechanism of therapeutic action amongst the scientific community. Lastly, the early 
preclinical data supporting the current widely accepted paracrine mediated mechanism of action 
primarily responsible for the improvements in cardiac function observed after the administration of 
stem cells will be discussed. 
The initial strategy of cell-based therapy for AMI was focused on an intracoronary infusion of bone 
marrow mononuclear cells (BMMNCs) in conjunction with percutaneous coronary intervention to 
prevent further myocardial damage by limiting cardiomyocyte necrosis.42 BMMNCs were the 
predominant cell choice because they do not require ex vivo expansion therefore, they could be 
harvested, isolated, and refused into the same patient efficiently. Initial encouraging results from 
TOPCARE-AMI (Transplantation of Progenitor Cells and Regeneration Enhancement in Acute 
Myocardial Infarction)43 and BOOST (Bone Marrow Transfer to Enhance ST-Elevation Infarct 
Regeneration)44 clinical trials showed improvements in left ventricle ejection fraction (LVEF) and a 
reduction in infarct size after 4-6 weeks in the cell treated group however, these results were limited 
by the lack of a control group and the open label nature of the study, respectively. Despite the 
deficiencies in those initial trials, two double-blinded trials, Leauven-AMI45 and FINCELL46 (Finish 
Stem Cell study), also reported increases in LVEF amongst the cell treated group. These findings were 
further confirmed in the REPAIR-AMI (The Reinfusion of Enriched Progenitor Cells and Infarct 
Remodeling in Acute Myocardial Infarction),47 study. This was a phase III, double-blinded, placebo-
controlled clinical trial that reported an average 5.5% improvement in the LVEF of the BMMNC group 
compared with only 3.0% in the placebo group after 4 months. Furthermore, a reduction in composite 
of death, MI and need for repeat revascularization after 1 year, along with a reduction in mortality at 5 
years was also reported. However, despite these results, the subsequent trials showed contradictory 
results, including the multicenter, double-blinded, placebo-controlled TIME (Use of Adult Autologous 
Stem Cells in Treating People Who Have Had a Heart Attack),48 LateTIME (Use of Adult Autologous 
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Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack),49 SWISS AMI trial (Swiss 
Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction),50 BOOST-2 trial,44 and 
MiHeart/AMI trial.51 Given the inherent heterogeneity of BMMNCs, Quyyumi et al. selected a CD34+ 
subpopulation of endothelial progenitor cells isolated from bone marrow to study in their PreSERVE-
AMI study (The NBS10 Versus Placebo Post ST Segment Elevation Myocardial Infarction)52 trial. 
After 1 year, there was no significant improvement in LVEF or resting myocardial perfusion however, 
when the data was adjusted using duration of ischemia, a dose-dependent improvement in LVEF, 
infarct size, and mortality were observed indicating how a purified cell population may provide 
beneficial effects.  
As the preclinical evidence on the immunomodulatory, anti-fibrotic, and angiogenic behavior of 
mesenchymal stem cells isolated from bone marrow, adipose tissue, umbilical cords, and Wharton’s 
jelly has expanded, IHD clinical trials have conducted studies analyzing the safety and efficacy of 
mesenchymal stem cells as well. The majority of clinical trials have focused on bone marrow-derived 
stem cells (BMSCs). One of the initial clinical trials using BMSCs was a phase II randomized, placebo-
controlled trial called TAC-HFT (Transendocardial Autologous Cells hBMC in Ischemic Heart 
Failure),53 which compared autologous, BMSCs, BMMNCs and placebo. Despite the lack of 
significant improvement in LVEF in response to either cell treatment, several quality of life (QoL) 
scores significantly increased and an average reduction in infarct size of 19% was reported in the 
BMSC group while the BMMNC and placebo group remained the same. These results indicate that 
BMSCs may have had an anti-fibrotic effect causing a positive effect on exercise capacity. In addition, 
the results suggest that a significant reduction in LVEF may not be necessary for statistically significant 
improvements in QoL and function capacity. Another randomized, double-blinded trial called 
TRIDENT (Transendocardial Stem Cell Injection Delivery Effects on Neomyogenesis),54 analyzed the 
effect of allogenic BMSC dose on LVEF. Although a larger follow-up clinical trial with definitive end 
points is needed, they observed a significant reduction of 3.7% in LVEF after 12 months only in the 
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group that received 100 million cells and not in the 20 million cell dose group. These results support 
the general understanding that a large cell dose will most likely be needed in order to overcome low 
engraftment and viability after cell delivery. The POSEIDON trial (Percutaneous Stem Cell Injection 
Delivery Effects on Neomyogenesis)55 was the first to analyze the immune-privilege properties of 
BMSCs by comparing the safety and efficacy of autologous and allogeneic cells at 3 different doses in 
a randomized, double-blinded phase I/II trial. At 1 year, the scar size was 33% less than baseline and 
the left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) 
decreased in both groups. However, a significant reduction in the LVEDV was only detected in the 
allogeneic group therefore, supporting the hypothesis that the potency of MSCs derived from young, 
healthy donors is greater as compared with those from older patients with IHD. Finally, the MSC-HF 
trial assessed the transendocardial stem cell injection (TESI) of autologous BMSCs in a severe IHD 
patient population with LVEF <45%. There was a significant increase in the LVEF of 6.2% and 
reduction of LVESV in the BMSC group compared to the placebo. This difference in these results 
compared to the TAC-HFT and POSEIDON trails could be due to a higher baseline, difference in cell 
selection and dose. When taken together, the results from these 3 clinical studies have proven the safety 
of BMSCs and indicate that they may improve LVEF, functional capacity, cardiac remodeling, and 
QoL. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) represent another MSC population 
that has clinical potential due to their high proliferative potential, longevity, immunomodulatory 
properties, and noninvasive isolation procedure.56 The RIMECARD (Randomized Clinical Trial of 
Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells on Cardiomyopathy),57 trial 
investigated the intravenous infusion of allogeneic UC-MSCs in a phase I/II randomized, double-
blinded, placebo-controlled trial. After 1 year, the UC-MSC treated patients were the only group that 
showed a significant increase in LVEF of 7%, improvement in NYHA class, and QoL scores. Lastly,  
ASCs represent the third main clinically relevant source of MSCs for IHD due to their 
immunomodulatory, homing, angiogenic, and reparative properties as well as the relative ease of an 
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abundant isolation from subcutaneous tissue.58 A small trial called the PRECISE trial (Randomized 
Clinical Trial of Adipose-Derived Stem Cells in Treatment of Non Revascularizable Ischemic 
Myocardium),59 demonstrated the safety and feasibility of a TESI of autologous adipose-derived stem 
cells (ASCs). The larger Athena trials60 that followed PRECISE assessed a similar protocol with 2 
doses of autologous ASCs (40 and 80 million cells) versus a placebo however, the only improvement 
that was observed was in QoL scores in the cell treatment groups.  
Despite the heterogeneity between the clinical trials summarized above, one consistent observation 
amongst the majority of the studies is the lack of cell retention and subsequent engraftment within the 
damaged myocardium. Regardless of the cell type, many studies have shown that the majority of cells 
that were successfully delivered to the heart die within the first weeks.40, 61 Furthermore, in the trials 
that showed positive therapeutic results, the number of cells that actually differentiated into resident 
cell populations was not large enough to account for the observed clinical benefits.62 Therefore, 
scientists began to formulate a new hypothesis behind the therapeutic MSC mechanism of action that 
did not focus on the delivered cells transdifferentiating into new functional tissue. In 2004, Kinnaird 
et al. showed that BMSCs secreted vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF) and other cytokines into culture medium.63 These cells were used in a hindlimb ischemia 
preclinical model and showed a positive improvement in collateral perfusion that was presumably 
attributed to arteriogenic cytokines that were secreted by the injected cells. Then, in 2005 Gnecchi et 
al. demonstrated that an intracardiac injection of cell-free MSC culture medium modified to express 
the survival gene AKT1 could reduce the infarct size in rats with coronary occlusion.64,65 This scientific 
evidence marks the conception of the paracrine hypothesis in which the primary MSC mechanism of 
therapeutic action for cardiac regeneration is the secretion of paracrine signals that promote several 
endogenous reparative processes.66 Several studies have provided further support for this hypothesis 
and therefore, the paracrine hypothesis in now widely accepted as being primarily responsible for tissue 
regeneration and cardiac functional improvements observed after the administration of MSCs.67    
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2.3 Stem cell-derived secretome 
As stated in the previous section, the current clinical evidence shows that the primary regenerative 
mechanism of action of MSCs is the secretion of paracrine molecules (cytokines, growth factors, 
metalloproteinases,68, 69 mitochondrial transfer70 and extracellular vesicles (EVs)) that modulate the 
damaged tissue regeneration and stimulate endogenous repair mechanisms rather than the engraftment 
and transdifferentiation of the MSCs at the therapeutic site.62, 64, 65, 71 This mixture of bioactive 
paracrine molecules known as secretome can be isolated in vitro and has gained interest among 
scientists as a possible cell-free treatment option for tissue regeneration. The following sections will 
review the composition, therapeutic action and the available strategies to modulate secretome 
composition for cardiac regeneration post-AMI. The overview on secretome-based therapies will be 
concluded by a discussion on the vital aspects to consider to facilitate the translation of this type of 
treatment into the clinic. However, the discussion will not take into consideration the use of secretome 
paracrine factors to influence cardiac metabolism, contractility, stem or progenitor cell recruitment and 
cardiomyocyte proliferation since these topics are out of the scope of this thesis.1, 72, 73   
2.3.1 Secretome composition and therapeutic action in cardiac regeneration 
The broad repertoire of paracrine molecule types in secretome is ideal for the activation of multiple 
therapeutic pathways to address complex pathologies. This is particularly advantageous for myocardial 
regeneration because, although fibrotic scar formation is the ultimate result of LV remodeling caused 
by IHD, a complex series of interconnected processes are ultimately responsible for this outcome.72 
These processes include lack of proper blood supply to the LV, cardiomyocyte apoptosis followed by 
necrosis, inflammation, extracellular matrix degradation, and fibrosis.74 To date, dedicated efforts 
investigating the MSC-derived secretome have been focused on identifying and promoting the 
secretion of growth factors, cytokines, miRNA, and extracellular vesicles that are of interest for 
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myocardial regeneration due to their anti-apoptotic, immunomodulatory, and angiogenic properties. 
The main components based on their relevance to promote cardiac regeneration are summarized in 
Table 2.2. These soluble proteins, small nucleic acids and vesicles are molecular signals that are 
secreted by cells to interact with other recipient cells either directly or indirectly. Precisely, secretome 
can influence intracellular pathways of damaged cells or indirectly can induce the secretion of other 
functional biomolecules from nearby cells.72 Additionally, the secretome composition has been found 
to vary depending on the type of MSCs and their tissue of origin.75-78  
2.3.2 Methods of Modifying the Secretome Composition 
As stem cell therapy research has progressed, it has become clear that signaling cues can modify the 
composition of paracrine molecules secreted by stem cells in addition to influencing stem cell behavior. 
Therefore, scientists have used this knowledge to promote the in vitro production of MSC-derived 
secretome with a composition that has a higher therapeutic efficacy in promoting cardiac regeneration. 
One established method is defined as physiological conditioning in which MSCs are cultured in 
hypoxic (5% O2) and serum deprived conditions (0% serum) to mimic the ischemic myocardium. 
Several studies have demonstrated that under these culture conditions MSCs will secrete a significantly 
higher concentration of angiogenic and cardioprotective growth factors, miRNA encapsulated in 
exosomes, and cytokines.79-82 One specific study demonstrated that the secretome isolated from MSCs 
cultured in serum deprived conditions was able to exhibit proangiogenic and cardioprotective behavior 
in vitro. Similarly, the isolated secretome could, promote capillary formation within the peri-infarct 
region, reduce the infarct size and the extent of cardiomyocyte apoptosis, and limit ventricular 
remodeling in vivo.83 In order to gain insight into the specific molecules that were responsible for these 
promising therapeutic results a gene array of the MSCs and cytokine array of the secretome were 
completed and compared to fibroblasts and secretome isolated from fibroblasts, respectively. In the 
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MSC group 32 overexpressed genes encoding for secreted factors and 15 cytokines were present at a 
higher concentration in the secretome.  
Another method used to enhance the secretome composition is genetic manipulation.84 In their seminal 
paper, Gnecchi et al. used this method to overexpress protein kinase B (Akt) in MSCs and observed 
after culturing these cells in hypoxic conditions that the resulting secretome had cardioprotective 
effects on isolated adult rat ventricular cardiomyocytes and significantly reduced the infarct size in a 
rodent AMI model after MSC delivery.65 Specifically, the secretome was able to inhibit cardiomyocyte 
apoptosis and reduce Caspase 3 release. In later publications, these results were attributed to the 
presence of hypoxic induced Akt regulated stem cell factor in the secretome and upregulation of 
secreted frizzled related protein 2  in the Akt-MSCs.85  
Molecular and pharmacological conditioning using cytokines, growth factors and lipopolysaccharides 
represents another method to modulate the secretome composition. Although there have been no 
studies to date assessing the myocardial regeneration efficacy of MSC-derived secretome using this 
conditioning method, MSC studies have shown that TNF-α increases the secretion of VEGF, 
antioxidants and angiogenic growth factors are secreted more after melatonin treatment causing 
increased angiogenic efficacy, and MSCs conditioned with lipopolysaccharides secreted a significantly 
greater concentration of anti-inflammatory cytokines.86-88  
Additionally, cell-cell interactions and physical conditioning has been proven to have a profound 
impact on the MSC secretome profile. For example, by culturing MSCs in 3D spheroids scientists have 
shown a significant increase the secretion of proangiogenic and anti-inflammatory growth factors and 
cytokines including, VEGF, bFGF, angiogenin, HGF, FGF2, angiopoietin, STC1, PGE2 and TSG-6.89-
93 Ylostalo et al. reported that the secretome isolated from MSCs spheroids inhibited the pro-
inflammatory behavior of lipopolysaccharide-stimulated macrophages. Specifically, the MSC 
spheroid-derived secretome inhibited the secretion of pro-inflammatory cytokines (TNFα, CXCL2, 
IL6, IL12p40, and IL23), promoted the secretion of anti-inflammatory cytokines (IL10 and IL1ra), and 
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modulated the expression of the activated M2 marker CD206.93 These results were attributed to the 
presence of PGE2 in the MSC spheroid secretome through microarray analysis and PGE2 inhibitor 
studies using silencing RNA. This study proves that MSC secretome is individually capable of 
promoting anti-inflammatory processes under the optimal culture conditions. Furthermore, Skiles et 
al. determined that the cell number used to form each spheroid influenced both the VEGF concentration 
secreted and the angiogenic efficacy assessed by an in vitro HUVEC proliferation assay.94 These results 
highlight the importance of optimizing and maintaining specific culture conditions to ensure a precise 
control over the MSC-derived secretome composition. Other physical conditioning parameters that 
have been studied for secretome production include, shear stress and substrate mechanical 
properities.95, 96 Overall, this vast array of culture parameters that influence the profile of secreted 
paracrine factors by MSCs emphasizes the importance in thorough optimization and characterization 
of the MSC culture conditions for ideal therapeutic efficacy of MSC-derived secretome for myocardial 
regeneration.      
2.3.3 Clinical Translation of secretome-based therapies 
A secretome-based treatment has several advantages over traditional stem cell-based therapies, 
including potential in vitro modulation of paracrine molecule composition, reduced potential for an 
oncogenic response, greater ease of delivery, and lack of an immunogenic response allowing for an 
allogenic or off-the-shelf treatment option. Despite these advantages and the promising results 
described in the previous section, there are unresolved concerns associated with secretome-based 
therapies that will need to be addressed prior to clinical translation. One immediate challenge is the 
presence xenogeneic serum in the media used to culture MSCs for the production of a therapeutic 
secretome in preclinical studies. The presence of serum creates two main issues for clinical translation. 
First, from a regulatory and safety perspective, xenogeneic components pose a risk of contamination 
with infectious agents such as prions and viruses and therefore, their use as stem cell therapy products 
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is highly discouraged by the Food and Drug Administration (FDA), European Medicines Agency 
(EMA), and other regulatory bodies.97, 98 Furthermore, serum is a highly abundant in proteins, which 
makes the identification and isolation of low-abundance secreted proteins challenging using analytical 
techniques.99 In addition, although the complete removal of serum from the culture media would be an 
apparent solution, studies have shown that its removal impacts MSC behavior and the profile of 
secreted factors further emphasizing the importance of data-driven choices in auxiliary media 
component selection.100  
As described in the previous section, the heterogeneous composition of MSC-derived secretome 
provides the opportunity to promote several different endogenous regenerative responses that would 
lead to a more holistic repair of the myocardium. However, this complex composition poses numerous 
translational challenges. One of the main challenges to date is the development of robust and accurate 
potency assays which accurately quantify the biological activity of the MSC secretome.101 According 
to the International Conference on Harmonization (ICH), potency assays quantitatively measure the 
biological activity of a product based on the product attribute that has been correlated to the relevant 
biological properties.102 Therefore, potency assays are mandated by the FDA and EMA as vital 
components of the drug approval process because they set the efficacy standard that ensures 
consistency from drug discovery to market release. The first step to the development of a potency assay 
is the identification of the main mode of action (MOA) of the secretome and the paracrine molecules 
that are responsible for this response. To date, the majority of the studies have focused on the 
therapeutic benefit of exosomes or complete secretome without characterizing the therapeutic efficacy 
of the individual components. Due to the proven pleiotropic nature of the paracrine molecules that are 
present in the MSC-derived secretome, it will be paramount to characterize the influence MSC-
secretome has on each type of cell that collectively forms the heterogeneous myocardium.72, 103 In 
addition, the development and use of animal models that accurately mimic current clinical protocols 
for AMI will be vital in obtaining representative data that can predict clinical trial success.104 
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Furthermore, this characterization will require intricate analytical separation and characterization 
techniques for the enrichment and purification of only essential components. The heterogeneous 
composition of MSC-secretome makes this challenging because these methods rely on specific 
chemical and physical characteristics of each molecule.99 It is likely that there will be remaining non-
essential components present in the final product which will need to be proven nontoxic in pre-clinical 
animal models. 
Following robust preclinical results, clinical studies will require large scale manufacturing that will 
demand strict quality control guidelines to be established and maintained due to the sensitivity of the 
secretome composition in regards to changes in the MSC microenvironment.101 Once the optimal 
therapeutic dose concentration, number of doses and time of administration after an MI have been 
identified, the stability over time and under distribution conditions will need to be studied. These 
stability studies will determine the formulation and storage methods that allows for the necessary shelf-
life duration and distribution process which is ultimately determined by the treatment duration and 
location of the patient population. Once again, the complexity of the MSC secretome composition will 
pose a unique challenge in determining the optimal formulation that will retain the bioactivity of each 
crucial component and concessions will likely need to be made. Lastly, the cost of the treatment will 
be of the utmost importance throughout the entire development process to ensure the treatment is 
feasible for the patient population once it reaches the market.  
 
2.4 Injectable hydrogels* 
Injectable hydrogels represent an ideal strategy for the delivery of therapeutic secretome for cardiac 
regeneration due to several parameters required for hydrogel synthesis that can be modified in order to 
                                                          
* Sections published as Hasan, A., Khattab, A., Islam, M. A., Hweij, K. A., Zeitouny, J., Waters, R., ... & 
Paul, A. (2015). Injectable hydrogels for cardiac tissue repair after myocardial infarction. Advanced 
Science, 2(11), 1500122. 
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tune the delivery properties of the resulting hydrogel. These include the type of polymer, the degree of 
crosslinking and the mechanism of gelation, which provide great versatility in the design of the ideal 
hydrogel carrier for secretome delivery. Additionally, injectable hydrogels can be applied with 
minimally invasive procedures and can provide a spatio-temporal control over the dose released, which 
minimizes off target effects and associated risks to the patient. Precisely for AMI patients, 
intramyocardial injections are ideal because the dose can be delivered directly into the LV using an 
epicardial method or a catheter technique. The main factors that are essential to consider in the 
development of injectable hydrogels for myocardial regeneration are the physical and material 
properties, primarily related to hydrogel mechanics, and the biological properties involved in processes 
such as cell adhesion.105 In the following sections the different types of polymers and hydrogels will 
be discussed with a particular focus on the benefits and drawbacks of using natural versus synthetic 
polymers. Then, the unique and beneficial properties of composite hydrogels will be reviewed with 
specific examples given. Lastly, the use of injectable hydrogels for the delivery of biomolecules will 
be discussed because these strategies can give insight into effective strategies for the delivery of stem 
cell-derived secretome.  
2.4.1 Natural vs. Synthetic Polymers 
Injectable hydrogels can be made from a vast range of polymers that can be classified as either natural 
or synthetic in origin.106 Both natural and synthetic biomaterials present strengths and weaknesses in 
terms of biomedical applications that must be considered prior to the hydrogel synthesis. Naturally-
derived hydrogels are largely biocompatible and supportive of cellular activities however, they exhibit 
low mechanical strength, may induce an immune response, and are subject to batch-to-batch variations. 
Furthermore, structural modification of natural polymers is difficult due to the complexity and 
relatively less amount of control over the degree of functionalization.107 Despite these drawbacks, 
naturally-derived biomaterials continue to be a promising component of hydrogels due to their 
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bioactivity, biodegradability, and the fact that many of them are naturally present in the human body. 
This correlation can be extremely valuable because one of the major goals of hydrogel synthesis is to 
produce a structure or delivery device that is analogous to the native tissues. Some examples of natural 
polymers that have shown significant utility in regenerative medicine include collagen, gelatin, 
hyaluronic acid, fibrin, and decellularized extracellular matrix (ECM), among several others.105 
Collagen and gelatin exhibit ideal biocompatibility, and thermal reversibility however, their low 
physical strength can be a concern that is commonly overcome by using crosslinking mechanisms.108 
Hyaluronic acid is a component of glycosaminoglycans that is both biocompatible and biodegradable 
and has been investigated for wound healing applications. Fibrin hydrogels use the naturally occurring 
process of fibrinogen polymerizing with thrombin at ambient temperatures to form a crosslinked 
hydrogel.109 Cell-associated enzymatic activity promotes the degradation of fibrin during cell 
migration facilitating matrix remodeling.110 Lastly, ECM hydrogels have been used because they are 
capable of replicating the native cellular microenvironment with specific characteristics based on the 
tissue from which they are extracted. Their composition consists of native chemical and biophysical 
cues and therefore improve the attachment, survival and function of the transplanted cells. Besides, 
each tissue has a distinct composition of fibrous proteins, proteoglycans, and glycosaminoglycans that 
make up its ECM.111 Conversely, synthetic hydrogels are particularly useful for tissue engineering and 
regenerative medicine applications because they traditionally exhibit strong mechanical properties and 
can be chemically modified with relative ease.112 However, a significant drawback that needs to be 
properly accounted for is that synthetic polymers are also generally biologically inert because they lack 
cell binding motifs. Some of the most predominant synthetic polymers that have been used for delivery 
devices in regenerative medicine include poly(acrylic acid) derivatives (PAA), polyethylene glycol 
(PEG), and polypeptides.105 For PAA hydrogels, the permeability and hydrophilicity can be tailored 
by selecting particular cross-linking mediators however, PAA is not completely biodegradable which 
can interfere with native tissue growth.113 In contrast, PEG is a biocompatible and hydrophilic polymer 
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that has been approved by the FDA for several biomedical applications. PEG is specifically used to 
prepare biological conjugates,114 modify surfaces,115 and stimulate cell membrane synthesis.113 It does 
not cause immune responses and has low cell adhesion and protein binding which can serve as a benefit 
or a hindrance depending on the application.116, 117 Lastly, polypeptides can form nanofiber hydrogels 
by means of charge interactions, hydrogen bonding, and other interactions.118 The use of peptides is 
very beneficial since they can act as a scaffold that mimics natural extracellular matrices (ECM).119  
2.4.2 Composite hydrogels 
In addition to various natural and synthetic polymer-based hydrogels, a number of hybrid and 
composite hydrogels have also been tested for application in cardiac repair. Some specific examples 
include ECM-fibrin hydrogels,120 alginate-chitosan hydrogels,121 and ECM-polyethylene glycol 
hydrogels.122 More specifically, a fibrin-alginate composite hydrogel was injected into the heart of an 
AMI animal model and the results showed that the expansion of the infarcted region of the left ventricle 
stopped upon injection of the hydrogel. Additionally, myocardial stiffness was relatively higher than 
those of control groups and fibrous collagen in the myocardium border region was increased.123 Hence, 
the soluble collagen content in the infarcted zone was decreased, which accounts for the deceleration 
of damaged tissue enlargement. Thus, injection of fibrin-alginate as well as other suitable composite 
hydrogels may provide an effective treatment to suppress the expansion of infarcted tissue. Another 
recent strategy for achieving multiple functionalities in hydrogels is to incorporate various 
nanoparticles within them, thereby developing nanocomposite hydrogels. The nanoparticles to be 
incorporated can be polymeric, metallic, ceramic, inorganic, or carbon-based while the strategies of 
incorporation can be physical entrapment, noncovalent immobilization, or covalent immobilization.124, 
125 The addition of such nanoparticles to a polymer network can improve the mechanical and electrical 
properties of the hydrogel to better align with the native tissue. Specifically, in the case of myocardial 
regeneration applications, carbon-based or metal nanomaterials have been incorporated in polymer 
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networks to match the electrical conductivity of the myocardium therefore, causing minimal 
disturbance to the heart beat and providing a representative environment for the MSCs that can guide 
them towards a cardiac lineage.126, 127 The introduction of a nanomaterial within a polymer network 
can also modulate the physical properties of the hydrogel causing it to be thixotropic.128 This is 
particularly advantageous for injectable hydrogels because it allows the treatment to be easily 
administered through a syringe but it regains its mechanical integrity once the sheer stress is removed. 
This effect helps to maximize the retention of the gel at the therapeutic site while minimizing 
undesirable off-target effects of the treatment. Scientists have successful formulated injectable 
nanocomposite hydrogels that exhibit these properties using nanosilicate and have used them to for the 
controlled delivery of therapeutic growth factors.129, 130 
2.4.3 Biomolecule delivery using injectable hydrogels 
The encapsulation of biomolecules within injectable hydrogels has been shown to result in the 
controlled release of molecules such as growth factors, chemokines, miRNA and EVs therefore, 
providing optimal sustained release while increasing the molecules half-life compared to a direct bolus 
injections.106  An example of this is the use of a pH and temperature responsive hydrogel that increased 
the retention of bFGF in the acidic microenvironment of the ischemic heart.131 After 28 days, there was 
a significantly greater increase in capillary density, arteriolar density, and fractional shortening in the 
growth factor-loaded hydrogel group indicating an improvement in angiogenesis and cardiac function. 
Another study using a thermosensitive hydrogel composed of poly δ-valerolactone and polyethylene 
glycol assessed how different VEGF loading methods effected the therapeutic efficacy of the resulting 
VEGF-loaded hydrogel in vivo.132 They observed that when VEGF was conjugated, instead of being 
simply mixed into the hydrogel, there was a significant increase in blood vessel density and an 
improvement in heart function. These results further emphasize the influence of biomolecule release 
kinetics and hydrogel design has on the efficacy of regenerative treatments. As stated in the previous 
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section on stem cell-derived secretome, one major challenge associated with myocardial tissue 
regeneration is the heterogeneity of the native tissue. With regards to the use of biomolecules, scientists 
have focused on delivering more than one therapeutic factor per treatment in an effort to promote 
multiple endogenous regenerative processes. To support this multifactor delivery, scientists have 
developed hydrogels that will sequentially release therapeutic growth factors leading to a greater 
degree of spatio-temporal controlled delivery and therefore, a more favorable progression of 
myocardial regeneration.133 Ruvinov et al. formulated an injectable affinity-binding hydrogel for the 
dual delivery of IGF-1 and HGF. This hydrogel design exploits the difference in heparin binding 
affinities between the two growth factors which directly correlates to their rate of release from the 
hydrogel. The resulting progressive release of IGF-1 followed by HGF lead to an attenuation of infarct 
expansion, reduced fibrosis, increased angiogenesis and induced cardiomyocytes cell cycle re-entry. 
In addition, the hydrogel matrix was able to protect the growth factors from proteolytic degradation. 
Similar outcomes in angiogenesis and decreases in infarct size were seen in another study with the dual 
delivery of SDF-1 and an angiogenic peptide (Ac-SDKP) when using a biomimetic hyaluronic acid 
(HA) injectable hydrogel as opposed to each of the therapeutic factors being delivered individually.134 
These studies highlight how beneficial a thorough hydrogel design can be to increase the therapeutic 
efficacy of biomolecule regenerative medicine strategies. Other examples of reported positive effects 
in myocardial regeneration resulting from the encapsulation of therapeutic factors within injectable 
hydrogels include the use of self-assembling peptides for PDGF-BB and FGF-2 delivery,135 sonic 
hedgehog protein and IL-10 encapsulated in a PEG hydrogel,136 recombinant TIMP-3 delivered using 
a HA hydrogel,137 endothelial progenitor cell-derived extracellular vesicles delivered within a modified 
HA shear-thinning hydrogel,138 miR-29B delivery using a hyaluronan-based hydrogel,139 and miR-
1825 encapsulation in a gelatin-silicate nanocomposite hydrogel.140 Together, these studies highlight 
the broad array of biomolecules that can be released by injectable hydrogels formulated to overcome 
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specific drawbacks associated with the delivery of the free biomolecules therefore, promoting a more 
efficient myocardial regenerative response. 
 
3. CONCLUSIONS 
As the burgeoning field of myocardial regeneration advances and scientist’s knowledge grows, the 
underlying goal to restore proper function to a damaged heart post-AMI remains. This chapter provided 
an appropriate overview of the complexity that encompasses this goal beginning with the 
pathophysiology of an AMI and IHD, largely focusing on the cellular biology. Salient phase I-III 
clinical trials using adult stem cells were highlighted and, although adult stem cell therapy has not been 
definitely shown to be effective in the treatment of AMI, together these studies did demonstrate that 
stem cells act via paracrine mechanisms and not through long-term engraftment.66 Therefore, the 
subsequent sections of the chapter have emphasized the use of stem cell-derived secretome as an 
alternative treatment for myocardial regeneration in AMI patients with IHD. Several conditioning 
strategies are being used to alter and optimize the stem cell-derived secretome composition including, 
mimicking the physiological ischemic tissue, genetic modification, the addition of proteins and 
lipopolysaccharides to the culture media, and the promotion of cell-cell interactions by altering the 
physical arrangement of the stem cells in culture. Each of these techniques has been shown to promote 
the secretion of a greater concentration or more diverse composition of paracrine molecules into the 
stem cell secretome that are able to promote therapeutic processes such as angiogenesis, 
immunomodulation, cardioprotection and anti-fibrosis. Although promising, these studies largely lack 
a thorough characterization of the heterogeneous secretome composition and the effect these 
pleiotropic paracrine molecules have on each of the cell types that comprise the myocardium. This type 
of detailed characterization will be essential in identifying the secretome therapeutic MOA and 
therefore, the clinical translation of a MSC-derived secretome treatment for myocardial 
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regeneration.101 In addition to the importance of a thorough understanding of the biological activity of 
the MSC-derived secretome, the development of the device that delivers a precise secretome dose to 
the damaged myocardium at the correct time is vital to ensure optimal therapeutic efficacy of the 
treatment. As previously mentioned, injectable hydrogel strategies have gained attention for this 
purpose due to the opportunity for more minimally invasive, clinically relevant delivery procedures.105 
However, it is important to note that an ideal injectable hydrogel formulation should be composed of 
materials that produce a hydrogel which is biocompatible, regains mechanical integrity after injection 
and can modulate the release of the diverse paracrine molecules present in the MSC-derived secretome. 
Thus, nanocomposite hydrogels that fulfill these criteria may provide the ideal delivery vehicle for 
MSC-derived secretome to promote myocardial regeneration.
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CHAPTER 3. STEM CELL SECRETOME-RICH NANOCLAY 
HYDROGEL: A DUAL ACTION THERAPY FOR MYOCARDIAL 
REGENERATION†
 
ABSTRACT 
Several strategies can be adopted to augment the secretome composition in angiogenic growth 
factors. For example, it is well known that stem cells when cultured in stressful condition such as 
hypoxia and serum deprivation can secrete a larger amount of angiogenic growth factors leading 
to the production of a more beneficial secretome. Another effective approach to induce stress in 
the cells, which has been investigated in this study, consists of culturing stem cell as spheroids. 
Precisely, human bone marrow derived stem cells (hMSCs) have been cultured as spheroids using 
a polydimethylsiloxane (PDMS) microwell device. The concentration of the angiogenic growth 
factors secreted by hMSCs spheroids has been compared to the secretome produced by hMSCs 
cultured in a traditional monolayer. Subsequently, the secreted growth factors have been loaded in 
a nanocomposite scaffold composed of gelatin methacrylamide (GelMA) and nanosilicate with the 
goal of identifying a model hydrogel delivery system to promote the sustained release of 
angiogenic growth factors present in the secretome. The release profile of key angiogenic growth 
factors from the secretome-loaded nanocomposite hydrogels was evaluated and it was confirmed 
that nanosilicate could control the rate of release of the loaded proteins. Finally, the angiogenic 
and cardioprotective properties of the released growth factors were confirmed upon delivery from 
the model hydrogel platform using several angiogenic and cardioprotective cell assays in vitro. 
                                                          
† Published as Waters, R., Pacelli, S., Maloney, R., Medhi, I., Ahmed, R. P., & Paul, A. (2016). Stem cell 
secretome-rich nanoclay hydrogel: a dual action therapy for cardiovascular regeneration. Nanoscale, 
8(14), 7371-7376. 
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3.1 INTRODUCTION 
Nanocomposite hydrogels have emerged as a valuable tool in tissue engineering and regenerative 
medicine as they provide tunable platforms to facilitate the formation of functional tissues.141-143 
In addition, they can be used as a carrier of drugs or growth factors by selecting a suitable 
nanomaterial, which can efficiently interact with the loaded biomolecule.144 Specifically, the 
surface area, charge density and presence of reactive functionalities of the nanomaterial are the 
major parameters that dictate the loading efficiency and release kinetics. A variety of nanoscale 
materials are available for these applications, such as synthetic polymers, carbon-based nanotubes 
(CNTs), graphene oxide (GO) and nanodiamonds.145-148  
These nanomaterials have been successfully embedded in polymeric networks as a delivery 
platform for therapeutics. However, their clinical potential in regenerative medicine, particularly 
for carbon based materials, is currently limited by inefficient loading of multiple therapeutic 
molecules, non-ideal release kinetics, biodegradability and associated cytotoxicity.149, 150   
A possible alternative to address these problems is the use of biodegradable, biocompatible, two 
dimensional synthetic nanoclay materials.151 Laponite (Na+0.7 [(Si8Mg5.5Li0.3)O20(OH)4]
-0.7) is an 
example of synthetic clay from the smectite family that consists of disk-shaped particles with a 
diameter of approximately 25 nm and a 1 nm thickness.152, 153 These nanoparticles provide superior 
physical, chemical, and biological utility when compared to other 2D nanoparticles, such as 
graphene oxide, due to their uniform shape, discotic charged surface, and high surface-to-volume 
ratio.152 These properties allow for anisotropic interactions with anionic, cationic, and neutral 
polymers to form physically crosslinked networks. In addition, these same interactions can be 
useful in modulating the release kinetics of drugs and biomolecules.154 A previous study has 
reported successful retention and controlled release of vascular endothelial growth factors (VEGF) 
by adsorbing the bioactive Laponite surface through electrostatic interactions.155 The 
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VEGF/Laponite complex was then encapsulated in a collagen scaffold showing enhanced 
angiogenesis in vivo when compared to a collagen scaffold just containing VEGF. This result was 
attributed to the sustained release in the presence of the synthetic clay.  
Nonetheless, scientists have proven that the delivery of multiple growth factors simultaneously 
can provide an increased therapeutic benefit when compared to monotherapy.133, 156, 157 This is 
particularly true for cardiovascular diseases in which a mixture of paracrine growth factors has 
been shown to promote local angiogenesis and regenerate myocardial tissue. A natural way of 
producing growth factor-rich conditioned media, also known as secretome, is culturing 
mesenchymal stem cells (MSCs) under specific stressful conditions such as hypoxia and serum 
deprivation.  
The secretome, isolated from MSCs, has been shown to have cardioprotective abilities, as well as, 
promote angiogenesis when injected into the peri-infarct area.158-160 However, the efficacy of this 
treatment has been hindered by the lack of retention of the secretome components at the site of 
injury. A nanocomposite hydrogel platform may offer a possible solution to achieve its full 
therapeutic benefits. This method will also offer an alternate strategy to the widely used stem cell 
transplantation approach for delivering the paracrine factors. 
Here we investigated the possibility of using Laponite nanosilicates and gelatin methacrylate 
(GelMA) to form a nanocomposite hydrogel for controlled release of stem cell secretome.  The 
overall efficacy of this therapeutic device will be determined following the assessment of two main 
objectives. First, the effect of nanoclay in controlling the release kinetics of the growth factors 
present in the secretome needs to be assessed. Second, the proangiogenic and cardioprotective 
ability of the bioactive nanocomposite hydrogel had to be determined. These two aspects are 
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necessary for the successful application of this nanocomposite hydrogel for cardiac regeneration 
as shown in the schematic (Fig 3.1). 
 
3.2 MATERIALS AND METHODS 
3.2.1 Preparation of the nanocomposite hydrogels  
Synthetic silicate nanoplatelets (Laponite XLG) SiO2 (59.5%), MgO (27.5%), Na2O (2.8%) and 
Li2O (0.8%) with low heavy metals content were supplied by Southern Clay Products, Inc. 
(Louisville). Gelatin type A from porcine skin, methacrylic anhydride, Irgacure 2959, were used 
without further modification from the manufacturer (Sigma-Aldrich, St Louis, MO). 
Nanocomposite hydrogels were prepared by mixing a GelMA solution (5% w/v) with different 
concentrations of Laponite (0.4, 0.8, and 1.0% w/v). Irgacure 2959 (0.5% w/v) was added prior to 
photoirradiation under UV light. In order to load the nanocomposite hydrogels with secretome 250 
μL of polymeric mixture was combined with the 250 μL of media containing secretome prior to 
photoirradiation. Hydrogels with a thickness of approximately 3.5 mm and a diameter of 4 mm 
were photocrosslinked at 5 mW/cm2 for 10 minutes for mechanical testing. Young’s Modulus was 
calculated using the slope of the stress strain curve in the region up to 10% of strain161.  
3.2.2 Harnessing the MSC secretome using a microfluidic device 
A microfluidic device was fabricated using a method previously reported.162 hMSCs were first 
cultured in 2D conditions using DMEM supplemented with 1% L-glutamine, 1% 
penicillin/streptomycin, and 10% FBS. hMSCs (passage 2-5) were then trypsinized and a 250 μL 
solution with a cell density of 5 x 106 cells ml-1 was injected into the device ensuring an even 
distribution throughout all the wells. The hMSCs were incubated in a vertical position at 37oC 
incubator for 48h to allow formation of spheroids and secretion of paracrine factors in conditioned 
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media (secretome). Quantification of the growth factors in the secretome was carried out using 
respective ELISA kits (R&D Systems). 
 
3.2.3 Characterization of nanocomposite hydrogels  
Compression studies of the nanocomposite hydrogels were investigated using an RSA-III dynamic 
mechanical analyser (TA Instrument; New Castle, NE). Samples were cyclically compressed (n=2) 
up to 25% of their original height at a rate of 0.005 mm/s in order to obtain stress versus strain 
curves. Then, the compressive modulus was calculated as the slope of the stress versus strain curve 
from 0% to 10% strain. After the mechanical characterization, secretome release kinetic studies 
were carried out. The secretome loaded nanocomposite hydrogels were incubated at 37°C in 100 
µL of phosphate buffer solution (PBS) for 15 days. The PBS was changed every 3 days and ELISA 
was used to quantify the amount of VEGF and FGF2 in the PBS incubation solution at each time 
point.  
3.2.4 Analysis of angiogenic potential of hydrogels 
For cell study purposes, HUVECs were cultured in normal endothelial growth medium with 
growth supplements (EGM-2 BulletKit without additional VEGF and FGF, Lonza, Walkersville, 
MD) and 1% penicillin/streptomycin. Passage 6-9 HUVECs were used in all 3D encapsulation 
experiments. Prior to encapsulation experiments, HUVECs were trypsinized, centrifuged to obtain 
a pellet, and mixed with GelMA/Laponite polymeric solution under sterile conditions. The 
HUVEC cell density in the polymer solution was 3x106 cells per mL. Each gel was fabricated in a 
96 well plate by adding 50 μL of the cell suspended hydrogels from different groups (equal volume 
of secretome and prepolymer gel for NS+ group). After photocrosslinking for one minute, the gels 
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containing cells were grown for 3 days. Calcein staining was performed to investigate the 
morphology of the cells and the stained gels were washed with DPBS and high-resolution z-stack 
images were obtained using a confocal microscope (Olympus FV1200). For the microchannel 
migration assay, HUVECs were suspended in culture media (without VEGF and FGF) and seeded 
inside the microchannels. After 36 hours, photomicrographs were taken and analysed in Image J 
for percentage of area covered by adhered and migrated HUVECs in the different experimental 
groups163.  
3.2.5 Analysis of the cardioprotective properties of hydrogels 
All experimental procedures were performed in accordance with the standard human care 
guidelines of the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and protocol No. 15-06-17-01 
approved by the Institutional Animal Care and Use Committee, University of Cincinnati. The 
neonatal CMs used for this study were isolated from newborn (1–3 day) Fisher-344 rat pups using 
the Worthington Neonatal CMs Isolation System (Worthington Biochemical) following the 
manufacturer’s protocol and earlier published work164. Minced harvested hearts were 
enzymatically digested by incubation overnight at 4° C in trypsin 50 mg/mL. The tissue was then 
oxygenated for 1 min and incubated with 5 mL collagenase at a concentration of 300 U/mL on the 
shaker (2–4 rounds/min) for 30–45 min at 37° C. Following this, the tissue was oxygenated and 
triturated several times, and undigested tissue was filtered out. The cells were allowed to settle for 
20 min at an ambient temperature and centrifuged at 100 x g for 5 min before preplating twice (45 
min each) in DMEM media (Hyclone), supplemented with 10% FBS (Hyclone) and 
Penicillin/Streptomycin at 37°C.  
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After culturing CMs for 48 hours on the hydrogels in 10% FBS and 5% O2, the culture conditions 
were changed to 0% FBS and 1% O2 for 24 hours to induce cell apoptosis. The resulting cell 
apoptosis was quantified by monitoring Caspase 3/7 activity using an Apo-ONE ® Caspase-3/7 
Assay (Promga) for 12 hours and using a Dead EndTM Colorimetric TUNEL Assay (Promega)165, 
166. Cell necrosis was quantified using an MTS assay. ROS production under previously mentioned 
stressed condition on different hydrogel formulations was determined by Intracellular ROS assay 
at 0 hour and 24 hour using fluorescence imaging. 
3.2.6 Scanning Electron Microscopy (SEM) 
 Hydrogels in fully swollen state were frozen in nitrogen liquid and lyophilized afterwards. 
Subsequently, the lyophilized samples were cut to expose their cross-sections and coated with gold 
using a sputter coater. The detailed structure of the sample cross-sections was imaged using an 
SEM (Hitachi Model S4700, Japan). 
3.2.7 Swelling studies 
Swelling studies were performed on freeze-dried nanocomposite hydrogels in phosphate buffer 
(PBS, pH 7.4, ionic strength I = 0.1). Aliquots (20 mg) of the gels were placed in the buffer and 
allowed to swell at 37.0±0.1°C. After defined intervals of time the hydrogels were weighed and 
placed back in the media. The results were expressed as swelling ratio over time according to this 
formula:  
 
                                Swelling ratio (%) = ((Ws –Wd) / Wd) x100                                 [Eq 1] 
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where Ws and Wd are the weights of the swollen and dry hydrogels, respectively. Each experiment 
was carried out using 4 sample for each group.  
3.2.8 Statistical analysis 
Quantitative variables are presented as mean ± Standard Deviation (SD) from independent 
experiments as described in the figure legends. Statistics were performed using two-way and/or 
one-way Analysis of variance (ANOVA) by Bonferroni’s multiple comparison post-hoc test. All 
statistical analyses were performed with Prism 5 (GraphPad Software). P value <0.05 was 
considered significant.  
 
3.3 RESULTS AND DISCUSSION 
3.3.1 Spheroid formation and secretome characterization 
To efficiently harness a high concentration of secretome, hMSC spheroids were prepared. This 
method was chosen because spheroid culture provides a high ratio of cells to media volume that 
allows for the production of a highly concentrated secretome. Microfabrication technology was 
used to develop microscale arrayed wells in order to generate the human bone marrow-derived 
mesenchymal stem cell (hMSC) spheroids.162 Concave microwells (300 µm wide) were fabricated 
starting from microfluidic channels combined with pentagonal chambers using 
polydimethylsiloxane (PDMS). Subsequently, a PDMS solution was introduced into the 
microfluidic channel filling these chambers. Finally, using suction and a pressing and rolling 
technique the excess PDMS solution was removed from the chambers. This leads to the production 
of the concave microwells after curing of the remaining PDMS solution. The formation of this 
final product is directly attributed to the surface tension of PDMS (Fig 3.2A). An hMSC 
suspension was introduced into the culture device through the inlet port which resulted in a uniform 
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number of cells trapped in each concave well (Fig 3.2B). Spheroids were cultured for 48 hours in 
order to promote the secretion of paracrine factors. The amount of growth factors in the media was 
quantified using ELISA and compared to hMSCs cultured in 2D under the same conditions. 
Specifically, the amount of vascular endothelial growth factor (VEGF), fibroblast growth factor 2 
(FGF2), angiogenin, and bone morphogenetic protein 2 (BMP2) were found to be significantly 
higher in the spheroid culture (Fig 3.2C). Among all the bioactive molecules, these were chosen 
due to their integral role in cardiac regeneration by promoting angiogenesis, attenuating apoptotic 
pathways, and remodeling the damaged myocardium.167  
3.3.2 Nanocomposite hydrogel characterization 
A possible strategy to improve their therapeutic efficacy is to design a delivery platform that can 
control their release over time in the site of cardiac injury. For this reason, different nanocomposite 
photochemical hydrogels based on GelMA and Laponite were fabricated for the delivery of 
secretome. GelMA is a chemically modified version of gelatin that can easily form a photo-
crosslinkable hydrogel due to the presence of methacrylic groups. The systems tested in this study 
were prepared using GelMA (5.0% w/v) with a medium degree of methacrylation (~50% amine 
substitution)168. The presence of a microporous network was confirmed by scanning electron 
microscopy (SEM) (Fig 3.2D). The concentration of Laponite was shown to have no effect on the 
porosity of the hydrogel network (Fig S3.1). The influence of Laponite over the mechanical 
properties of the photo-crosslinkable hydrogel was investigated through unconfined uniaxial cyclic 
compression studies (Fig 3.2E). As the concentration of Laponite in the GelMA hydrogel was 
increased from 0.4% to 1% w/v a corresponding enhancement in the mechanical properties was 
observed. As expected, GelMA hydrogels with the highest concentration of nanoclay showed the 
greatest Young’s Modulus value (Fig 3.2F). This observed increase in stiffness is comparable to 
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previously reported results using the same nanocomposite system.152 These results can potentially 
be attributed to the electrostatic interactions between the surface of the clay and the polymer 
chains.169 The very same electrostatic interactions can play a fundamental role in modulating the 
release of the previously mentioned growth factors. For this reason, the in vitro release studies in 
PBS were carried out for VEGF and FGF2 to assess how the concentration of Laponite could affect 
their release kinetics (Fig 3.2G and H). A better control over the release of VEGF and FGF2 was 
observed in the formulations containing the higher amount of clay although no significant 
difference in the swelling behavior was detected between the groups (Fig S3.2). Specifically, 
Laponite was able to slow down the amount of growth factors released over time (15 days). This 
observed effect was directly dependent on clay concentration.  We hypothesize that the mechanism 
responsible for the controlled release of VEGF and FGF2 is mainly due to electrostatic interactions 
between the growth factors and Laponite, however, hydrogen bonding and ion-dipole interactions 
could also be involved. In addition, the nanocomposite hydrogels (0.8% and 1.0 % w/v), 
minimized the initial amount of growth factor detected (t=0). This indicates that the increase in 
Laponite concentration leads to a more compact matrix capable of better retaining the growth 
factors for a prolonged period of time. For this reason nanocomposite hydrogels with a 
concentration less than 0.8% w/v were not further considered in the study. 
3.3.3 Angiogenic studies 
Next, the angiogenic potential of the hydrogels was tested in order to evaluate the bioactivity of 
the nanocomposite hydrogel using HUVECs as a model cell line. In particular, nanocomposite 
hydrogels loaded with secretome were further tested to prove their ability to influence HUVEC 
proliferation overtime. Growth factors were loaded by mixing the secretome solution with GelMA 
prior to UV gelation, therefore, it was necessary to verify whether the therapeutic ability of 
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secretome is maintained after the photo- crosslinking process.  HUVEC (3 x 106 cells ml-1) were 
encapsulated    in three different groups: GelMA hydrogel (Ctrl Gel), GelMA/Laponite hydrogel 
(NS Gel), and GelMA/Laponite secretome loaded hydrogel (NS Gel+). All of the studies reported 
used a nanocomposite hydrogel with a Laponite concentration of 0.8% w/v. Results using 1.0% 
w/v of Laponite were included in the supporting information as the stiffness of the matrix hindered 
the HUVEC spreading in the 3D polymeric network (Fig S3.3). 
At day 3 a statistically significant increase in HUVEC proliferation was observed for the NS Gel+ 
(Fig 3.3A) with respect to the other groups. In addition, the formation of tubular-like structures 
was more evident in the NS Gel+ system (Fig 3.3B) indicating the formation of a more mature cell 
network. HUVECs were able to spread throughout the total thickness of the NS Gel+ at day 3 (Fig 
3C) as shown by the 3D reconstruction of the gel using confocal imaging. Subsequently, a 
microchannel migration assay was used to further assess the angiogenesis potential of the NS Gel+ 
system. The microchannel was fabricated throughout the thickness of the hydrogels by inserting a 
200 μm needle into the polymeric solution prior to gelation (Fig 3.3D). NS Gel+ showed the 
greatest potential for lumen formation due to a significant increase in percentage of microchannel 
area covered (53.5±11.7%) when compared to the Ctrl Gel (25.4±3.3%) and NS Gel (22.6±6%). 
Overall these findings suggest that the bioactivity of the loaded secretome was not lost after gel 
formation as demonstrated by the positive influence on HUVEC proliferation and their 
reorganization into monolayers. These two factors represent fundamental aspects of angiogenesis, 
which is essential for the regeneration of cardiac tissue.  
3.3.4 Assessment of the secretome cardioprotective properties 
Apart from angiogenesis, another important mechanism influencing the recovery of cardiac 
function is the prevention of cell apoptosis and necrosis. Soluble paracrine factors present in 
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secretome have been shown to have an anti-apoptotic paracrine effect essential for the 
improvement of heart function post-infarction170. For this reason, the anti-apoptotic paracrine 
effect of the secretome loaded nanocomposite hydrogels was another focus of this study.  
Cardiomyocytes (CMs) were seeded on the NS Gel+ in 24 well plate (105 cells/well) and cultured 
for 3 days (Fig 3.4A). Fluorescent phalloidin (F-actin) and DAPI (nuclei) staining showed 
morphology indicative of healthy CMs. (Fig 3.4B). Then an induction of cell apoptosis was 
necessary in order to mimic the conditions present in the post-infarct myocardium. This was 
accomplished by culturing the cells in hypoxia (1% O2) and serum deprived conditions (0% FBS) 
for 24 hours after the confirmation of their beating functionality. A TUNEL assay was used to 
detect the presence of apoptotic cells on the different hydrogels characterized by double-stranded 
DNA breaks (Fig 3.4C). In the Ctrl Gel and NS Gel an increase in the presence of red staining was 
observed, which is indicative of apoptotic cells. On the contrary CMs seeded on the NS Gel+ 
showed a minimal amount of red staining. This result confirms the cardioprotective ability of 
secretome which is capable of increasing cardiomyocyte survival and preserving CMs 
morphology. Specifically, the percentage of apoptotic cells was significantly lower in the NS Gel+ 
(15.7±3.4%) than the other groups (Ctrl Gel: 28.6±1.8%; NS Gel: 27.1±4.9%) (Fig 3.4D).  
However, MTS assay showed no significant difference in the amount of necrotic cardiomyocyte 
cells. Another method to confirm the beneficial anti-apoptotic ability of the loaded secretome in 
the nanocomposite hydrogels is to quantify the production of reactive oxygen species (ROS). An 
increase in relative fluorescence intensity, indicative of ROS production, was observed only in the 
Ctrl Gel and NS Gel, whereas no significant change was detected for the NS Gel+ system after 24 
hours of induced apoptosis (Fig 3.4E). In addition, activity of Caspase 3/7 was evaluated for 12 
hours, as they represent important proteases involved in the execution-phase of cell apoptosis. 
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Throughout the experiment a higher enzymatic activity was detected for the Ctrl Gel and NS Gel 
compared to the NS Gel+ confirming the protective ability of the loaded secretome in reducing the 
apoptosis process (Fig 3.4F). 
 
3.4 CONCLUSIONS 
In conclusion, we report two principal findings. First, nanoclay can modulate the controlled release 
of multiple key growth factors present in stem cell derived secretome. The possible mechanism 
dictating this release profile is electrostatic interactions between the highly charged surface of 
Laponite nanoplatelets and the growth factors of the secretome. Second, a stem cell derived 
secretome loaded nanocomposite hydrogel provides a dual action therapeutic system through its 
proangiogenic and cardioprotective ability. After the hydrogel is implanted into the damaged 
myocardium, this approach has the potential to increase the therapeutic efficacy of stem cell 
derived secretome for cardiac regeneration by increasing its retention in the site of injury. 
Therefore, the encapsulation of stem cell derived secretome in a nanocomposite hydrogel provides 
a promising alternative to stem cell therapy for the regeneration of cardiac tissue post myocardial 
infarction. 
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CHAPTER 4. STEM CELL-DERIVED SECRETOME-RICH INJECTABLE 
HYDROGEL FOR MYOCARDIAL REGENERATION‡ 
ABSTRACT 
The objective of this study was to develop an injectable and biocompatible hydrogel that can 
deliver a cocktail of therapeutic biomolecules (secretome) secreted by human adipose-derived 
stem cells (hASCs) to the peri-infarct myocardium. Gelatin and Laponite® were combined to 
formulate a shear-thinning, nanocomposite hydrogel (nSi Gel) as an injectable carrier of secretome 
(nSi Gel+). The growth factor composition and the proangiogenic activity of the secretome were 
tested in vitro by evaluating the proliferation, migration and tube formation of human umbilical 
endothelial cells. The therapeutic efficacy of the nSi Gel+ system was then investigated in vivo in 
rats by intramyocardial injection into the peri-infarct region. Subsequently, the inflammatory 
response, angiogenesis, scar formation, and heart function were assessed. Biocompatibility of the 
developed nSi Gel was confirmed by quantitative PCR and immunohistochemical tests which 
showed no significant differences in the level of inflammatory genes, microRNAs, and cell marker 
expression compared to the untreated control group. In addition, the only group that showed a 
significant increase in capillary density, reduction in scar area and improved cardiac function was 
treated with the nSi Gel+. Our in vitro and in vivo findings demonstrate the potential of this new 
secretome-loaded hydrogel as an alternative strategy to treat myocardial infarction. 
4.1 INTRODUCTION 
On average, one person dies of cardiovascular disease (CVD) every 40 seconds in the United States 
2 making CVD the leading cause of death in this country. 3 Specifically, ischemic heart disease 
                                                          
‡ Published as Waters, R., Alam, P., Pacelli, S., Chakravarti, A. R., Ahmed, R. P., & Paul, A. (2018). Stem 
cell-inspired secretome-rich injectable hydrogel to repair injured cardiac tissue. Acta biomaterialia, 69, 
95-106. 
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(IHD), characterized by myocardium necrosis initiated by a lack of oxygen supply to the left 
ventricle, has a higher mortality rate worldwide than any other CVD. 5 Although many patients 
survive the myocardial infarction (MI) caused by IHD, the absence of robust intrinsic regenerative 
responses in the heart ultimately leads to heart failure due to the replacement of functional 
myocardium with fibrotic scar tissue.  
To overcome this adverse remodeling of the myocardium and restore proper heart function, 
scientists have aimed to promote myocardial regeneration using adult mesenchymal stem cells 
(MSCs). Promising results have been reported in preclinical and early phase clinical trials using 
MSCs which demonstrated their therapeutic ability by promoting cardioprotection, endogenous 
cardiac stem cell stimulation, angiogenesis, and antifibrosis. 171 However, recent evidence 
indicates that several of these positive outcomes are likely not due to the transdifferentiation and 
engraftment of the MSCs at the therapeutic site but mainly because of the release of paracrine 
factors (cytokines, growth factors, and exosomes) from the cells. 62, 65, 71 This mixture of bioactive 
molecules known as secretome can be isolated in vitro, and the biomolecule composition has been 
shown to greatly depend on the culture conditions that the stem cells are subjected to. Scientists 
have proven that several parameters such as oxygen percentage, serum concentration, and degree 
of cell-cell interactions can cause diverse biomolecule secretion profiles. 99, 172 Therefore, 
significant efforts have been dedicated to characterizing and optimizing the regenerative potential 
of stem cell-derived secretome, which has several advantages over traditional stem cell therapy. 
These include the lack of immunogenic rejection allowing for an off-the-shelf product, minimized 
concern of an oncogenic response, and the possible control over the protein milieu contents 
through the use of multiple in vitro techniques. 72 However, much like traditional stem cell therapy, 
a simple injection of secretome in the peri-infarct area without any additional carriers often results  
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in a lack of retention at the delivery site. In fact, therapies based on the bolus injection of multiple 
growth factors are generally associated with an insufficient local regenerative response along with 
undesirable off-target effects. 173 Therefore, a method that provides a prolonged retention of 
secretome at the injection site represents an essential requirement to observe optimal therapeutic 
efficacy. 174-177 
Injectable hydrogels developed from synthetic and natural biomaterials can potentially provide a 
method to achieve this goal. 105 Various physical and chemical crosslinking mechanisms can be 
used to develop hydrogel networks that respond to different stimuli including mechanical stress, 
pH, enzyme, ionic strength, and temperature variation. 178 Additionally, the introduction of a 
nanomaterial within the network can modulate their physical properties causing them to exhibit 
thixotropic behavior. 128 For instance, the formation of nanocomposite hydrogels through the 
incorporation of various carbon-based, polymeric, and inorganic nanomaterials within the 
polymeric network has emerged as a valuable method to achieve this desired behavior. 179-183 
Among them, synthetic nanoclay, specifically Laponite® ((Na0.7+ [(Si8Mg5.5Li0.3)O20(OH)4]
0.7−), 
represents an ideal choice for regenerative medicine applications. Laponite® is a smectite 
nanoclay comprised of disk-shaped nanoparticles with a diameter of approximately 25 nm and a 1 
nm thickness. These nanoparticles overcome biocompatibility concerns associated with some 
carbon-based nanoparticles while maintaining superior growth factor loading capabilities due to 
their high surface-to-volume ratio and discotic charged surface. 184, 185 In addition, Laponite® can 
modulate the release of biomolecules loaded in the hydrogel through electrostatic interactions 
allowing the use of this type of hydrogel in regenerative tissue applications. 185 Following this 
strategy, recent studies have demonstrated how the presence of this nanosilicate can help control 
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the release of growth factors at the site of administration and promote significantly more tissue 
regeneration than corresponding bolus injections of proteins. 155, 186, 187  
Previously, we have used these nanocomposite hydrogel characteristics to our advantage for the 
controlled delivery of stem cell derived secretome in vitro. 185 We demonstrated that a 
photocrosslinkable, methacrylated gelatin based nanocomposite scaffold containing Laponite® 
can control the release of key therapeutic growth factors present in bone marrow-derived 
mesenchymal stem cell secretome over a prolonged period of time. In addition, in vitro cell based 
assays showed that the secretome loaded nanocomposite hydrogel has both proangiogenic and 
cardioprotective ability. Building on these encouraging results and recent literature highlighting 
the proangiogenic potential of hASC-derived secretome in comparison to secretome from bone 
marrow and Wharton’s jelly derived stem cells, we aimed to develop an injectable nanocomposite 
hydrogel for the delivery of hASC-derived secretome to promote myocardial regeneration post 
myocardial infarction. 76 We hypothesized that the secretome loaded nanocomposite hydrogel 
would efficiently promote key therapeutic mechanisms including angiogenesis, scar area 
reduction, and cardioprotection. Through this strategy, we sought to improve cardiac function and 
demonstrate the potential of stem cell-derived secretome as an alternative to traditional stem cell 
therapy for myocardial regeneration.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Preparation and physical characterization of the nanocomposite hydrogels 
Synthetic silicate nanoplatelets (Laponite® XLG) containing SiO2 (59.5%), MgO (27.5%), Na2O 
(2.8%), Li2O (0.8%) and a low content of heavy metals were supplied by Southern Clay Products, 
Inc. (Louisville). Gelatin type A from porcine skin bloom grade 300 was used without further 
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modification from the manufacturer (Sigma-Aldrich, St Louis, MO). Phosphate buffer saline 
(PBS) was purchased from Sigma-Aldrich.  
A stock solution of 10% w/v gelatin was prepared by dissolving the protein in PBS (pH=7.4) at 37 
°C. Stock suspensions of 1, 2, 3, and 4% w/v Laponite® were prepared in ultrapure water at room 
temperature. The nanocomposite hydrogels were formed by mixing equivalent volumes of the 
gelatin stock and the corresponding nanoplatelet suspensions in order to obtain a final 
concentration of 5% w/v gelatin and 0.5, 1, 1.5, and 2% w/v nanosilicates. The hydrogels were 
used immediately after their preparation unless otherwise specified. Hydrogels were also frozen 
and freeze dried prior further characterization using elementary Energy-dispersive X-ray 
spectroscopy (EDX) and Fourier transform infrared spectroscopy (FT-IR). To carry out SEM and 
EDX characterization, freeze dried samples were mounted on a holder with double sided 
conductive carbon tape and sputter-coated with gold. SEM images were obtained at an acceleration 
voltage ranging from 1 to 10 kV with an in-lens detector. For FT-IR spectra analysis, the gels were 
mixed in KBr tablet, and spectra were recorded in the range of 400 to 4000 cm-1 (resolution of 1 
cm-1) using a Bruker Vector-22 FTIR spectrophotometer (PIKE Technologies, USA). 188 
Degradation studies were carried out to assess the stability of the nanocomposite hydrogels 
containing either 0, 1, or 2% (w/v) Laponite®. Each nanocomposite hydrogel was initially freeze 
dried and weighed prior to the study which was performed in PBS (pH 7.4) at 37 °C while shaking 
the gel at 60 rpm for 2 weeks. The PBS was replaced every two days. At various time points five 
samples of each Laponite® concentration were freeze dried and weighed to calculate the 
percentage of degradation indicated by weight loss using the following equation (1): 
𝑊𝐿(%) =
𝑊𝑖 − 𝑊𝑓
𝑊𝑖
× 100 
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Wi and Wf are the initial and final weight of the nanocomposite hydrogel after degradation, 
respectively. 
Finally, myoglobin was used to determine whether the Laponite® concentration within the 
nanocomposite hydrogel effected the release profile of a loaded protein.  
Nanocomposite hydrogels containing either 1 or 2% Laponite® were loaded with 5 mg/mL 
myoglobin and subjected to shaking of 60 rpm at 37 °C in the presence of PBS. The concentration 
of myoglobin within the PBS was determined at various time points by measuring the absorbance 
at 410 nm.    
4.2.2 Harnessing the hASCs secretome using a microchip device 
StemFIT 3D microwell® culture dishes were used to culture hASCs spheroids. Each culture dish 
was 300 mm in diameter containing 389 wells with a diameter of 600 µm. The hASCs used were 
purchased from Rooster Bio and originated from female donors between the ages of 31-45 years 
old. Flow cytometry was used by the company to determine that less than 20% of the cells 
expressed CD14, CD34, CD45 and greater than 70% of the cells expressed CD166, CD105, CD 
90, and CD73. In addition to a phenotype confirmation, the multipotency of the cells was tested 
using 3 week cell differentiation studies. Positive Oil Red O and Alizarin Red staining confirmed 
the adipogenic and osteogenic differentiation abilities of the cells. These polydimethylsiloxane 
(PDMS) concave microwells were purchased from Prodizen (Seoul, Korea) and used according to 
the manufacture’s protocol. hASCs (passage 2-6) were initially cultured in traditional 2D 
conditions (3.3 x 103 cells/cm2) using hASC High Performance Media (Rooster Bio). The hASCs 
were then trypsinized and resuspended in serum-free α-MEM media supplemented with 1% L-
glutamine and 1% penicillin/streptomycin. hASCs were seeded in the microchips at a cell density 
of 0.8 x 106 cells per milliliter. The cells were allowed to settle into the microwells of the 
46 
 
microchips for 20 minutes prior to removing all the media being cautious not to withdraw any of 
the cells in the microwells. This step is necessary to remove all the cells on the periphery of the 
wells and ensure optimal spheroid formation in the microwells. Finally, 1 mL of serum-free α-
MEM media supplemented with 1% of L-glutamine and 1% penicillin/streptomycin was added to 
each microchip. The hASCs were incubated for 72 hours at 37° C to allow spheroid formation and 
the secretion of paracrine factors into the media (secretome). The resulting spheroids were 
fluorescently stained with ethidium bromide (0.2% v/v) and calcein (0.05% v/v) dye to visualize 
dead and living cells, respectively and assess whether the culture conditions caused any significant 
cell death. After 72 hours the secretome was collected from the chips, centrifuged at 1000 RPM 
for 5 minutes, and the secretome supernatant was collected to ensure there was no cellular debris 
in the secretome. A human angiogenesis antibody array and cytokine array (R&D Systems) were 
used to detect the relative levels of 55 angiogenic-related proteins and 36 different cytokines, 
chemokines and acute phase proteins in the secretome. More specifically, images were taken of 
each chemiluminescent blot, and the mean spot pixel densities for each protein were calculated 
using ImageJ software. To quantify specific angiogenic growth factors such as VEGF and 
Angiogenin, their respective ELISA kits were used according to the manufacture’s protocols 
(R&D Systems and System Biosciences).  
4.2.3 Rheological analysis 
An AR2000 rheometer (TA Instruments, New Castle, DE) was used for mechanical 
characterization of the nanocomposite hydrogels containing varying concentrations of Laponite®. 
Viscosity measurements were performed immediately after the Laponite® was homogeneously 
distributed into the gelatin polymeric solution. The test was carried out using a cone-plate 
geometry (cone with 20 mm diameter, 1° angle) in the range of shear rates varying from 0.001 to 
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1000 s-1. The study was conducted at the temperature of 25 °C (n=3).  To study the hydrogel 
mechanical properties, cylindrical hydrogels were formed by introducing 0.5 mL of the gelatin-
silicate mixture into in a 24 well plate and allowed to gel overnight at 4 °C. Prior to testing, all 
gels were removed and allowed to reach 20°C. All tests were performed at 25 °C using a roughened 
plate geometry (20 mm diameter).  An initial strain sweep from 0.1% to 100% at 1 Hz was 
performed to determine the linear viscoelastic region of the hydrogel that was used for subsequent 
frequency sweep tests carried out in the range from 0.01 to 10 Hz (n=3). Recovery testing was 
conducted at 1 Hz by subjecting the hydrogels to 3 consecutive cycles of 5 minutes at 1% strain 
(within the linear viscoelastic region) and 5 minutes at 100% strain (outside the linear viscoelastic 
region) (n=3). Temperature sweeps from 25 °C to 40 °C were conducted at 1 Hz and 1% strain 
(n=3). 
4.2.4 Biocompatibility of the nanocomposite hydrogel in vitro 
Human umbilical vein endothelial cells (HUVECs) (8 x 104) were seeded in chamber slides with 
10% of the media volume replaced with the gelatin-silicate mixture deriving from each of the 
different test groups (Lap 0, 1, and 2% w/v). The positive control group (Cntrl+) contained only 
media. As a negative control (Cntrl-), camptothecin at a concentration of 50 µM was added to the 
media. After 24 hours, cells were fixed in 4% paraformaldehyde for 5 minutes at 37 °C. Diamidino-
2-phenylindole dilactate (DAPI, Invitrogen, USA) and phalloidin-AlexaFluor488 (Invitrogen, 
USA) were used to counterstain nuclei and actin, respectively. Immunofluorescence images were 
taken to observe whether or not the addition of the hydrogel had any effect on cell morphology.   
Additionally, HUVECs were seeded in a 24 well plate and allowed to reach confluency in 
endothelial growth medium (EGM-2 BulletKit Lonza, Waldersville, MD) at 37°C and 5% of CO2.  
Subsequently, to assess the cytotoxicity of the nanocomposite hydrogel, a Falcon® Permeable 
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Support (3.0 µm transparent PET membrane) containing 200 µL of the respective nanocomposite 
hydrogel from each of the different test groups (Lap 0, 1, and 2% w/v) was added to each well. As 
a control group, HUVECs were not treated with any gels. After 1 day, 3 days, and 5 days of gel 
exposure, cells were washed with fresh media and an MTS assay was carried out according to the 
manufacturer’s instructions. 189 The absorbance of each well was measured at 490 nm to determine 
the HUVECs’ mitochondrial activity (Cell Titer 96 Aqueous Non-Radioactive Assay, Promega). 
The number of cells was determined using a calibration curve in the range from 5 x 103 up to 2 x 
105 cells.  
4.2.5 HUVEC proliferation, migration and tube formation assays 
To assess the proangiogenic ability of the secretome, HUVECs (1 x 104 cells/well) were seeded in 
a 48 well plate and allowed to grow in the media (200 µL) without the addition of VEGF and 
human fibroblast growth factor-B (hFGF-B). After 3 hours, one-fourth of endothelial growth 
medium (50 µL) was replaced by secretome derived from the 2D monoculture (2D secretome) or 
the spheroids (3D secretome) providing a VEGF concentration of 0.15 ng/mL and 1.2 ng/mL, 
respectively. This volume of secretome was determined to be the optimal volume of α-MEM media 
tolerated by the HUVECs to allow for the observation of the proangiogenic ability of each type of 
secretome. As a negative control, cells were not supplemented with any growth factor in the media 
(Cntrl (-)). The degree of HUVEC proliferation in the presence of the secretome was assessed by 
MTS cell proliferation assay (n=5) after 24 hours as described in the previous section.  
Additionally, HUVECs were also cultured in a  24 well plate (2 x 104 cells/well) and allowed to 
become confluent in endothelial growth medium (400 µL) without the addition of VEGF and 
hFGF-B. Then, scratches were made in the cell monolayer using a cell scraper followed by several 
washes with PBS to remove the detached cells. 2D secretome and 3D secretome were 
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supplemented in the media (100 µL), and HUVECs were allowed to migrate through the scratch 
for 24 hours. Cells were stained with calcein, and fluorescent images were taken in the same 
positions along the scratch before and after the 24 hour migration period in all the groups. The 
cells that did not receive any growth factor supplement served as the negative control. The 
percentage of area recovered during the migration was calculated using Image J software. The 
original wound area was determined from the preliminary images and the area recovered was 
defined as the total wound area that was occupied by cells post 24-hour incubation. 179 
Finally, to determine the ability of the secretome to induce the formation of tubular-like structures, 
HUVECs were seeded on a growth factor depleted Matrigel-based on the manufacturer’s protocol 
(Matrigel matrix, Basement Membrane, BD). Briefly, 289 µL of growth factor depleted Matrigel 
Matrix (10 mg/mL) previously cooled to approximately 5 °C was added to a 24 well culture plate 
on ice. The plate was then incubated at 37°C for 60 minutes to allow the gel to form. Then, 
HUVECs (1.2 x105) were seeded on each gel with either endothelial growth medium without 
growth factors (Cntrl (-)) or supplemented with 2D and 3D secretome. After 10 hours, bright field 
images of the endothelial networks were taken for each group and the number of complete tubes 
formed, total network length and total segment length were determined using the Angiogenesis 
Analyzer for ImageJ. The average numbers from three independent wells were reported. 190 
4.2.6 qPCR analysis of apoptotic and stress-related genes in spheroids 
RNeasy Mini Kit (Qiagen, Germany) was used to extract mRNA from the hASCs spheroids and 
hASCs cultured in well plates following the manufacturer’s protocol. The total RNA concentration 
and purity were determined by measuring the optical density at 260 nm using a spectrophotometer 
(Nanodrop ND-1000; Thermo Scientific, USA). Complementary DNA (cDNA) was synthesized 
starting from the isolated RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied 
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Biosystem, USA). The qPCR analysis was performed in triplicate for each test group on a 
Mastercycler Realplex (Eppendorf, Germany) using predesigned primers and KiCqStart SYBR 
Green qPCR Ready Mix (Sigma-Aldrich, USA). Fold expression levels of BCL-2, EPAS1 and 
HIF1A were calculated using the relative ∆∆Ct method, using GAPDH as the housekeeping gene. 
The gene expression of the hASCs grown in traditional 2D tissue culture flasks was used as a 
reference group. 
4.2.7 Biocompatibility assessment of nanocomposite hydrogel in vivo 
In vivo biocompatibility experiments were performed using male adult Fischer 344 rats  (~8 
weeks), each weighing 250–300 g. 179 Animals were anesthetized with isoflurane gas followed by 
tracheal intubation and ventilation using Rodent Ventilator (Minivent, Type 845 Germany). 
Animal body temperature was maintained at 37ºC during the surgery. Nanocomposite hydrogels 
were formulated in accordance with the procedure used for the in vitro studies. The hearts were 
exposed by minimal left-sided thoracotomy and 100 µl of nanocomposite hydrogel (nSi Gel) [5.0% 
(w/v) Gelatin, 2.0% (w/v) Silicate] or PBS (Control) was intramyocardially injected at multiple 
sites (5 sites/heart). A total of 10 rats were used (n=5). The chest was closed, and animals were 
allowed to recover. The animals were maintained on buprinex after surgery for 24 h.  
For immunostaining paraffin embedded heart sections were deparaffinized by Xylene to 100% 
ethanol change (5 min each) and antigen retrieval was done using citrate buffer according to 
standard protocols. Heart sections were blocked by CAS-block Histochemical Reagent (Thermo 
Fischer Scientific, USA) for 2 hours at room temperature followed by three PBS washes for 5 
minute each. Primary antibodies for TnC (Sigma-Aldrich, USA) and TNFα (Sigma-Aldrich, USA) 
were used in a working dilution of 1:200 with CAS-Block and individually incubated for overnight 
at 4°C followed by three PBS washes for 5 minute each. The corresponding secondary antibodies 
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were used in a working dilution of 1:200 with CAS-Block and individually incubated for 2 hours 
at room temperature followed by three 5 minute PBS washes. Nuclei were stained by DAPI 
(Sigma-Aldrich, USA). Images were analyzed using fluorescent microscopy.  In addition to 
immunostaining, A TUNEL assay was performed on deparaffinized 5 μm thick sections with an 
In-Situ Cell Death Detection Kit, TMR Red (Roche Inc) according to the manufacturer’s 
instructions. 191 Nuclei were stained by 4′,6-diamidino-2-phenylindole (DAPI). The degree of 
apoptotic cell death was evaluated by calculating the ratio of TUNEL-positive cells to the total 
number of cells.  
Lastly a qPCR analysis of cardiac function and cardiomyocyte cell cycle genes was performed on 
the myocardium. The frozen tissue samples were homogenized by The Bullet Blender 
homogenizer (Next Advance, Inc, USA) followed by the total RNA isolation by using Ambion™ 
TRIzol™ Reagent (Fisher Scientific, USA). Quantification of RNA was done by NanoVue™ Plus 
Spectrophotometer (GE Healthcare, Buckinghamshire, UK) and RNA quality was checked on 
1.0% agarose gel. cDNA synthesis was performed with 1µg total RNA of each sample by using 
Omniscript Reverse Transcription kit (QIAGEN, USA) following the manufacturer’s protocol. 
RT-PCR expression analysis for APC, TNFα, CyclinD1, Rb1, and Meis2 was performed using 
specific RT-PCR primer pairs for each gene (Fig S4.8C). RT-PCR primers were synthesized by 
using Primer3web version 4.0.0 (http://bioinfo.ut.ee/primer3/), and primer quality was checked by 
UCSC In-Silico PCR (http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr). Amplification 
reactions were performed in duplicate in CFX Connect™ Real-Time PCR Detection System (Bio-
Rad, California, USA) using Applied Biosystems® SYBR Green PCR Master Mix (Thermo 
Fischer Scientific, USA) following the manufacturer’s amplification conditions. Quantification of 
RT-PCR data was performed by using the ΔΔCt method and β-actin served as control. 191 For the 
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miRNA qPCR, total RNA was isolated by Trizol method, as previously described. The miRNA 
cDNA synthesis was performed using the miScript II RT Kit dual-buffer system (Qiagen) and 
miScript HiSpec Buffer. The subsequent miRNA quantification was performed by using miScript 
Primer Assays according to the manufacturer’s protocol. Specific forward primers (Figure S4.8C) 
with a universal reverse primer were used for the RT-PCR reaction. 
(http://sabiosciences.com/manuals/BRO_GEF_miRNA_0212_lr.pdf). RT-PCR reactions were 
performed according to the standard manufacturer’s protocol. RNU6 served as internal control. 
The quantification of miRNA expression was performed using the ΔΔCt method previously 
described. 
4.2.8 In vivo acute myocardial infarction surgery 
 According to established protocols and in compliance with NIH Guide care and Use of Laboratory 
animals, in vivo experiments were performed using a myocardial infarction rat model with adult 
(~8 weeks) male Fischer 344 rats, each weighing 250–300 g. 179 Animals were anesthetized with 
isoflurane gas followed by tracheal intubation and ventilation using Rodent Ventilator (Minivent, 
Type 845 Germany). Animal body temperature was maintained at 37ºC during the surgery. 
Nanocomposite hydrogels were formulated in accordance with the procedure used for the in vitro 
studies. The hearts were exposed by minimal left-sided thoracotomy and an occlusion of the left 
ascending coronary artery was used to induce an acute MI according to conventional laboratory 
procedures. 140, 192, 193 Lyophilized 3D secretome was resuspended in PBS (0.125 mL) and mixed 
with Gelatin 20% w/v (0.125 mL) and Laponite 4% (0.25 mL) to obtain nSi Gel+. The nSi Gel 
was formulated using PBS in place of secretome.  Then, 15 minutes post infarction 100 µL of 
either the nanocomposite hydrogel (nSi Gel) or the 3D secretome loaded nanocomposite hydrogel 
(nSi Gel+, 8 ng VEGF/ rat, 5 ng ANG/rat) was injected in five different sites within the peri-infarct 
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region of the heart using a 28 gauge syringe (20 µL/injection) (n=5). The control group received 
an injection of PBS 15 minutes post infarction (n=5). As an additional control group, a secretome 
was also included and was injected with a secretome solution containing the same amount of 
VEGF and ANG in the nSi Gel+ 15 minutes post infarction (n=5). A total of 20 rats were used 
(n=5). The chest was closed, and animals were allowed to recover. The animals were maintained 
on buprinex after surgery for 24 h. For the heart function assessments, transthoracic 
echocardiography was performed at day 0, 3, 7, 14, and 21 after surgery for therapeutic efficacy 
studies. After day 21, the animals were sacrificed, and hearts were frozen or fixed with 4% 
formalin solution for molecular and histological studies.  
4.2.9 In vivo assessment of cardiac function 
Cardiac function was assessed by transthoracic echocardiography 0, 3, 7, 14, and 21 days after 
surgery using Vevo®2100 Imaging System, Visualsonics with a 24-MHz transducer, MS250 
followed an established protocol. 194, 195 Animals were anesthetized with isoflurane gas, 2-D 
imaging of hearts was performed and recorded for M-modes through the anterior and posterior left 
ventricle (LV) walls. Anterior and posterior wall thickness (end-diastolic and end-systolic), LV 
internal dimensions, LV end-systolic (LVESd) and end-diastolic (LVEDd) diameters were 
measured from at least 3 consecutive cardiac cycles. Indices of LV systolic function including left 
ventricle ejection fraction (EF), left ventricle fractional shortening (FS) and cardiac output (CO) 
were calculated as follows:  
𝐸𝐹 (%) =
(𝐿𝑉𝐸𝐷𝑑3 − 𝐿𝑉𝐸𝐷𝑆𝑑3)
𝐿𝑉𝐸𝐷𝑑3
× 100 
𝐿𝑉𝐹𝑆 =
(𝐿𝑉𝐸𝐷𝑑 − 𝐿𝑉𝐸𝑆𝑑)
𝐿𝑉𝐸𝐷𝑑
× 100 
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Cardiac output = heart rate x stroke volume. The results were expressed as percentage ± standard 
deviation. 
 
4.2.10 Immunostaining of heart sections 
Paraffin-embedded heart sections were deparaffinized by introducing the slides in xylene followed 
by a wash with 100% ethanol. Both steps were carried out for five minutes. Antigen retrieval was 
done using a standard citrate buffer protocol. 195 Heart sections were blocked by CAS-block 
Histochemical Reagent (Thermo Fischer Scientific, USA) for 2 hours at room temperature 
followed by three PBS washing with 5 minutes interval between each wash. Primary antibodies 
for von Willebrand Factor (vWF) (catalog # A0082, Dako, Agilent Pathology Solutions, USA) 
and smooth muscle actin (SMA) (catalog # A2547 SIGMA, Sigma-Aldrich, USA) were used at a 
working dilution of 1:200 with CAS-Block. Both antibodies were individually incubated overnight 
at 4°C followed by three PBS washing with 5 minutes interval within each wash. The 
corresponding secondary antibodies were used at a working dilution of 1:200 with CAS-Block and 
individually incubated for 2 hours at room temperature followed by three PBS washing with 5 
minutes interval within each wash. The nuclei were stained using DAPI (Sigma-Aldrich, USA). 
Images were analyzed using fluorescent microscopy. The results were compared by student’s t-
test and a p value ≤ 0.05 was considered as significant. Results were represented as mean ± 
standard deviation.   
4.2.11 Statistics 
All quantitative data are presented as mean ± standard deviation from individual experiments. A 
two-way or one-way analysis of variance (ANOVA) by Tukey’s multiple comparison posthoc test 
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was performed to assess statistical significance with a p-value of <0.05 considered significant. 
Prism 5 (GraphPad Software) was used to carry out all statistical analysis.  
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Secretome preparation and characterization 
Several different in vitro cell culture techniques have been used to modulate the concentration and 
composition of growth factors and cytokines present in the secretome to promote specific 
regenerative responses. 172 Here we used polydimethylsiloxane (PDMS) microwell culture devices 
to form hASCs spheroids for secretome production. The green fluorescent images of the spheroids 
showed that the spheroids were largely composed of living hASCs with a minimal presence of 
dead cells in each spheroid (Fig 4.1A). This technique was chosen based on the generally accepted 
idea that spheroid culture techniques promote a cellular environment more representative of an in 
vivo setting than traditional 2D monolayer culture. This assumption is based on the greater amount 
of cell to cell interactions and cellular interfaces with extracellular matrix components which occur 
within spheroids. 196 In addition, the spheroid structure relies on diffusion to control the transport 
of nutrients, oxygen, and waste throughout the entirety of the sphere. This diffusion limitation 
provokes a state of stress within the cells which has been shown to alter the growth factor secretion. 
91, 197 Lastly, the high ratio of cells to media used allows for the collection of a highly concentrated 
secretome. 185  
After 72 hours of culture, the hASCs spheroids showed an increased expression of the anti-
apoptotic gene BCL-2 as well as, the stress related gene HIF1A when compared to traditional 2D 
monolayer culture (Figure 4.1B). The increased gene expression has been previously reported to 
occur within spheroids and has been shown to be linked to hypoxia and hypoxia-dependent 
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pathways. 89 In addition to the difference in gene expression between the two culture techniques, 
a human antibody array was carried out to evaluate the composition of therapeutic growth factors, 
cytokines, and proteins present in the secretome (Figure 4.1C and D). The protein 
endostatin/collagen XVIII and the hepatocyte growth factor (HGF) were only detected in the 
spheroid secretome (Figure 4.1D). Recently, endostatin/collagen XVIII has been linked to the 
suppression of type I collagen expression in cardiac fibroblasts which is a vital component of scar 
formation post myocardial infarction. 198 Additionally, the inhibition of endostatin/collagen XVIII 
in a rat MI model was shown to cause an increase in matrix metalloproteinases (MMP) activity of 
MMP2 and MMP9, angiotensin converting enzyme activity, and collagen deposition. 199 These 
findings suggest that endostatin/collagen XVIII may have a significant cardioprotective ability and 
a precise role in limiting myocardium remodeling. The second component that was exclusively 
detected in the spheroid secretome, HGF, is an effective agonist for the tyrosine kinase surface 
receptor c-MET. 200 This cytokine has been documented to exhibit proangiogenic, anti-fibrotic, 
and cardioprotective ability in vitro and in vivo MI models. 201-204 Along with the previously 
discussed therapeutic biomolecules only being secreted by the spheroids, there were also several 
growth factors present at a greater concentration in the spheroid secretome when compared to the 
2D monolayer secretome. Specifically, the concentration of vascular endothelial growth factor 
(VEGF) and angiogenin was approximately eight and four times greater in the spheroid secretome, 
respectively (Figure 4.1E). These proteins are potent proangiogenic growth factors with a proven 
ability to promote endothelial proliferation, migration, and survival as well as, facilitate new blood 
vessel formation within the peri-infarct zone post-MI. 205-208 These results confirm that culturing 
hASCs in spheroids rather than a monolayer changes the genetic profile of the cells and 
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subsequently provokes the cells to secrete a greater amount and variety of therapeutic molecules 
involved in angiogenesis, cardioprotection, and improvement of the heart function post-MI.  
4.3.2 In vitro proangiogenic activity of secretome 
As mentioned previously, MI is initiated by the obstruction of blood flow to the myocardium as 
the result of an occlusion of the coronary arteries leading to the walls of the heart. The resulting 
ischemia causes several pathological changes within the myocardium such as hypoxia, 
inflammation, ventricular dilation, compromised contractile function, cardiomyocyte death, and 
tissue necrosis. 209, 210 Therefore, regardless of the method used, in order to repair the infarcted 
myocardium the reestablishment of sufficient vascularization throughout the heart is essential to 
ensure proper metabolic and structural homeostasis of the myocardium. 211 Therapeutic 
angiogenesis is an essential process involved in the revascularization, and consequently, the 
angiogenic potential of the hASCs derived secretome was characterized using several in vitro cell 
based assays. 
Initially, angiogenesis relies on endothelial cell migration and proliferation to form capillary 
sprouts 212. To assess cell proliferation, endothelial cells were seeded at a sub-confluent density in 
growth factor depleted endothelial growth media. Then, the two different hASCs derived 
secretome isolated respectively from 2D monoculture (2D secretome) and spheroids (3D 
secretome) were added to the media in different groups, and the cell number was quantified after 
24 hours.  
As a control group (Cntrl (-)), cells were grown in endothelial growth media without the addition 
of VEGF and human fibroblast growth factor-B (hFGF-B). The 3D secretome caused a significant 
increase in cell proliferation when compared to 2D secretome (Fig 4.2A). Next, an in vitro scratch 
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assay was performed to assess whether the secretome was able to promote endothelial cell 
migration.  
After 16 hours of treatment, differences in cell migration could be observed within the scratch that 
was made prior to the addition of secretome. Specifically, treatment with the 3D secretome resulted 
in a 75.7% wound closure which was significantly higher than the 2D secretome group (Fig 4.2B 
and D). These results align with previous reports of endothelial migration induced by angiogenic 
protein-based treatments. 181, 213 Lastly, a tube formation assay was carried out. This assay is 
essential because, following the formation of capillary sprouts via endothelial cell migration and 
proliferation, cellular alignment into tubules is essential for lumen formation of a functional 
capillary. 214 After 10 hours of exposure to the secretome, the test groups containing the 2D 
secretome as well as the 3D secretome showed an increase in tube formation. The groups that 
received the 2D and 3D secretome showed approximately four and five times more tubes per field 
when compared to the control, respectively (Fig 4.2C and E). In addition, the 2D and 3D secretome 
induced the formation of longer tube segments and a larger total tube length (Fig S4.4). Based on 
the results obtained from these three cell-based assays, the prediction that the secretome 
composition derived from hASCs spheroids has superior proangiogenic properties when compared 
to the secretome isolated from the hASCs cultured in a traditional monolayer can be confirmed. 
215    
4.3.3 Formation and characterization of the injectable nanocomposite hydrogel 
Strategic combinations of polymers and nanoparticles allow scientists to develop injectable 
physically crosslinked hydrogels to control the delivery of several types of biomolecules and 
therapeutic agents for tissue regeneration. Polymers and nanomaterials can be mixed before the 
gelation to form nanocomposite systems that can be easily injected through a needle. This avoids 
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the use of complex fabrication methods that can be difficult to translate into the clinic, as well as, 
the need for invasive surgery for their administration. 216 In this study, fully exfoliated Laponite® 
(0, 1, 2% w/v) was combined with gelatin (5% w/v) to form an injectable hydrogel for the delivery 
of stem cell derived secretome (Fig 4.3A). After the hydrogel was formed, FT-IR spectra of 
Laponite®, gelatin, and the nanocomposite hydrogel confirmed the polymer clay interactions 
through a slight shift in the characteristic Si-O stretching peak from 1013 cm-1 to a lower frequency 
of 1006 cm-1 (Fig S4.1A).  This peak shift has been reported to be seen from other nanocomposite 
hydrogels containing Laponite®, as well. 217, 218 A complimentary analysis of the nanocomposite 
hydrogel’s elemental composition using energy-dispersive X-ray spectroscopy (EDS) established 
the presence of silicon (Si) and magnesium (Mg) therefore, confirming the contribution of the 
Laponite® nanoparticles to the structural network of the hydrogel (Fig S4.1B and S4.1C). 219 To 
assess the effect of Laponite® on the viscoelastic behavior of the nanocomposite hydrogel several 
rheological techniques were used. Initial strain sweeps were carried out to determine the linear 
viscoelastic region for each of the Laponite® concentrations (Fig S4.2A). Frequency sweep 
measurements from 0.01 to 10 Hz at a strain of 1% showed consistent storage moduli (G’) 
approximately one magnitude higher than loss moduli (G’’), irrespective of the frequency (Fig 
S2B). This behavior indicates that, at the concentrations used, gelatin and Laponite® are able to 
form hydrogel networks that exhibit solid-like behavior (G’>G’’). 220 However, at higher 
oscillatory strain percentages the material begins to flow (G’<G’’) illustrating yielding behavior 
which is an important parameter for designing injectable hydrogel systems. The yield stress 
approximately doubled as the concentration of Laponite® increased from 1% to 2% within the 
nanocomposite hydrogel (Fig 4.3B). In addition, a similar trend was seen in the viscosity testing 
where an increase from 1% w/v to 2% w/v Laponite® caused the viscosity to rise by an order of 
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magnitude (Fig 4.3C). One probable cause for this direct correlation between the increased 
viscosity and the Laponite® concentration is the physical crosslinking occurring between the 
predominately negatively charged Laponite® disks and the positive charges of lysine ε-amino 
groups of gelatin. This crosslinking can be confirmed by monitoring the change in the loss factor, 
tan δ = G’’/G’, over a range of oscillatory frequencies. As the concentration of Laponite® 
increased from 1% w/v to 2% w/v, there was also a slight decrease in tan δ at a frequency of 0.1 
to 10 Hz (Fig 4.3D). This reduction in tan δ, combined with the significant rise in G’ with greater 
concentrations of Laponite®, confirms that Laponite® increases the crosslinking density within 
the nanocomposite hydrogel. This behavior has been observed with several other nanocomposite 
hydrogels containing various hydrophilic polymers and Laponite®. 221, 222 Although the exact 
interactions are not known, generally researchers consider hydrogen bonding, dipole, and ionic 
interactions to play a significant role in the physically crosslinked networks between polymers and 
nanosilicates. 186, 221. These interactions are more likely to occur at higher concentrations of 
Laponite® dictating a difference in the degradation profiles as observed in this study. Specifically, 
after 2 weeks the nanocomposite hydrogels containing 1% nanoclay were significantly degraded 
unlike the 2% nanoclay hydrogels which showed minimal degradation (Fig S4.3A). As well as 
improving the stability of the hydrogel, Laponite® can also influence the retention of proteins 
within the hydrogel matrix. This control over the amount of protein released is beneficial to treat 
cardiovascular injuries that require a prolonged presence of bioactive molecules consistently 
delivered to the damaged tissue. To prove this concept, we studied the influence of Laponite® 
concentration on the release of the model protein (myoglobin) and observed that a concentration 
of 2% nanoclay was able to reduce the percentage of protein released when compared to the 
formulation containing the lower Laponite® concentration (Fig S4.3B). As mentioned previously, 
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the ability for a hydrogel to pass readily through a needle is an important parameter to enable a 
straightforward delivery to the therapeutic site. The shear thinning behavior exhibited by this 
nanocomposite hydrogel at shear rates greater than 0.1 s-1 confirms its injectability (Fig 4.3D). 
However, after injection rapid recovery of the hydrogel stiffness is imperative to prevent the 
material from flowing out of the therapeutic site. Therefore, recovery testing was carried out with 
each nanocomposite hydrogel by monitoring the G’ during three cycles of high (100%) followed 
by low (1%) oscillatory strain for five minutes each (Fig 4.3E). At the beginning of each high 
strain cycle, all of the G’ values dropped to below 100 Pa, however, the hydrogels that contained 
1% w/v and 2% w/v of Laponite® regained a significant amount of their stiffness directly after the 
strain was decreased to 1% w/v. Specifically, after the first high strain cycle, the nanocomposite 
hydrogel that contained 1% w/v Laponite® exhibited a G’ value that was only 20% lower than the 
initial value during the primary low strain cycle. Despite this recovery behavior, after three cycles 
of high strain the hydrogel was only able to recover 66% of the original G’ value. Interestingly, 
this reduction in G’ values after multiple cycles of high strain was not observed in the 
nanocomposite hydrogel containing 2% w/v Laponite®. This hydrogel was able to recover to 98-
99% of the initial G’ value after each high strain cycle. These results confirm the thixotropic 
behavior of the hydrogel systems containing Laponite® previously observed with similar 
physically crosslinked hydrogel systems. 220, 222 In addition to the recovery studies, the stiffness of 
the hydrogel system was monitored from 25 °C to 40 °C in order to evaluate the mechanical 
integrity of the nanocomposite hydrogel at the physiological temperature of 37°C (Fig S4.2C). As 
expected there was a slight decrease in the G’ among all the groups at temperatures above 35°C 
however, this decrease was less pronounced in the hydrogels containing 2% Laponite® (Fig 
S4.2D). This indicates that the Laponite® is crucial in maintaining the integrity of the hydrogel 
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even at temperatures where gelatin is known to be in a sol state. Taken together, these studies 
further established that gelatin and Laponite® have the ability to form a robust injectable hydrogel 
network for regenerative medicine applications. Lastly, in vitro biocompatibility testing with the 
different hydrogel formulations was carried out using an MTS assay. Briefly, HUVECs were 
seeded with complete endothelial growth media and allowed to reach confluency prior the addition 
of the respective nanocomposite hydrogel. After 1 day, 3 days and 5 days, no significant difference 
in cell number between the groups was observed indicating that the hydrogel did not produce any 
cytotoxic effects irrespective of the concentration of Laponite® included in the network (Fig 
S4.5A). These results were also supported by immunofluorescent staining for F-actin of the 
HUVECs which showed no morphological difference between the groups (Fig S4.5B). Overall, 
due to the superior rheological properties and absence of cytotoxicity, the nanocomposite hydrogel 
containing 2% w/v of Laponite® was chosen for further in vivo testing. 
4.3.4 In Vivo Biocompatibility of the injectable nanocomposite hydrogels 
To ensure that no significant immune response was induced by the nanocomposite hydrogel, 
preliminary in vivo biocompatibility tests in immunocompetent rats were performed (n=5). 
Immunohistochemical staining of the myocardium indicated that there was no substantial 
inflammation (TNFα) or cardiomyocyte damage (TUNEL) caused by the hydrogel injections (Fig 
S6 and S7), 14 days post infarction. Similar results were obtained by qPCR that indicated that 
there was no significant difference in pro-inflammatory (TNFα, miR-146, miR-155) or 
cardiomyocyte apoptotic (miR-145, Cyclin D1, Rb1) gene and miRNA expression between the 
control and animals injected with the hydrogel (Fig S4.8). Lastly, upon injection of the 
nanocomposite hydrogel, no inhibition of proper cardiac function was observed (Fig S4.9). 
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Therefore, based on these combined results we can conclude that the nanocomposite hydrogel is 
biocompatible as seen in previous regenerative medicine studies. 186  
4.3.5. In vivo therapeutic efficacy in myocardial infarcted rat model 
Despite the multiple clinical trials and preclinical studies investigating stem cell therapy for the 
treatment of AMI, outcomes thus far have been sub-optimal due to the complex pathology 
resulting from this CVD and the lack of retention of the cells at the delivery site. Recent research 
has established paracrine signaling as the widely accepted mediator of the positive outcomes that 
have been observed from stem cell therapy in the heart. 65, 172 However, using the cocktail of 
therapeutic biomolecules produced by stem cells in vitro (secretome) to promote myocardial 
regeneration post acuteMI is still in its infancy. 83, 223 Specifically, there are few publications 
dedicated to using biomaterials in combination with secretome despite the well-established 
importance of biomaterial use in initiating an optimal local regenerative response in the heart upon 
cell, gene, or growth factor delivery. 105, 185 Therefore, in this study, we aimed to develop a 
biocompatible, injectable hydrogel containing stem cell-derived secretome for acute MI therapy. 
Taking advantage of the relatively high protein adsorption capacity of Laponite® and its ability to 
contribute to hydrogel stiffness we developed a nanocomposite hydrogel loaded with stem cell 
derived secretome and hypothesized that it would successfully treat pathologies associated with 
acute MI in vivo. 
Subsequent studies to investigate the therapeutic efficacy of the secretome loaded nanocomposite 
hydrogel were assessed in an acute MI rat model using established methods (Fig 4.4A). 179, 192 
Preliminary baseline echocardiographs (Fig 4.4A and B) were collected (EF% ≈ 50, FS% ≈ 27, 
and CO ≈ 42 L/min for all groups) and subsequent echocardiographs were taken at day 3, 7, 14 
and 21 (Fig 4.4A). Initially, there was no significant difference in heart function observed on day 
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3 (Fig 4.4 C and E). However, on day 7 all three cardiac function parameters were significantly 
increased in the nSi Gel+ group (EF%=56.9, FS%=31.1, CO=10.9 L/min) with respect to the 
control and nSi Gel groups (Fig 4.4C and E). This trend continued on day 14 with the exception 
of the cardiac output (EF%= 57.0±4.6, FS% = 31.1±3.3) (Fig 4.4C and E). Once again on day 21, 
all three heart function parameters significantly improved in the nSi Gel+ group (EF%= 62.8±3.0, 
FS% = 33.8±2.8, CO = 66.7±6.6) with respect to the control (EF%= 45.2±5.0, FS% = 23.5±3.1, 
CO = 48.3±7.6) and the nSi Gel (EF%= 46.7±6.8, FS% = 23.4±3.8, CO = 50.2±13.2) groups (Fig 
4.4C and E). These three assessments are vital systolic functional parameters that are commonly 
used to assess the extent by which acute MI pathologies have affected myocardial function. 223-226  
Therefore, we can confidently conclude that the secretome loaded nanocomposite hydrogel is able 
to improve heart function after the characteristic initial decline caused by acute MI cardiac 
remodeling. In addition, we observed that the secretome loaded nanocomposite hydrogel was able 
to improve cardiac function significantly better than the injection of the secretome solution alone 
indicated by the EF% of 62.8±3.0 % and 50.5±3.2 % at day 21 (Fig S4.10), respectively. This 
confirms the importance of the hydrogel delivery vehicle for a greater therapeutic outcome. 
As mentioned previously, vascular repair mechanisms constitute a paramount means to reduce 
myocardial injury and therefore, they are necessary for the improvement of the heart function after 
acute MI. 83, 223 In order to assess the therapeutic potential of the nSi Gel+ to promote angiogenesis 
within the infarcted heart (Fig 4.5A) of an acute MI rat model, the animals were sacrificed, and 
the myocardium was stained for vWF and SMA within the peri-infarct region (Fig 4.5B). A 
significantly larger density of vWF and SMA positive vessels was seen in the animals treated with 
the nSi Gel+ when compared to the nSi Gel and control group (Fig 4.5C). In addition, the increased 
presence of SMA staining was also observed in the nSi Gel+ group (Fig 4.5B).  
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These results indicate that there was not only more capillary formation within the nSi Gel+ group 
but also the presence of more mature vessel morphology shown by the SMA staining. These results 
indicate that the proangiogenic growth factors and cytokines detected within the stem cell derived 
secretome were indeed able to promote angiogenesis in the heart post-acute MI when delivered 
using the nanocomposite hydrogel. Another result of acute MI that impairs proper myocardial 
function is the replacement of functional myocardium with fibrous scar tissue known as cardiac 
remodeling that is caused by cardiomyocyte necrosis. 83, 131, 179 A histological analysis of the hearts 
from each group was used to assess if the nSi Gel+ was able to reduce the extent of this cardiac 
remodeling (Fig 4.5D). The results showed that the nSi Gel+ was able to significantly limit the 
infarct size to 15.6±4.5% of the total heart while the infarct accounted for 38.4±9.0% and 
31.6±9.0% of the control and nSi Gel hearts, respectively (Fig 4.5E). These results were further 
supported by the calculated heart weight to body weight ratios that indicated the ratio obtained 
from the nSi Gel+ group hearts was significantly greater (Fig 4.5F). This decrease in cardiac 
fibrosis combined with an increase in angiogenesis has been associated with the improvement of 
the cardiac function post-acute MI in other studies, 83, 131, 179, 223 and may represent the potential 
mechanisms that likely facilitated the improvement in cardiac function that we observed in this 
work. 
 
4.4 CONCLUSIONS 
We have successfully designed an injectable therapeutic nanocomposite hydrogel that represents 
a promising alternative to traditional stem cell therapy for the treatment of acute myocardial 
infarction. The shear thinning hydrogel was made by mixing the gelatin solution with a Laponite® 
dispersion and was used as a carrier for the delivery of stem cell derived-secretome. As expected, 
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the increase in Laponite® concentration up to 2% w/v was responsible for the formation of a highly 
physically crosslinked gel which could sustain high strain and recover its original stiffness once 
the strain was reduced to 1%. This property is essential to prevent the material from flowing out 
of the therapeutic site once injected and thus enabling longer retention of the secretome.  
Additionally, the secretome was easily isolated from hASCs cultured as spheroids using PDMS 
microwell devices. Spheroids secreted a more concentrated and diverse composition of 
proangiogenic and cardioprotective growth factors, proteins, and cytokines when compared to cells 
grown in a traditional 2D monolayer environment. Therefore, spheroid culture provides an ideal 
opportunity to deliberately adjust the secretome composition to directly promote key therapeutic 
processes needed for cardiac regenerative medicine applications. The injection of the secretome 
loaded hydrogel in the peri-infarct area in an acute myocardial infarction rat model promoted 
increased angiogenesis, reduction in cardiac remodeling, and cardioprotection in vitro and in vivo. 
Overall these results suggest that the stem cell-derived secretome loaded hydrogel represents a 
viable option for the promotion of myocardial regeneration and myocardial therapy post-acute MI. 
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CHAPTER 5. DEVELOPMENT OF SUPERIOR THERAPEUTIC 
SECRETOME ENRICHED WITH MIR-146A FOR MYOCARDIAL 
REGENERATION§ 
ABSTRACT 
Secretome-based therapies have the promising potential to become the next generation of viable 
treatments to restore a proper cardiac function after acute myocardial infarction (AMI). However, 
to advance their translation into the clinic, it is important to design precise strategies aimed to 
refine and control the secretome composition to further enhance their therapeutic regenerative 
potential. Here in this chapter, we present a possible approach in this direction by describing a 
method to enhance the secretome composition. Specifically, this control was achieved by 
transfecting human adipose-derived stem cells (hASCs) with the well-characterized microRNA-
146a (miR-146a), which is a potent regulator of several processes including angiogenesis and 
inflammation. The preliminary hypothesis was that by transfecting hASCs with this type of 
microRNA (miRNA) it is possible to obtain a stem cell-derived secretome with a superior 
angiogenic and anti-inflammatory response. To test this hypothesis, the composition of the 
secretome obtained from the transfected hASCs (secretome146a) was thoroughly characterized to 
evaluate possible changes in angiogenic and anti-inflammatory growth factor, cytokine and 
miRNA composition in comparison to the secretome retrieved from non-transfected hASCs. Then 
to confirm the superior angiogenic response of secretome146a, several in vitro assays were carried 
out to test the proangiogenic effect on the proliferation, migration and tubular morphogenesis of 
human umbilical vein endothelial cells (HUVECs). Finally, HUVECs were exposed to IL-1β to 
                                                          
§ Submitted as Waters R., Subham S., Pacelli S., Modaresi S., Chakravarti A., and Paul A. (2019 Development of 
microRNA-146a enriched stem cell secretome for superior myocardial therapy. Biotechnology and bioengineering. 
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induce a state of endothelial cell activation similar to the initial stages of the inflammatory response 
and evaluate the anti-inflammatory effect of the secretome146a. Specifically, the gene expression 
and protein activity of key mediators involved in endothelial cell activation were monitored before 
and after secretome treatment. Overall, the findings of this study serve to validate whether this 
strategy can potentially be applied to design a secretome with superior therapeutic response for the 
treatment of myocardial infarction. 
5.1 INTRODUCTION 
 
Ischemic heart disease resulting from AMI remains the leading cause of death in the United States, 
accounting for approximately 16% of total deaths worldwide.4 Survival rates have improved 
significantly after AMI due to surgical revascularization and percutaneous coronary intervention. 
However, despite advancements in the pharmacological treatment of the symptoms, heart 
transplantation remains the only solution to prevent heart failure. This is caused by the lack of an 
intrinsic regenerative response within the heart, which leads to the myocardium being replaced 
with fibrotic scar tissue that inhibits a proper cardiac function. Therefore, over the past two decades 
scientist have focused their efforts in using stem cells as a strategy to regenerate the myocardium 
and restore the heart function.66   
To accomplish this goal, several adult stem cell types have been used in clinical trials based on the 
hypothesis that stem cells would induce the formation of a new functional tissue upon long-term 
engraftment in the myocardium.66 However, this hypothesis does not align with the results reported 
in several preclinical and small scale clinical trials because of the lack of observed stem cell 
retention, engraftment and transdifferentiation in these studies. Based on this evidence, the positive 
therapeutic effect has been attributed to the secretion of therapeutic paracrine molecules that 
promote endogenous reparative and regenerative responses within the infarcted myocardium. This 
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pivotal discovery has led to a significant effort in identify novel cell-free treatments which are 
based on the delivery of key angiogenic, anti-apoptotic, anti-inflammatory and anti-fibrotic 
paracrine factors. This milieu of therapeutic factors, known as secretome, has been proven to be 
effective in promoting an intrinsic regenerative response in the myocardium by restoring the 
functionality of the damaged tissue101, 172, 227. 
The secretome is a complex array of pleiotropic molecules secreted by stem cells which includes 
growth factors, cytokines, miRNA, and extracellular vesicles (EVs).1, 211 Specifically, EVs are 
small bi-layered particles that have been originally identified as a strategy of stem cells to discard 
undesired cellular material. However, in recent studies, EVs have been identified as regulators of 
cell-cell communication by carrying essential paracrine factors.228 There are two types of EVs 
regularly secreted by healthy cells. The first ones are known as exosomes (30-150 nm) and the 
second type are defined as micro-vesicles which possess a broader size distribution (100-1000 
nm). Both types of EVs are composed of a phospholipid bilayer membrane containing ligand 
receptors and major histocompatibility complex molecules which facilitate binding to cell 
receptors that are necessary to trigger signaling cascades within the target cell. In addition, EVs 
have also been shown to transport an array of RNA types including, messenger RNA (mRNA),229, 
230 and, of particular note, miRNA1, 229, 231. miRNA are small (21-23 nucleotides), endogenous, 
non-coding RNAs that negatively regulate gene expression on a posttranscriptional level and act 
as powerful regulators of pathophysiological processes.232 In the context of cardiovascular 
regeneration, stem cell-derived EVs have been shown to promote angiogenesis, modulate 
inflammation, inhibit apoptosis, and induce proliferation due to the presence of specific miRNA 
types loaded within their bilayer structure.228, 233 Precisely, among the different types of miRNA, 
miR-146a has been shown to be a potent regulator of inflammation234, 235 in addition to, its ability 
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to promote angiogenesis and inhibit cardiomyocyte apoptosis.236, 237 Based on these studies, it is 
evident that optimizing the miRNA composition within EVs represents an innovative strategy to 
develop a cell-free therapeutic treatment that exhibits a greater therapeutic efficacy for cardiac 
regeneration. 
In this study, we aimed to enhance the therapeutic efficacy of hASC-derived secretome by 
transfecting the cells with miR-146a to induce the secretion of EVs carrying this therapeutic 
miRNA. A schematic representing the overall strategy is reported (Fig 5.1). The hypothesis was 
that the presence of the miR-146a within the EVs would cause an increase in the proangiogenic 
and anti-inflammatory response of the secretome in comparison to the one produced by hASCs 
that were not transfected. To test this hypothesis, the angiogenic and anti-inflammatory growth 
factor, cytokine, and miRNA composition of the two types of secretome were compared to identify 
changes in therapeutic paracrine molecule composition after transfection. Finally, the angiogenic 
and anti-inflammatory properties of the two different types of secretome were tested and compared 
in vitro by evaluating their modulation on endothelial cell proliferation, migration, tube formation, 
inflammatory activation, gene expression and protein activity.  
 
5.2 MATERIALS AND METHODS 
5.2.1 hASCs culture conditions and transfection with miR-146a 
hASCs were purchased from Rooster Bio and originated from female donors between the ages of 
31 and 45 years old. Passages 2-6 were used for all the experiments, and cells were cultured in 
traditional 2D conditions (3.3×103 cells/cm2) using hASC High performance media (Rooster Bio 
media) at 37℃ and 5% CO2.  
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hASCs were seeded in 6 well-plates (1×105 cells/well) and cultured 24 hours in Rooster Bio media 
containing 10% of fetal bovine serum (FBS). Upon 70% of confluency, cells were washed three 
times with phosphate buffer saline (PBS) at pH 7.4. The media was then switched to endothelial 
growth medium (EGM-2 BulletKit, Lonza), without the addition of FBS and angiogenic growth 
factors including the vascular endothelial growth factor (VEGF) and human fibroblast growth 
factor-B (hFGF-B). hASCs were then transfected with the XMIR-146a-5p RNA Oligo (10 µM) 
(System Bioscience) using the Purefection Transfection Reagent (System Bioscience). 
Specifically, 30 µL of the oligonucleotide suspension and 7.5 µL of the transfection reagent were 
mixed prior addition to the cells in 200 µL of DMEM media without any FBS. The mixture was 
vortexed briefly and incubated at room temperature for 15 minutes. Then, the complex was added 
to the cells to reach a final concentration of 100 nM of oligonucleotide in each well. The well plate 
was kept on a shaker incubator for 30 minutes followed by incubation at 37℃ for 24 hours 
according to the manufacturer’s protocol. As a control group, hASCs were treated in the same 
culture condition without being transfected with the oligonucleotide miR-146a. The media was 
collected from both groups, centrifuged at 16,000 x g for 10 minutes at 4℃ to remove cellular 
debris, and used fresh or stored at -20℃ for further analysis. 
5.2.2 EV isolation from transfected cells and morphological characterization 
The secretome146a and the control group (secretome) was collected as reported in the previous 
sections. After centrifugation, the exosomes were isolated using the exoEasy Maxi Kit (Qiagen). 
Briefly, the supernatant was mixed with an equal volume of the XBP buffer (Qiagen) and 
centrifuged at 500 x g for 1 minute followed by subsequent washing steps according to the 
manufacturer’s protocol.  The isolated exosomes were retrieved in the XE elution buffer in a final 
volume of 400 µL.  
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Exosomes morphological analysis was carried out by transmission electron microscopy (TEM) 
and scanning electron microscopy (SEM) analysis. TEM and SEM samples were prepared by 
adding 5 μL of the exosome sample onto the carbon-coated 200-mesh copper grids for 5 minutes 
to allow the exosomes to adsorb to the surface. The grids were dried for several hours in a 
desiccator. The dried grids were analyzed with a Philips CM100 microscope operated at 100 kV. 
High-resolution TEM images were recorded on FEI Tecnai F20XT, 200 kV (FEI, Hilsboro, OR). 
SEM images were obtained at an acceleration voltage ranging from 1 to 10 kV with an in-lens 
detector of a FEI Versa 3D Dual Beam microscope. 
Finally, the exosome size distribution and concentration were assessed by nanoparticle tracking 
analysis (NTA) using a Malvern Panalytical NanoSight LM10. Exosomes samples were suspended 
in PBS and injected into the sample chamber using sterile syringes. The samples were loaded by 
filling the chamber without the introduction of air bubbles. The detection threshold was fixed to 
60 particles per field of view and camera level was set in standard mode. All measurements were 
performed in triplicate at room temperature with every measurement lasting for 1 minutes. The 
concentration values and the particle sizes were determined using the NanoSight software. 
5.2.3 Western blot analysis of isolated EVs 
Western blot analysis was carried for both the exosomes and the cell lysates samples to verify the 
presence of specific protein markers in the exosome population. hASCs were cultured following 
the cell culture conditions described in the section 5.2.1 and the exosomes were isolated based on 
the procedure described previously in 5.2.2.  The cell lysate was prepared by treating hASCs with 
RIPA buffer containing Tris-HCl (pH 7.6, 25 mM), NaCl (150mM), NP-40 (1% w/v), sodium 
deoxycholate (1% w/v) and sodium dodecyl sulfate (0.1% w/v). The protein concentration was 
determined by measuring the optical density at 280 nm using a spectrophotometer (Nanodrop ND-
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1000; Thermo Scientific). The exosomes samples were normalized using the same sample volume 
in the pre-casted gel for western blot analysis (29 µL).  
The protein samples (80 µg of cell protein or 29 uL of exosomes in each well) were resolved by 
SDS-PAGE (BoltTM 4-12% Bis-Tris Plus) at 180V for 42 minutes. The proteins bands were 
transferred to PVDF membranes (Immobilon-P Transfer Membranes), blocked in 0.5% Tween 20 
and probed with antibodies which were diluted in the corresponding blocking buffer. The cellular 
protein cytochrome c was resolved under reducing conditions while the exosome protein CD63 
was resolved under non-reducing conditions. The antibodies used were anti-CD63 antibody 
(ab59479) dilution 1:2000, and anti-cytochrome c antibody (ab110325) dilution 1:2000 in the 
blocking buffer. Goat anti-Mouse IgG H&L (HRP) (ab205719) was used as the secondary 
antibody at dilution of 1:4000. The protein band signals were detected using an X-ray film and 
enhanced by a chemiluminescent reagent. The signals were detected using an ECL Plus detection 
system according to the manufacturer's protocol. 
5.2.4 miRNA analysis of isolated EVs 
Exosomes isolated from the transfected and the non-transfected groups, as reported in section 
5.2.2, were assessed to evaluate their miRNA content and composition. miRNA was isolated from 
the exosomes using the exoRNeasy Serum/Plasma Maxi Kit (Qiagen). The total RNA 
concentration and purity were determined by measuring the optical density at 260 nm using a 
spectrophotometer (Nanodrop ND-2000; Thermo Scientific). Complementary DNA (cDNA) was 
synthesized starting from the isolated RNA using the miScript II RT Kit (Qiagen). The qPCR 
analysis was performed in triplicate for each test group on a Mastercycler Realplex4 (Eppendorf) 
using predesigned primers and miScript SYBR Green PCR Kit (Qiagen). Fold expression levels 
of miR-146a in the transfected group (secretome146a) were calculated using the relative ΔΔCt 
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method, using RNU6 as the housekeeping gene. Similarly, following the same protocol, qPCR 
analysis was carried out using a miSCript miRNA PCR array 96 well-plate (Qiagen) to detect the 
composition of the miRNA present in the exosomes samples upon transfection compared to the 
non-transfected group. 
5.2.5 Assessment of transfected cell-derived secretome protein composition 
The secretome obtained from the transfected (secretome146a) and non-transfected hASCs 
(secretome), was assessed using a human angiogenesis antibody array and human cytokine array 
(R&D Systems). The two arrays were used to detect the differences in composition between the 
two different types of secretome by analyzing the relative levels of 55 angiogenic related proteins 
and 36 different cytokines, chemokines and acute phase proteins, respectively. The studies were 
carried out according to the manufacturer’s protocols. Images of the corresponding 
chemiluminescent dot blots were taken and the mean spot pixel density for each protein was 
calculated using ImageJ software. 
5.2.6 HUVEC proliferation assay with secretome146a 
Furthermore, angiogenic studies were carried out to assess the superior proangiogenic ability of 
the secretome146a. Immortalized HUVECs were cultured in endothelial basal medium [EGM-2 
BulletKit, (Lonza), 2% FBS, and 1% penicillin/streptomycin] with complete endothelial growth 
supplements. HUVECs from passage 2-5 were used in all the in vitro angiogenic studies.  HUVECs 
(0.2×105 cells/mL) were seeded in a 48 well plate and allowed to grow overnight in EGM-2 media, 
without the addition of FBS and angiogenic growth factors, VEGF and hFGF-B. The cells were 
then washed with PBS and the media was then replaced with media supplemented with different 
type of secretome as described in section 5.2.1. Precisely, three groups were tested: a negative 
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control consisting of HUVECs cultured in EGM-2 media without growth factors (Ctrl (-)), 
endothelial cells cultured in the same media supplemented with secretome isolated from non-
transfected ASCs (secretome), and a test group where the media without growth factors was 
supplemented with secretome isolated from transfected ASCs (secretome146a) (n=5). The final 
volume in each well was 200 µL and the volume of secretome for both test group was 100 µL. The 
degree of HUVEC proliferation in the presence of the secretome was assessed by MTS 
proliferation assay (Promega) after 24 hours using a standard calibration curve in the range of 
5x103 up to 1x105 cells. The absorbance measurements were carried out at 490 nm according to 
the manufacturer’s protocol 
5.2.7 HUVEC migration and tube formation assay with secretome146a 
HUVECs (3×105 cells/mL) were seeded in Ibidi 3-well culture inserts within a 24 well plate as per 
the company’s protocol to perform a cell migration assay (n=3). Specifically, 70 µL of the cell 
suspension was added to each well and the cells were allowed to culture overnight in EGM-2 
media. Next, the inserts were removed, and the media was changed according to same groups used 
in the proliferation assay reported in the previous section. Brightfield images were taken in the 
same positions along the scratch at 0, 6 and 24 hours after treatment to monitor HUVEC migration 
into the gap for each group. The average percentage of area recovered during the migration was 
calculated using Image J software considering 10 images per group. The area of the original gap 
was determined from the images taken at the 0 hour time point. 
Finally, to determine the ability of the secretome to induce the formation of tubular-like structures, 
HUVECs were seeded on a growth factor depleted Matrigel-based on the manufacturer’s protocol 
(Matrigel matrix, Basement Membrane, BD). Briefly, 289 mL of growth factor depleted Matrigel 
Matrix (10 mg/mL) previously cooled to 5℃ was added to a 24 well culture plate on ice. The plate 
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was then incubated at 37℃ for 60 min to allow the gel to form. Then, HUVECs (1.2×105 cells/mL) 
were seeded on the Matrigel matrix and treated with one of the same three treatment groups used 
for the proliferation and migration assays. After 10 hours, bright field images of the endothelial 
networks were taken for each group and the number of nodes, number of meshes, the total segment 
length, number of segments and number of isolated segments were determined using the 
Angiogenesis Analyzer in ImageJ. Results are reported as mean ± deviation standard considering 
at least 10 images per group. 
5.2.8 Assessment of anti-inflammatory properties of secretome146a on HUVECs 
HUVECs were seeded in 24 well plates at the cell density of 5x104 cells/well and cultured for 24 
hours using EGM-2 media without any angiogenic growth factor. Then, cells were treated with 
interlukin-1 (IL-1β) at the concentration of 10 ng/mL to induce an endothelial cell activation 
similar to the endothelial cell state in the early stages of inflammation. Three groups were tested 
in this study: a positive control where HUVECs were left untreated, and two test groups were the 
media was supplemented with the secretome derived from hASCs non-transfected (secretome), 
and the one obtained from hASCs transfected with miR-146a (secretome146a), respectively. Half 
of the volume of the media in each well was replaced with secretome for both test groups.  
After 4 and 24 hours the mRNA was extracted from the HUVECs using the RNeasy Mini Kit. The 
total RNA concentration and purity were determined by measuring the optical density at 260 nm. 
cDNA was synthesized starting from the isolated RNA using the miScript II RT Kit (Qiagen). The 
qPCR analysis was performed in triplicate for each test group on a Mastercycler Realplex4 
(Eppendorf) using predesigned primers and miScript SYBR Green PCR Kit (Qiagen). Fold 
expression levels of several genes including vascular cellular adhesion molecule-1 (VCAM-1), 
intracellular adhesion molecule-1 (ICAM-1), tumor necrosis factor receptor associated factor 6 
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(TRAF6), and monocyte chemoattractant protein-1 (MCP1) were evaluated at 4 and 24 hours post-
treatment. The data was analyzed using the relative ΔΔCt method, and GAPDH was used as the 
housekeeping gene. 
In addition to the gene analysis, the anti-inflammatory effect of the two types of secretome was 
investigated by studying the expression of ICAM and the secretion of MCP-1 by the IL-1β 
activated HUVECs. HUVECs were washed with PBS three times after 8 hours post-treatment with 
one of the secretomes. Cells were blocked with 5% w/v goat serum for 15 minutes, followed by 
incubation for 30 minutes with primary antibody against ICAM (2µg/mL in 1% goat serum). Cells 
were then washed three times with PBS and incubated for 30 minutes with the secondary antibody 
Anti-Mouse IgG H&L (Alexa Fluor® 488) (ab150113) for ICAM stained samples at the of dilution 
1:2000. Cells were washed with PBS three times, recovered using trypsin, resuspended in PBS and 
FACs analysis was carried out to quantify the amount of fluorescent positive stained cells in the 
three different groups using the Attune NxT flow cytometer (Thermo Fischer Scientific).  
Finally, HUVECs secretion of MCP-1 was assessed using an ELISA kit for MCP-1 (R&D 
Systems). A standard curve in the range of 31.3 pg/ml to 1000 pg/mL was used to correlate the 
absorbance values at 450 nm with the amount of protein present in each sample.  
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Isolation and characterization of miR-146a enriched EVs derived from hASC   
The regenerative potential of mesenchymal stem cell (MSC)-derived secretome in restoring proper 
heart function within the damaged myocardium after AMI relies on the combination of multiple 
paracrine molecules secreted by MSCs. These include an array of angiogenic, anti-inflammatory, 
cardioprotective, and anti-fibrotic growth factors, cytokines, and EVs.172 Specifically, EVs are 
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emerging as key components of the MSC therapeutic paracrine mechanism due to their ability to 
carry proangiogenic, anti-inflammatory and anti-apoptotic miRNA. Therefore, tailoring their 
miRNA content represents an ideal approach to increase the therapeutic efficacy of secretome 
leading to a superior regenerative response in the myocardium.  
In the present study, hASCs were successfully genetically modified to overexpress miR-146a in 
the secreted exosomes. We chose to use hASCs over other MSC sources because their minimally 
invasive isolation technique has a low morbidity and produces a high cell yield making this method 
more clinically feasible than other MSC isolation procedures.77 Specifically, hASCs were transfected 
with a miR-146a oligonucleotide fused to a RNA sequence tag that specifically targets small RNAs 
into exosomes for packaging (Fig 5.1). After transfection, the hASCs were cultured for 24 hours 
and the resulting secretome146a was isolated for characterization and therapeutic assessment. EVs 
within the hASC-derived secretome were separated to characterize their size, morphology, protein 
composition, and miRNA content. Electron microscopy images showed that the hASC-EV 
particles had bilayer membrane with a primarily uniform circular morphology (Fig. 5.2A and B, 
Figure S5.1). NTA analysis revealed that the average diameter of the EVs was 201.2 ± 12.7 nm 
with 90% of the population having a diameter less than 360.3 nm (range 60-600 nm) (Fig. 5.2C). 
In addition, the most prevalent subpopulation within the EVs had a diameter of 138.1 nm indicating 
an exosome-enriched EV population with generally limited size heterogeneity.238 Western blot of 
hASCs and hASC-EVs confirmed the presence of transmembrane tetraspanin protein CD63 and 
absence of the mitochondrial protein cytochrome c within the hASC-EVs (Fig. 5.2D). These 
results confirm the endosomal origin of the EVs.239 Tetraspanins have been shown to bind several 
integrins and MHC molecules therefore, the enrichment of CD63 is important for potential protein-
protein interactions between EVs and cellular membranes.230, 240 
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Lastly, the transfection efficiency was confirmed by comparing the miRNA composition of the 
EVs isolated from secretome (hASCs not transfected) and secretome146a using RT-qPCR, which 
revealed that EVs from secretome146a were highly enriched with miR-146a (p < 0.001) (Fig. 5.2E). 
5.3.2 Angiogenic properties of secretome146a  
An efficient secretome-based therapy aimed to restore myocardial function after AMI needs to 
provide the necessary angiogenic cues required to re-establish proper blood perfusion to the 
damaged myocardium. The secretome obtained from non-transfected hASCs displayed a slightly 
greater amount of angiogenin and VEGF however, the secretome146a contained larger amounts of 
several key angiogenic growth factors including, urokinase-type plasminogen activator (uPA), 
dipeptidyl peptidase IV (DPP IV), endothelin 1, hepatocyte growth factor (HGF), and fibroblast 
growth factors 1 and 2 (FGF-1 and FGF-2) (Fig. 5.3A). Specifically, uPA regulates angiogenesis 
through proteolytic degradation of the extracellular matrix that facilities the subsequent 
proliferation and migration of endothelial cells.241, 242 FGF-2 has been shown to induce 
proliferation, promote migration, and inhibit apoptosis of endothelial cells in vitro in addition to, 
improve revascularization, cardiac function and reduce in infarct size in AMI in vivo studies.211, 
243, 244 Similarly, HGF has been proven to promote endothelial cells proliferation and migration as 
well as, improve heart function post-AMI attributed to induced angiogenesis. 202, 211, 245 In addition 
to a greater presence of angiogenic growth factors in the secretome146a, several proangiogenic 
miRNAs were significantly more  concentrated in the secretome146a EVs when compared to the 
EVs in the secretome including, miR-126-3p (p < 0.01), miR-210 (p < 0.01), miR-143-3p, and 
miR-130a-3p (p < 0.05) (Fig. 5.3B). These specific miRNAs have been shown to increase 
endothelial cell proliferation, promote neovascularization, and improve cardiac function post-
AMI.1, 193, 246, 247 Lastly, the secretome146a EVs also contained significantly less anti-angiogenic 
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miRNA compared to the secretome including, miR-26a-5p (p < 0.05), miR-92a-3p (p < 0.05), 
miR-15-5p (p < 0.01), and miR-222-3p (p < 0.05) (Fig. 5.3C).103, 248 
The angiogenic efficacy of the two groups was assessed using three different in vitro HUVEC 
assays. HUVECs cultured in endothelial growth media without the addition of VEGF and FGF-B 
was used as the control group (Ctrl (-)). Angiogenesis is a tightly regulated multistep physiological 
process that begins with the migration and proliferation of activated endothelial cells through the 
perivascular tissue to form capillary sprouts originating from existing vessels.211 Therefore, first 
an MTS assay was used to determine the effect each secretome type had on HUVEC proliferation. 
After 24 hours, a higher cell number was observed in the secretome146a group when compared to 
the control and the secretome group (p < 0.05) (Fig. 5.3E). Next, the ability of the secretome to 
promote HUVEC migration was determined using silicone inserts that allowed the formation of a 
defined cell-free gap of 1 mm in the center of a confluent HUVEC monolayer. After 6 hours 
minimal migration had occurred in all three groups however, at 24 hours the HUVECs treated with 
the secretome146a had migrated to cover 55% of the cell-free area as opposed to the HUVECs in 
the Ctrl (-) and secretome groups which only covered 27% and 37%, respectively (p < 0.001 and 
p < 0.05, respectively; Fig. 5.3D and F).  
After the formation of the capillary sprouts, it is necessary for endothelial cells to properly align 
and form tubes with a patent lumen that can provide the scaffold needed for basement membrane 
deposition.214 The capacity of the secretome to induce the formation of tube-like structures by 
HUVECs was evaluated using a Matrigel assay. HUVECs were culture on Matrigel-coated wells 
either in the presence of secretome or secretome146a for 16 hours before images were taken (Fig. 
5.4A). Similar to the proliferation and migration assay, the secretome146a caused the formation of 
significantly greater number of nodes (p < 0.01; Fig. 5.4B), complete tubes (p < 0.01; Fig. 5.4C), 
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and segments (p < 0.001; Fig. 5.4D) as well as longer segment lengths (p < 0.001; Fig. 5.4E). 
Additionally, a reduction in the number of isolated segments (p < 0.001; Fig. 5.4F) was also 
observed in the secretome146a group compared to the secretome group. Similar trends were seen 
when comparing the secretome146a to the Ctrl (-) group (p < 0.001; Fig. 5.2B-F). These three assays 
together confirmed the superior angiogenic efficacy of secretome146a. Therefore, based on these 
results and the composition analysis, the transfection of hASCs with miR-146a resulted in the 
production of a secretome with superior proangiogenic efficacy compared to the one isolated from 
non-transfected hASCs. These results are in agreement with a previous study that correlated the 
improvement of cardiac function, cardioprotection and angiogenesis post-AMI after treatment 
with exosomes that displayed an abundant presence of miR-146a.236 
5.3.3 Immunomodulatory properties of secretome146a  
After AMI, an acute inflammatory response is needed for proper clearance of damaged 
extracellular matrix and necrotic cardiomyocytes. However, the intensity and duration of this 
inflammatory response must be tightly regulated to prevent further damage to the tissue. Therefore, 
a potential strategy for an efficient secretome-based therapy could also be to modulate the 
inflammatory response to promote cardiac regeneration.249  
We compared the cytokine and miRNA composition of the two different types of secretome to 
identify paracrine molecules that could potentially modulate an inflammatory response. The 
comparison of the inflammatory cytokine composition of each secretome indicated that only one 
cytokine, granulocyte colony-stimulating factor (G-CSF), was expressed exclusively in the 
secretome146a (Fig 5.5A). Despite the fact that G-SCF has not been shown to have anti-
inflammatory properties, its known ability to recruit stem/progenitor cells, inhibit apoptosis and 
promote angiogenesis in the context of myocardial regeneration could support any enhanced 
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therapeutic efficacy observed with secretome146a treatment.250, 251  The remaining cytokines 
including CCL-1, CCL-2, TRAP, and IL-4 were detected at comparable levels in the two different 
secretomes. Furthermore, the miRNA present in the EVs originating from the two different 
secretomes was compared and showed that several anti-apoptotic miRNA were significantly 
upregulated in the secretome146a (miR-22-3p (p < 0.05), miR-214-5p (p < 0.05), miR-24-3p (p < 
0.01)) in addition to, a significant downregulation in multiple pro-apoptotic miRNAs (miR-29b-
3p (p < 0.05), let-7c (p < 0.01), and let-7b-5p (p < 0.05)) (Fig. 5.5B and C).252-255 Therefore, the 
miRNA in the secretome146a EVs represent an ideal treatment for the inhibition of inflammation 
within the myocardium due to the fact that the damage-associated molecular patterns (DAMPs) 
released by apoptotic and necrotic cardiomyocytes are key regulators in the activation of 
endothelial cells to an inflammatory state. 
A key target of the inflammatory process within the damaged myocardium is the endothelium, 
which directly controls the extravasation of leukocytes that are recruited to the infarct area from 
the spleen.7 Precisely, in the initial stages of inflammation, an upregulation of leukocyte adhesion 
molecules (VCAM, ICAM, E-selectin) on endothelial cells is vital for efficient capture of 
neutrophils and subsequent mediation of their tethering and rolling process along the venular 
endothelium.7 To mimic the process of endothelial cells inflammatory activation by circulating 
cytokines, we exposed HUVECs to the pro-inflammatory cytokine, IL-1β, and assessed the ability 
of the secretome to modulate the subsequent HUVEC inflammatory activation.  
The anti-inflammatory efficacy of the secretome and secretome146a was then assessed evaluating 
the gene expression of several genes involved in the regulation of the inflammatory response in 
HUVECs. First, IL-1β was shown to cause an upregulation in the gene expression of ICAM, MCP-
1, and VCAM and there was no difference in gene expression between all three test groups 4 hours 
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after treatment (Fig. 5.5D). However 24 hours after treatment, the secretome146a was shown to 
significantly decrease the gene expression of ICAM (p < 0.01), MCP-1 (p < 0.01), and VCAM (p 
< 0.05) compared to the secretome treated group (Fig. 5.5E).  
In addition to the gene upregulation of adhesion molecules for leukocytes, activated endothelial 
cells also serve as an important source of cytokines and chemokines within the infarct zone.7, 256 
Therefore, we also studied the effect the two different types of secretome had on MCP-1 secretion 
by IL-1β activated endothelial cells. Secretome146a was also able to significantly suppress the 
secretion of MCP-1 by HUVECs after IL-1β treatment compared to the Ctrl (-) and secretome 
group (p < 0.001 and p < 0.05, respectively; Fig. 5.5F). The expression of adhesion protein ICAM 
was also shown to decrease upon secretome treatment with the secretome146a group, which 
exhibited the lowest expression amongst the three test groups (Fig. 5.5G).  
Together these results demonstrate that secretome146a has the capacity to modulate several of the 
inflammatory responses exhibited by endothelial cells upon activation by inflammatory cytokines 
such as IL-1β. Additionally, these results confirm that the secretome retrieved from transfected 
hASCs has superior anti-inflammatory properties and could potentially be used in late stage 
resolution of the acute inflammation post-AMI to downregulate endothelial cell activation and 
therefore, inhibit excessive transmigration of neutrophils into the myocardium.      
 
5.4 CONCLUSIONS 
 
In this study we have successfully enhanced the therapeutic efficacy of hASC-derived secretome 
by transfecting hASC with miR-146a. By using this specific miRNA sequence tagged 
oligonucleotide we efficiently caused the EVs secreted by hASC to be enriched with the known 
therapeutic miRNA. The resulting EV population exhibited a size and protein composition 
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indicative of an exosome-enriched population, a subpopulation of EVs that have been implicated 
in an increase in cardiac function post-AMI. Within the EVs secreted by the transfected hASCs, 
we detected an increased concentration of proangiogenic and anti-apoptotic miRNAs as well as, a 
decreased concentration of anti-angiogenic and pro-apoptotic miRNAs when we compared them 
to the EVs secreted by non-transfected hASCs. Furthermore, the growth factor and cytokine 
composition of this secretome showed a significantly higher concentration of several key 
proangiogenic, chemotactic, and anti-apoptotic proteins which are shown to improve cardiac 
function post-AMI. The enhanced composition of therapeutic paracrine molecules present in the 
secretome146a also corresponded to a superior therapeutic efficacy in vitro. Specifically, the 
secretome146a was shown to significantly upregulate the proliferation, migration and tube 
formation of endothelial cells proving enhanced proangiogenic properties. Additionally, the 
secretome146a was able to suppress the pro-inflammatory behavior of IL-1β activated endothelial 
cells by reducing the expression of leukocyte adhesion molecules and the secretion of pro-
inflammatory cytokines. Overall these results suggest that the secretome146a represents a viable 
treatment option for the promotion of angiogenesis and modulation of the inflammation and 
therefore, could potentially be used to promote myocardial regeneration post-AMI.  
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CHAPTER 6. CONCLUSIONS  
Secretome represents a promising alternative to traditional stem cell therapy due to its observed 
therapeutic efficacy in pre-clinical studies that have been attributed to the presence of specific 
paracrine molecules secreted by adult stem cells in vitro.172, 257 Several conditioning strategies are 
currently being investigated to modify the growth factor, cytokine, miRNA, and EV composition 
of the secretome with the final goal being to optimize its therapeutic efficacy. Specifically, these 
methods include hypoxia, serum deprivation, genetic manipulation, molecular and 
pharmacological agents, and the promotion of cell-cell interactions.73, 172 Despite the success in 
using these methods, the clinical translation of secretome-based therapies has been hindered by its 
inherent heterogeneity, pleiotropic nature and the lack of studies characterizing its complete 
composition to thoroughly identify the components that are responsible for the positive 
outcomes.101 In addition, the lack of retention at the delivery site reduces the therapeutic 
response.105  Therefore, the work in the current thesis aimed to address these two concerns by using 
different secretome production methods and by designing an injectable hydrogel-based delivery 
device to promote the efficient retention at the therapeutic site.  
Initially, we cultured hMSC in spheroids to induce a mild state of stress and promote cell-cell 
interactions in an effort to promote the production of a more therapeutic secretome composition. 
We observed that the secretome isolated from hMSC spheroids contained a greater concentration 
of proangiogenic growth factors including VEGF, FGF2, and angiogenin when compared to 
secretome produced by hMSCs cultured in a traditional 2D monolayer. Then, we developed photo-
crosslinkable hydrogel composed of GelMA (5% v/v) and varying concentration of Laponite® 
(0.4, 0.8, 1.2% w/v) for the delivery of the isolated secretome. Higher Laponite® concentrations 
were shown to control the release of key angiogenic growth factors present in the loaded 
secretome. These results are likely due to electrostatic interactions between the surface of the clay, 
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and the growth factors.220, 258 Aside from the release study, the model nanocomposite hydrogel was 
used as a platform to determine the therapeutic efficacy of the secretome-loaded hydrogel in vitro. 
Specifically, HUVECs were encapsulated in the nanocomposite hydrogels containing GelMA and 
Laponite® and two different groups were compared including, the nanocomposite hydrogel 
containing the secretome (NS Gel+) and without the secretome (NS Gel). The studies showed that 
the NS Gel + promoted greater HUVEC proliferation, migration and tube formation therefore, 
exhibiting superior proangiogenic efficacy compared to the NS Gel. This enhanced therapeutic 
efficacy of the NS Gel+ was also observed in cardioprotective assays. Specifically, the NS Gel+ 
inhibited apoptosis, ROS production and Caspase 3/7 activity of cardiomyocytes. Together this 
study demonstrated hMSCs spheroids produce superior angiogenic and cardioprotective secretome 
and Laponite® can effectively modulate the release of therapeutic growth factors contained in the 
secretome.  
The next goal of the thesis was to formulate a secretome-based treatment that was more clinically 
feasible by developing an injectable nanocomposite hydrogel for the delivery of stem cell-derived 
secretome to the myocardium. To accomplish this goal, while leveraging the knowledge gained in 
the previous study, we combined gelatin (5% w/v) with varying concentrations of Laponite® (0, 
1, 2% w/v). Rheological testing of the resulting nanocomposite hydrogels was done to assess the 
effect Laponite® had on the mechanical properties and to ensure their thixotropic behavior. The 
results indicated a positive correlation between the increase in Laponite® concentration and the 
resulting rheological properties including an improvement in yield stress, viscosity, and thixotropic 
behavior. One of the likely causes for this direct correlation can be explained by the possible 
electrostatic interactions occurring between the predominately negatively charged Laponite® 
disks and the positive charges of lysine ε-amino groups of gelatin. This hypothesis was confirmed 
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by the observed decrease in the loss factor, tan δ = G’’/G’, between the hydrogel containing 1% 
(w/v) versus 2% (w/v) Laponite® over a range of oscillatory frequencies from 0.01 to 10 Hz. This 
reduction in tan δ coupled with the significant increase in G’ at greater concentrations of 
Laponite®, confirms that Laponite® increases the crosslinking density within the nanocomposite 
hydrogel. Similar results have been observed with several other nanocomposite hydrogels 
containing various hydrophilic polymers and Laponite® therefore, further validating our 
observations.221, 222 Although the exact interactions were not studied in this current thesis, this type 
of physical crosslinking between polymers and nanosilicates is generally attributed to hydrogen 
bonding, dipole, and ionic interactions.186, 221. An increase in the Laponite® concentration also 
caused a reduction in the degradation rate of the hydrogel and superior control over the release of 
an encapsulated model protein. Therefore, we have concluded based on these studies that a 
nanocomposite hydrogel containing gelatin and Laponite® has the ideal properties to support the 
delivery of stem cell-derived secretome to the heart. Furthermore, similar to the previous study 
and in order to produce a therapeutic secretome, hASCs were cultured in a microwell device in 
order to form spheroids. The hASC spheroid-derived secretome (3D secretome) contained key 
angiogenic growth factors that were not present in the hASC monolayer-derived secretome (2D 
secretome) including, endostatin/collagen XVIII and HGF. In addition, the superior angiogenic 
efficacy of the 3D secretome was confirmed using several HUVEC cell assays in vitro.  
Due to the positive in vitro studies, an AMI rat model was used to assess the therapeutic efficacy 
of the 3D secretome-loaded injectable nanocomposite hydrogel (nSi Gel+). Preliminary tests of 
the nanocomposite hydrogel (nSi Gel) showed no difference between the pro-inflammatory or 
cardiac stress proteins and the miRNA of the nSi Gel compared to the PBS treated group, which 
confirmed the biocompatibility of the nSi Gel. Furthermore, in the following therapeutic 
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assessment studies, after injection into the peri-infarct region 15 minutes post-AMI induction, the 
group treated with the nSi Gel+ exhibited a significant increase in heart function demonstrated by 
the increase in ejection fraction, fractional shortening, and cardiac output after 7, 14, and 21 days. 
The histological analysis of the peri-infarct region after 21 days showed significantly more 
expression of SMA+ and VWF+ in the nSi Gel+ group compared to the control groups in addition 
to a significant reduction in infarct size. Together these results indicate that the nSi Gel+ was 
indeed able to improve cardiac function post-AMI by promoting angiogenesis and limiting fibrotic 
scar development within the per-infarct region.   
As previously mentioned, the inherent heterogeneity and pleiotropic nature of the secretome’s 
paracrine molecule composition poses a challenge for clinical translation.101 Therefore, the use of 
precise methods for promoting the secretion of therapeutic paracrine molecules and a thorough 
characterization of the secretome composition is vital to facilitating the transition of secretome-
based treatments into the clinic. Therefore, for the final study we genetically modified hASCs to 
cause the enrichment of a well characterized therapeutic miRNA, miR-146a, within EVs present 
in the resulting secretome. The EV population present in the isolated secretome contained an 
exosome-rich population as demonstrated by a prevalent vesicle diameter of 138.1 nm and the 
confirmed CD63 protein composition. The transfection of hASCs was verified by the observed 
significant enrichment in miR-146a within the secretome (secretome146a) prior the therapeutic 
assessment in vitro. The focus of this study was to address two essential regenerative processes 
within the myocardium that are mediated by ECs. First, we observed the superior angiogenic 
efficacy of secretome146a compared to the secretome originating from non-transfected cells 
(secretome). Precisely, a significant increase in HUVEC proliferation, migration and tube 
formation was observed in the secretome146a group. The analysis of the proangiogenic composition 
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of growth factors and miRNA showed that the secretome146a contained a significantly larger 
concentration of uPA, DPPIV, endothelin 1, HGF, FGF-1, FGF-2, miR-126-3p, miR-210, miR-
143-3p, and miR-130a-3p in addition to, the decreased concentration of anti-angiogenic miR-26a-
5p, miR-92a-3p, miR-15-5p, and miR-222-3p compared to the secretome obtained from not 
transfected hASCs. These two analysis further supported our cell assay findings that the 
secretome146a has a superior angiogenic efficacy. 
 In addition to angiogenesis, the endothelium plays a crucial role in regulating the inflammatory 
response by controlling the extravasation of leukocytes into the damaged myocardium. Therefore, 
we studied whether secretome146a was capable of inhibiting hallmark EC behavior that is indicative 
of ECs being in an activated inflammatory state that could facilitate these initial stages of 
inflammation after the commencement of cardiomyocyte apoptosis. To mimic this activation 
HUVECs were treated with IL-1β and two different responses were studied; the expression of 
leukocyte adhesion molecule ICAM and secretion of pro-inflammatory cytokine MCP-1. 
Interestingly, secretome146a was able to significantly inhibit both processes compared to secretome 
from not transfected hASCs which implies that secretome146a has superior anti-inflammatory 
properties. An analysis of the inflammatory cytokine and miRNA composition of the secretome146a 
did not show any significant presence of anti-inflammatory paracrine molecules. However, several 
well characterized anti-apoptotic paracrine molecules were significantly more concentrated in the 
secretome146a including, G-SCF, miR-22-3p, miR-214-5p, miR-24-3p. Furthermore, similar to the 
angiogenic paracrine molecule analysis, several pro-apoptotic miRNA were downregulated in the 
secretome146a including, miR-29b-3p, let-7c, and let-7b-5p. These results support the idea that 
secretome146a is a viable proangiogenic and anti-inflammatory treatment option and therefore, 
could potentially be used to promote myocardial regeneration post-AMI. 
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Figure 2.1 Schematic diagram of an acute myocardial infarction. 
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Figure 3.1 Development of hMSC secretome-loaded hydrogel treatment schematic. 1) Photo-
crosslinkable nanocomposite hydrogels comprised of silicate nanoplatelets, gelatin methacrylate 
and hMSC derived growth factors (secretome). 2) Microbioreactor with deep concave wells to 
harness hMSC secretome. 3) Photo-crosslinked nanocomposite hydrogel encapsulating secretome. 
4) The hydrogel can promote endothelial proliferation, migration and significantly attenuate 
cardiac cell apoptosis under stressed (hypoxic and serum starved) conditions.   
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Figure 3.2 In vitro characterization of the developed nanocomposite hydrogel carrying secretome 
of hMSC spheroids. A) Microfluidic chip with concave microwell array. Optical microscopy 
image of the microfluidic chip (Scale bar: 1mm). B) hMSC spheroid formation in the deep concave 
microwell arrayed microfluidic chip. Scale bar indicate 500 μm. C) After 48h, the conditioned 
media (secretome) was harvested from the microfluidic chip leaving behind the spheroids. hMSC 
spheroids secreted higher concentration of growth factors (VEGF, FGF, Angiogenin and BMP2) 
compared to 2D culture in plates as quantified by ELISA. D) Scanning electron microscopic 
images of 0% and 0.8% NS hydrogels demonstrate the porous microstructures of the hydrogel. 
Scale bar: 100 μm E-F) Cyclic stress versus strain curves and corresponding compressive modulus 
of the hydrogel showing the effect of Laponite concentration over the mechanical properties G-H) 
Effect of NS concentration on release of VEGF and FGF2 growth factors from different NS 
hydrogel formulations over time. *** = P<0.001, n=3. 
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Figure 3.3 Angiogenic potential the developed bioactive nanocomposite hydrogel. A) Proliferation 
of HUVECs in 3D hydrogels with (NS Gel+) and without secretome (NS Gel). As a control group, 
hydrogel without NS (Ctrl Gel) was used. Cell proliferation was detected by MTS colorimetric 
assay while data (n=3) presented in the graph were normalized with data from the control gel group 
at Day 0. NS+ Gel group showed significantly higher proliferation compared to other groups. B) 
Representative photomicrographs of calcein stained HUVECs encapsulated in each hydrogel 
group. Importantly, HUVEC in NS+ Gel group also demonstrated highly branched tube-like 
structures which were absent in other groups. C)  Confocal fluorescence microscope image of 
HUVECs grown in 3D NS+ hydrogel, with blue nuclei stained with DAPI. The image confirms 
proliferation of the HUVEC all throughout the thickness of the hydrogel with highly branched 
tube-like microstructures. D) i-ii. HUVEC adhesion and migration assay inside microchannels 
fabricated from the different hydrogel groups. The microchannel was made by needle (200 μm) 
insertions and photocrosslinking. Data are expressed as mean value± Standard Deviation (SD). *** 
= P<0.001 compared to Control Gel, n=3. Scale bars: 100μm. 
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Figure 3.4 Cardioprotective nature of the developed bioactive nanocomposite hydrogel. A) 
Schematic of culturing neonatal CMs on nanocomposite hydrogels. B) Fluorescence microscope 
images of CMs grown in standard condition on NS+ hydrogel. The cells were immunostained with 
cardiac specific marker, sarcomeric α-actinin, and nuclei with DAPI (Scale bar: 10μm). C-D) 
Apoptosis assay on CMs under stressed condition by Deadend Colorimetric TUNEL assay. (Scale: 
bar: 50μm). Number of apoptotic cells per well was quantified and represented in graph as 
percentage apoptotic cells per group. MTS assay was also performed to quantify the percentage of 
necrotic cells. The picture on lower right panel shows CM cells grown on the NS+ hydrogel under 
the above mentioned stressed condition still retained expression of intact cardiac marker, 
sarcomeric α-actinin. E) Detection of ROS-induced apoptosis. Intracellular ROS quantified in 
terms of relative fluorescence intensities normalized to Ctrl gel value at 0h. F-G) To investigate 
the anti-apoptotic effects of the NS+ hydrogel, Caspase-3/7 activity was measured as an early 
indicator of apoptosis using Apo-ONE® homogeneous caspase-3/7 assay Kit (Promega, Madison, 
WI, USA). Data are expressed as mean value± Standard Deviation (SD). *** = P<0.001 and ** = 
P<0.01 compared to Control Gel, n=3. 
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Figure S3.1. SEM images of Gel-MA nanocomposite hydrogels having different concentration of 
Laponite Scale bar: 100 μm. 
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Figure S3.2. Swelling equilibrium profiles of the different nanocomposite hydrogels over time. 
The study was carried out in PBS (pH 7.4) n=4. 
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Figure S3.3 Calcein staining of HUVECs in 3D GelMA nanocomposite hydrogels having different 
concentration of Laponite. Scale bar: 100 µm 
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Figure 4.1 Preparation and characterization of secretome isolated from both hASC spheroids (3D 
secretome) and hASC monolayer (2D secretome). A) Microwell culture dish used for hASCs 
spheroid culture and characteristic fluorescent microscopy image of resultant spheroids 
superimposed on an equivalent bright-field image. Calcein and ethidium bromide was used to 
visualize live and dead cells, respectively. (Black scale bar: 1 mm, white scale bar: 200 µm). B) 
Gene expression analysis of hASCs culture in a traditional monolayer and in spheroids using 
qPCR. The data in the graph represents fold changes in the expression levels of anti-apoptotic and 
stress related genes between the two groups. Data are expressed as mean value ± standard deviation 
* p<0.05, ** p<0.01, (n = 3). C) i) Human angiogenic dot blot array of 2D hASCs monolayer 
derived secretome and corresponding quantification of the mean pixel density quantified using 
ImageJ software. ii) Human angiogenic dot blot array of hASCs spheroid-derived secretome, and 
the corresponding quantification of the mean pixel density quantified using ImageJ software. The 
presence of key cardioprotective and angiogenic factors such as endostatin/collagen XVIII and 
hepatocyte growth factor (HGF) were only detected in the secretome derived from hASCs 
spheroid. D) ELISA quantification of the concentration of VEGF and angiogenin (ANG), present 
in the secretome. The data are represented as the fold increase in growth factor concentration in 
the secretome derived from hASCs spheroids with respect to the secretome isolated from the 
monolayer hASCs culture. Data are expressed as mean value ± standard deviation (n=3). 
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Figure 4.2 In vitro superior angiogenic potential of hASCs spheroid-derived secretome. A) The 
proliferation of HUVECs was carried out in endothelial growth medium without VEGF and hFGF-
B. Cells were treated with hASCs monolayer derived secretome (2D secretome), and hASCs 
spheroid-derived secretome (3D secretome) for 24 hours. As control group (Cntrl (-)), cells were 
cultured without growth factors. HUVECs number was determined using an MTS assay. Data are 
reported as mean ± standard deviation (n=5). B) Quantification of the % of area covered by 
HUVECs after 16 hours in the different groups. The analysis was carried out by quantifying the 
area occupied by the HUVECs within the wound area post 16hour incubation using ImageJ 
software. C) Quantification of complete tube formation after 24 hours in the different groups. Data 
are expressed as mean of tubes formed in each group ± standard deviation (n=3).  * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.001. D) Fluorescent images of HUVECs stained with calcein 
showing their migration within the scratch area in the different groups after 16 hours. Scale bar: 
100 µm. Data are reported as mean ± standard deviation (n=3).  E) Representative bright-field 
images of a Matrigel tube formation assay for the different groups after 10 hours. Scale bar: 200 
µm.  
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Figure 4.3 Effect of Laponite® on the rheological properties of the nanocomposite hydrogel. A) 
Schematic representation of the injectable hydrogel main components and representative image of 
the injectable nanocomposite hydrogel using a 22 gauge needle along with SEM image illustrating 
the hydrogel porosity. Scale bar: 100 µm B) Yield stress values of the nanocomposite hydrogel 
plotted as a function of the Laponite® concentration. Data are expressed as mean ± standard 
deviation (n=3). C) Viscosity curves showing an increase in the viscosity as the Laponite® 
concentration increases D) Representative Tan δ (G”/G’) profiles as a function of the frequency 
(0.01-10 Hz) for the different system containing a different concentration of Laponite®. A 
decrease in the tan δ was observed for the system containing Laponite® 2% w/v, which is 
indicative of a higher degree of physical crosslinking. E) Recovery properties of the hydrogels 
were assessed by monitoring the storage moduli of the hydrogels while subjecting them to 
alternating high (100%) and low (1%) strain. Laponite® was found to greatly enhance the 
thixotropic behavior of the hydrogels.  
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Figure 4.4 Positive effect of the secretome loaded nanocomposite hydrogel on cardiac function in 
vivo. A) Schematic representing the design of the study. Specifically, either phosphate buffer saline 
(No Treatment), the nanocomposite hydrogel (nSi Gel), or the secretome loaded nanocomposite 
hydrogel (nSi Gel+) were injected into the peri-infarct region of rat hearts with an induced acute 
myocardial infarction 15 minutes post infarction. Subsequent echocardiographs were taken at day 
3, 7, 14, and 21 followed by histomorphometric studies of the rat hearts. B) Representative 
echocardiograph data for each test group used to calculate the cardiac function parameters. C) 
Calculated heart ejection fractions (EF %) at each time point. A significant increase in the nSi 
Gel+ group EF% was observed when compared to the nSi Gel group. D) Fractional shortening (FS 
%) calculations at each time point. The nSi Gel+ showed a substantial increase in FS% in 
comparison to the nSi Gel group at each time point except at day 3. E) Cardiac output (L/min) was 
monitored for each group throughout the study. The cardiac output for the nSi Gel+ group was 
significantly greater than the nSi Gel group on days 7 and 21. Data are expressed as mean value ± 
standard deviation f, * p<0.05, ** p<0.01, *** p<0.001, (n = 5).  
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Figure 4.5 Assessment of the in vivo proangiogenic and scar area reduction capability of the 
secretome loaded nanocomposite hydrogel. A) An illustration (left) and image (right) of the 
infarcted region of the acute myocardial infarction model where either phosphate buffer saline (No 
Treatment), nanocomposite hydrogel (nSi Gel), or secretome loaded nanocomposite hydrogel (nSi 
Gel+) was injected. B) Representative micrographs of immunohistochemically stained sections of 
the peri-infarct region highlighting cell nuclei (DAPI), endothelial cells (vWF) and mural cells 
(SMA), 21 days post treatment injection. Scale bar: 100 µm. C) Quantification of vessels stained 
positive for vWF+ and SMA indicating a significant increase in the blood vessel density in the 
hearts that received the nSi Gel and nSi Gel+ treatment. D) Characteristic Masson’s trichrome 
stained cross-sections of the rat hearts displaying the scar formation in each group. Scale bar: 5 
mm. E) The percentage of the myocardium that was replaced with infarcted tissue was quantified 
for each test group. A significant decrease in infarct size was observed in the nSi Gel and nSi Gel+ 
group. F) The heart weight to body weight ratio (HW/BW) was calculated for each group and a 
significant increase in the ratio was observed in the nSi Gel+ group when compared to the control. 
Data expressed as mean value ± standard deviation * p<0.05, ** p<0.01, *** p<0.001, (n = 5).  
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Figure S 4.1. Characterization of the injectable nanocomposite hydrogel A) FT-IR spectra of 
Laponite and the nanocomposite hydrogel confirming the gelatin Laponite interactions due to the 
shift observed in the stretching of the Si-O bond highlighted in blue. B) EDX analysis of gelatin 
hydrogel and C) nanocomposite hydrogel confirming the presence of the Laponite by the detection 
of Mg and Si. 
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Figure S4.2. Effect of Laponite on nanocomposite hydrogel stiffness. A) Strain sweeps at 1 Hz to 
determine the linear viscoelastic region of each hydrogel. B) Frequency sweeps of each hydrogel 
obtained in the range of frequencies from 0.01 to 10 Hz at 25 °C. C) Temperature sweeps at 1 Hz 
to monitor the stiffness of the hydrogel at physiological temperatures. D) Storage modulus (G’) of 
each hydrogel at 25 °C and 37 °C (n=3). Data is expressed as mean value ± st. dev., ** p<0.01, 
*** p<0.001. 
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Figure S4.3. Influence of Laponite concentration on the injectable hydrogel stability and protein 
release. A) Degradation profiles of the nanocomposite hydrogels in PBS at 37 °C. B) Release of 
the model protein myoglobin from the nanocomposite hydrogel in PBS at 37 °C. Data is expressed 
as mean value ± st. dev. (n=5). 
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Figure S4.4. Effect of secretome on in vitro tube network length using tube formation assay. A) 
The total segment length of each HUVEC tube network after the addition of secretome in tube 
formation assay.  B) The total length of the tube network formed during in vitro tube formation 
assay after adding secretome. Data is expressed as mean value ± st. dev. (n=3), * p<0.05, ** 
p<0.01. 
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Figure S4.5. Biocompatiblity assessment of the injectable nanocomposite hydrogels A) 
Quantification of HUVECs using an MTS assay after 1 day, 3 days, and 5 days of incubation with 
the respective nanocomposite hydrogel. Positive control group (Cntrl) received only complete 
endothelial growth media. Data is expressed as mean value ± st. dev. (n=5). B) Immunofluorescent 
images of HUVECs counterstained for F-actin and nuclei after 24 hour incubation with media 
containing 10% of the respective nanocomposite hydrogel. Complete endothelial growth media 
was used as a positive control (Cntrl+) and the negative control (Cntrl-) received camptothecin (50 
nM) in the media.  Scale bar: 200 µm. 
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Figure S4.6. In vivo assessment of pro-inflammatory markers post nanocomposite hydrogel 
injections. Immunohistochemical analysis of the injection site and peripheral tissue of healthy rats 
that received either a PBS injection or a nanocomposite hydrogel injection was carried out. No 
visual difference in pro-inflammatory marker TNFα was seen among the regions of the two groups. 
Scale bar: 20 µm. 
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Figure S4.7. Cardiac damage assessment post in vivo nanocomposite hydrogel injections. 
Immunohistochemical analysis of the injection site and peripheral tissue of healthy rats that 
received either a PBS injection or a nanocomposite hydrogel injection was carried out. No visual 
difference in cardiac apoptotic marker TUNEL was seen among the regions of the two groups. 
Scale bar: 20 µm. 
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 Figure S4.8. In vivo biocompatibility of the injectable nanocomposite hydrogel. Healthy rat 
models that either received an injection of the nanocomposite hydrogel or no treatment were tested 
A) Expression of cardiac stress and inflammatory marker specific miRNA was assessed using 
qPCR. The data represents the fold increase in the expression of the miRNA within animals that 
received the nanocomposite hydrogel injections with respect to the animals that did not. The data 
from each group was normalized to RNU6. No significant difference among the groups was 
determined. B) Gene expression of cardiac stress, cell cycle and inflammatory genes were 
quantified using qPCR. The data represents the fold increase in the gene expression within animals 
that received the nanocomposite hydrogel injections with respect to the animals that did not. The 
data from each group was normalized to GAPDH prior to the fold increase calculations. C) 
Specific primers used for each gene and miRNA. No significant difference in gene expression was 
detected among the groups (n=5). 
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Figure S4.9. Retention of cardiac function post intramyocardial injection of nanocomposite 
hydrogel. Healthy rats received an intramyocardial injection of either PBS (control) or the 
nanocomposite hydrogel (nSi Gel) A) Representative echocardiograph data used to calculate the 
cardiac function parameters for each test group is shown. B) Calculated heart ejection fractions 
(EF%) showed no significant change among the groups. C) No significant change in the calculated 
fractional shortening (FS%) was detected D) Cardiac output (L/min) was monitored for each group 
and showed no substantial difference. E) The heart weight to body weight ratio was calculated for 
each group and no significant increase in the ratio was observed between groups. Data is expressed 
as mean value ± st.dev. (n=5). 
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Figure S4.10. In vivo cardiac function assessment after secretome delivery with and without the 
nanocomposite hydrogel. A) Schematic representing the design of the study. Specifically, either 
phosphate buffer saline (No Treatment), the secretome solution (Ctrl Secretome), or the secretome 
loaded nanocomposite hydrogel (nSi Gel/Secretome) were injected into the peri-infarct region of 
rat hearts with an induced acute myocardial infarction 15 minutes post infarction. Subsequent 
echocardiographs were taken at day 3, 7, 14, and 21. B) Calculated heart ejection fractions (EF%) 
at each time point. A significant increase in the nSi Gel/Secretome group EF% was observed when 
compared to the Ctrl Secretome group at day 21. Data are expressed as mean value ± standard 
deviation f, * p<0.05, (n = 5).  
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Figure 5.1 Schematic representing the process of hASCs transfection with miR-146a. Upon 
transfection, hASCs start secreting enriched extracellular vesicles containing miR-146a. The 
enriched secretome will possess a proangiogenic and anti-inflammatory effect on endothelial cells 
due to the presence of the miR-146a carried in the exosome subpopulation of EVs. Abbreviations: 
human adipose-derived stem cells (hASCs), multi-vescular body (MVB), vascular cell adhesion 
protein (VCAM), intercellular adhesion molecule (ICAM), and monocyte chemoattractant protein-
1 (MCP-1). 
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Figure 5.2. Characterization of EVs-derived from transfected hASCs. A) TEM images of the 
extracellular vesicles secreted by hASCs. Scale bar = 200 nm. B) Corresponding higher 
magnification where it is evident the presence of the double bilayer of the exosomes. Scale bar 
=100 nm. C) Representative size distribution curve obtained by the NTA analysis of the 
extracellular vesicle population secreted by hASCs. It is evident a bimodal distribution with the 
larger population displaying a smaller size in the range of 150-200 nm. D) Western blot analysis 
was carried out to test the presence of specific protein markers in the exosome population 
compared to the whole cell lysate. E) Relative fold expression of miR-146a in the exosomes 
obtained from the transfected hASCs. Results are normalized based on the level expression in the 
control group using RNU6 as the housekeeping gene.  
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Figure 5.3. Comparison of the growth factor composition and angiogenic properties of the 
secretome derived from transfected vs non-transfected hASCs with miR-146a. The group named 
secretome146a refers to hASCs transfected with the miR-146a. A) Angiogenic array analysis 
displaying the difference in the secreted amount of several angiogenic growth factors. B) qPCR 
analysis of the main proangiogenic miRNA found in the EVs of the two types of secretome. C) 
qPCR analysis of the main anti-angiogenic miRNA found in the EVs of the two types of secretome. 
D) Representative bright field images of the scratch assay carried out at 6 and 24 hours for the free 
different groups. The dotted white lines define the original area of the scratch. Scale bar = 200 µm. 
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E) HUVEC cell proliferation monitored after 24 hours using an MTS assay (n=5). Cells were 
treated with different type of secretome and compared to the cells cultured without the addition of 
any angiogenic growth factor (Ctrl (-)). F) Corresponding quantification of the area covered by the 
HUVECs over 24 hours of migration. Image J analysis was used to quantify the percentage of area 
covered (n=10). Results are reported as mean ± deviation standard. * = p<0.05, ** = p<0.01 *** 
= p<0.001. 
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Figure 5.4. Tube formation assay of HUVEC to test the proangiogenic properties of the secretome. 
A) Bright field images of HUVECs cultured on Matrigel and treated with different types of 
secretome. The negative control group (Ctrl (-)) was represented by endothelial cells cultured 
without any angiogenic growth factor. Scale bar = 200 µm. Image J quantification of several 
parameters regarding the network structure including B) number of nodes C) number of meshes 
D) number of segments E) total segments length in the network, and F) number of isolated 
segments. The results are reported as mean ± deviation standard (n=10). * = p<0.05, ** = p<0.01 
*** = p<0.001. 
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Figure 5.5. Assessment of the anti-inflammatory response of the secretome146a. A) Cytokine array 
results of the different types of cytokines found in the two different types of secretome. B) Anti-
apoptotic miRNA found in the EVs of the two types of secretome. C) Pro-apoptotic miRNA found 
in the EVs of the two types of secretome. D-E) qPCR analysis of main genes involved in the 
inflammatory response of HUVECs upon exposure to IL-1β. Gene profiles of ICAM, MCP-1, 
TRAF6, NOS3 and VCAM, were studied at 4 and 24 hours. F) Quantification of MCP-1 secreted 
by HUVECs after being exposed to IL-1β and subsequent treatment with the different types of 
secretome. G) FACs analysis reporting the mean fluorescent intensity of positive fluorescent 
stained HUVECs expressing the cellular molecular adhesion protein ICAM. Results are reported 
as mean ± deviation standard. * = p<0.05, ** = p<0.01 *** = p<0.001. 
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Figure S5.1 SEM image displaying the morphological structure of EV (highlighted by the black 
arrows). Scale bar= 500 nm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
APPENDIX B: Tables 
Chapter 1: No Tables  
Chapter 2: Tables 2.1-2.2 
Chapter 3: No Tables  
Chapter 4: No Tables  
Chapter 5: No Tables  
Chapter 6: No Tables  
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Table 2.1 Clinical Trials Assessing Adult Stem Cell Therapy for AMI and IHD 
Trial Follow
-Up 
n Cell Type, 
Dose, and 
Treatment 
Groups 
Delivery 
Method 
End Point 
Evaluation 
LVEF LV 
Volumes 
Scar 
Size 
Perin et al.259 
  
4 mo 21 25.5×106 
BMMNCs 
vs control 
TESI Echo ↑ ↓ESV NA 
TOPCARE 
CHD Assmus 
et al. 260 
3 mo 75 22×106 
CPCs vs 
205×106 
BMMNCs 
vs control 
IC LVG BMMNC
↑EF 
NS NS 
FOCUS 
CCTRN 
Perin et al.261  
6 mo 92 100×106 
BMMNCs 
vs placebo 
TESI Echo 
SPECT 
NS NS NS 
MSC-HF 
Mathiasen et 
al.262  
6 mo 55 77×106 
BM-MSC 
vs placebo 
TESI cMRI or 
CT 
↑ ↓ ESV ↓ 
SCIPIO Bolli 
et al.263  
4 mo 23 1×106 
CSCs vs 
control 
IC Echo/cMRI ↑ NA ↓ 
POSEIDON 
Hare et al.264  
13 mo 30 20, 100, or 
200×106 
BM-MSCs 
(allo vs 
auto) 
TESI cMRI NS Allo: 
↓EDV 
↓ 
CADUCEUS 
Makkar et 
al.265  
6 mo 31 12.5–
25×106 
CDCs vs 
control 
IC cMRI NS NS ↓ 
CHART-1 
Bartunek et 
al.266  
39 wk 351 9.7×108 –
1.2×109 
Cardiopoiet
ic cells vs 
sham 
TESI Echo NS  NS NA 
TAC-HFT 
Heldman et 
al.53  
12 mo 65 100×106 
BM-MSCs 
vs 100×106 
BMMNCs 
vs placebo 
TESI cMRI/CT NS NS MSC
: ↓ 
RIMECARD 
Bartolucci et 
al.57  
12 mo 30 1×106 /kg 
UC-MSC 
vs placebo 
IV Echo/cMRI ↑ ↑EDV NA 
ATHENA 
Trials Henry 
et al.60  
12 mo 31 80×106 vs 
40×106 
ARDCs vs 
placebo 
TESI Echo NS NS NA 
TOPCARE-
AMI 
Schächinger 
et al.43 
12 mo 59 CPCs; 
BMMNCs 
7. 3×106 
IC LVG ↑ ↓ ESV ↓ 
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BOOST 
Wollert et 
al.44 
6 mo 60 2.4×109 
BMMNCs 
vs control 
IC cMRI ↑ NS NA 
REPAIR-
AMI 
Schächinger 
et al.47 
4 mo 204 198×106 
BMMNCs 
vs placebo 
IC LVG ↑ NS NA 
TIME 
Traverse et 
al.48 
6 mo 120 150×106 
BMMNCs 
vs placebo 
IC cMRI NS NS NS 
LateTime 
Traverse et 
al.49 
 
6 mo 87 150×106 
BMMNCs 
vs placebo 
IC cMRI NS NS NS 
SWISS AMI 
Sürder et al.50 
 
12 mo 192 153×106 
BMMNCs 
vs control 
IC cMRI NS NS NS 
BOOST-2 
Wollert et 
al.267 
 
6 mo 188 20.6×108 
vs 7.0×108 
BMMNCs 
vs placebo 
 
IC cMRI  
 
NS NS NS 
Pre-SERVE-
AMI 
Quyyumi et 
al.52 
 
12 mo 161 14.9×106 
CD34+ 
vs placebo 
IC cMRI NS NS NS 
Hare et al.268 6 mo 
 
34 
 
BM MSC, 
allogeneic 
0.5×106 
1.6×106 
5×106 
 
IV Echo/cMRI ↑ EF    
Bartolucci et 
al.57 
 
12 mo 15 UC MSC, 
allogeneic 
1×106  
 
IV Echo/cMRI ↑ EF   
Butler et 
al.269 
 
90 d 10 BM MSC, 
allogeneic 
1×106 
IV cMRI ↑ EF   
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Table 2.2 Key Paracrine Molecules for Cardiac Regeneration   
Protein  Main cardiac functions Refs. 
Insulin-like growth factor-1 
(IGF-1) 
 
Anti-apoptotic; promote stem cell growth and 
differentiation 
270-273 
Hypoxia-inducible factor-1a 
(HIF-1a) 
 
Trigger release of angiogenic growth factors and 
nitric oxide 
244, 274-276 
Sonic hedgehog (Shh)  
 
Induce cardiac morphogenesis; anti-apoptotic 243, 277 
 
Fibroblast growth factor-1 
(FGF-1) 
 
Initiation of angiogenesis; stimulate cardiomyocyte 
proliferation 
243, 276, 278, 279 
Fibroblast growth factor-2 
(FGF-2) 
 
Initiation of angiogenesis; upregulate proliferation, 
migration, and survival of endothelial cells; induce 
chemotaxis; anti-apoptotic 
243, 244, 275, 276, 280, 281 
Vascular endothelial growth 
factor-A (VEGF-A  
 
 
Initiation of angiogenesis; upregulate proliferation, 
migration, and survival of endothelial cells; trigger 
nitric oxide release 
243, 244, 275, 276, 282 
Platelet-derived growth 
factor-BB (PDGF-BB) 
 
Upregulate proliferation and chemotaxis of 
pericytes; promote angiogenesis and neovessel 
maturation; anti-apoptotic 
270, 275, 283, 284 
Hepatocyte growth factor 
(HGF) 
 
Angiogenic, anti-apoptotic; chemotactic on 
stem/progenitor cells 
133, 272, 285 
Granulocyte colony- 
stimulating factor (G-CSF) 
Chemotactic on stem/progenitor cells; anti-
apoptotic; angiogenic 
 
250, 251 
Stromal cell-derived factor 1-
a (SDF1-a) 
Chemotactic on stem/progenitor cells; angiogenic  
 
134, 286-289 
Erythropoietin (EPO) 
 
Chemotactic on stem/progenitor cells; angiogenic; 
anti-apoptotic 
290-295 
Thymosin-b4 Chemotactic on stem/progenitor cells; angiogenic 270, 296 
 
Neuregulin-1 (NRG-1) Induce cardiomyocyte proliferation; anti-apoptotic 297-300 
Tissue inhibitor of 
metalloproteinases-1 (TIMP-
1) 
Inhibit MMP activity and ECM degradation; anti-
apoptotic 
 
281, 301, 302 
Tissue inhibitor of 
metalloproteinases-3 (TIMP-
3) 
Inhibit MMP activity and ECM degradation; anti-
apoptotic; anti-inflammatory 
 
137, 281, 302-305 
Interleukin-10 (IL-10) 
 
Anti-inflammatory; anti-apoptotic 306, 307 
Monocyte chemoattractant 
protein-1 (MCP-1) 
Pro-inflammatory; angiogenic; chemoattractant 
 
308, 309 
miR-24 Targets the proapoptotic Bcl-2-like protein 11 
(Bim); anti-apoptotic 
310, 311 
miR-214 Targets the proapoptotic Bcl-2-like protein 11 
(Bim); anti-apoptotic 
312, 313 
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miR-210 Targets antiangiogenic receptor tyrosine kinase 
ephrin-A3 and proapoptotic tyrosine-protein 
phosphatase non-receptor type 1 (PTP-1B); 
angiogenic, anti-apoptotic 
314,315 
miR-126 Targets phosphoinositol-3 kinase regulatory subunit 
2 (PIK3R2); angiogenic 
316 
miR-132 Inhibits RAS GTPase-activating protein (Ras p21 
protein activator); angiogenic 
317 
miR-146 downregulates NRAS; anti-apoptotic, angiogenic 235, 318 
miR-22 Inhibits methyl CpG binding protein 2 (Mecp2); 
anti-apoptotic 
81 
miR-221 Inhibits levels of p53 up-regulated modulator of 
apoptosis (PUMA); anti-apoptotic 
319 
miR-21 suppression of Fas ligand targeting PDCD4; anti-
apoptotic 
320 
 
